2024Q30001124140false--12-31http://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent1xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureexas:positionexas:segment00011241402024-01-012024-09-3000011241402024-11-0400011241402024-09-3000011241402023-12-3100011241402024-07-012024-09-3000011241402023-07-012023-09-3000011241402023-01-012023-09-300001124140us-gaap:CommonStockMember2023-12-310001124140us-gaap:AdditionalPaidInCapitalMember2023-12-310001124140us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001124140us-gaap:RetainedEarningsMember2023-12-310001124140us-gaap:CommonStockMember2024-01-012024-03-310001124140us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-3100011241402024-01-012024-03-310001124140us-gaap:RetainedEarningsMember2024-01-012024-03-310001124140us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001124140us-gaap:CommonStockMember2024-03-310001124140us-gaap:AdditionalPaidInCapitalMember2024-03-310001124140us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001124140us-gaap:RetainedEarningsMember2024-03-3100011241402024-03-310001124140us-gaap:CommonStockMember2024-04-012024-06-300001124140us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-3000011241402024-04-012024-06-300001124140us-gaap:RetainedEarningsMember2024-04-012024-06-300001124140us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001124140us-gaap:CommonStockMember2024-06-300001124140us-gaap:AdditionalPaidInCapitalMember2024-06-300001124140us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001124140us-gaap:RetainedEarningsMember2024-06-3000011241402024-06-300001124140us-gaap:CommonStockMember2024-07-012024-09-300001124140us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001124140us-gaap:RetainedEarningsMember2024-07-012024-09-300001124140us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001124140us-gaap:CommonStockMember2024-09-300001124140us-gaap:AdditionalPaidInCapitalMember2024-09-300001124140us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001124140us-gaap:RetainedEarningsMember2024-09-3000011241402023-09-300001124140us-gaap:CommonStockMember2022-12-310001124140us-gaap:AdditionalPaidInCapitalMember2022-12-310001124140us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001124140us-gaap:RetainedEarningsMember2022-12-3100011241402022-12-310001124140us-gaap:CommonStockMember2023-01-012023-03-310001124140us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-3100011241402023-01-012023-03-310001124140us-gaap:RetainedEarningsMember2023-01-012023-03-310001124140us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001124140us-gaap:CommonStockMember2023-03-310001124140us-gaap:AdditionalPaidInCapitalMember2023-03-310001124140us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001124140us-gaap:RetainedEarningsMember2023-03-3100011241402023-03-310001124140us-gaap:CommonStockMember2023-04-012023-06-300001124140us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-3000011241402023-04-012023-06-300001124140us-gaap:RetainedEarningsMember2023-04-012023-06-300001124140us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001124140us-gaap:CommonStockMember2023-06-300001124140us-gaap:AdditionalPaidInCapitalMember2023-06-300001124140us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001124140us-gaap:RetainedEarningsMember2023-06-3000011241402023-06-300001124140us-gaap:CommonStockMember2023-07-012023-09-300001124140us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001124140us-gaap:RetainedEarningsMember2023-07-012023-09-300001124140us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001124140us-gaap:CommonStockMember2023-09-300001124140us-gaap:AdditionalPaidInCapitalMember2023-09-300001124140us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001124140us-gaap:RetainedEarningsMember2023-09-300001124140us-gaap:RestrictedStockMember2024-07-012024-09-300001124140us-gaap:RestrictedStockMember2023-07-012023-09-300001124140us-gaap:RestrictedStockMember2024-01-012024-09-300001124140us-gaap:RestrictedStockMember2023-01-012023-09-300001124140exas:EmployeeAndNonEmployeesStockOptionMember2024-07-012024-09-300001124140exas:EmployeeAndNonEmployeesStockOptionMember2023-07-012023-09-300001124140exas:EmployeeAndNonEmployeesStockOptionMember2024-01-012024-09-300001124140exas:EmployeeAndNonEmployeesStockOptionMember2023-01-012023-09-300001124140us-gaap:EmployeeStockMember2024-07-012024-09-300001124140us-gaap:EmployeeStockMember2023-07-012023-09-300001124140us-gaap:EmployeeStockMember2024-01-012024-09-300001124140us-gaap:EmployeeStockMember2023-01-012023-09-300001124140us-gaap:PerformanceSharesMember2024-07-012024-09-300001124140us-gaap:PerformanceSharesMember2023-07-012023-09-300001124140us-gaap:PerformanceSharesMember2024-01-012024-09-300001124140us-gaap:PerformanceSharesMember2023-01-012023-09-300001124140us-gaap:ConvertibleNotesPayableMember2024-07-012024-09-300001124140us-gaap:ConvertibleNotesPayableMember2023-07-012023-09-300001124140us-gaap:ConvertibleNotesPayableMember2024-01-012024-09-300001124140us-gaap:ConvertibleNotesPayableMember2023-01-012023-09-300001124140us-gaap:RestrictedStockMember2024-07-012024-09-300001124140us-gaap:RestrictedStockMember2023-07-012023-09-300001124140us-gaap:RestrictedStockMember2024-01-012024-09-300001124140us-gaap:RestrictedStockMember2023-01-012023-09-300001124140us-gaap:PerformanceSharesMember2024-07-012024-09-300001124140us-gaap:PerformanceSharesMember2023-07-012023-09-300001124140us-gaap:PerformanceSharesMember2024-01-012024-09-300001124140us-gaap:PerformanceSharesMember2023-01-012023-09-300001124140exas:EmployeeAndNonEmployeesStockOptionMember2024-07-012024-09-300001124140exas:EmployeeAndNonEmployeesStockOptionMember2023-07-012023-09-300001124140exas:EmployeeAndNonEmployeesStockOptionMember2024-01-012024-09-300001124140exas:EmployeeAndNonEmployeesStockOptionMember2023-01-012023-09-300001124140exas:ScreeningMemberus-gaap:ProductMember2024-07-012024-09-300001124140exas:ScreeningMemberus-gaap:ProductMember2023-07-012023-09-300001124140exas:ScreeningMemberus-gaap:ProductMember2024-01-012024-09-300001124140exas:ScreeningMemberus-gaap:ProductMember2023-01-012023-09-300001124140exas:ScreeningMemberus-gaap:ServiceMember2024-07-012024-09-300001124140exas:ScreeningMemberus-gaap:ServiceMember2023-07-012023-09-300001124140exas:ScreeningMemberus-gaap:ServiceMember2024-01-012024-09-300001124140exas:ScreeningMemberus-gaap:ServiceMember2023-01-012023-09-300001124140exas:ScreeningMemberus-gaap:ProductAndServiceOtherMember2024-07-012024-09-300001124140exas:ScreeningMemberus-gaap:ProductAndServiceOtherMember2023-07-012023-09-300001124140exas:ScreeningMemberus-gaap:ProductAndServiceOtherMember2024-01-012024-09-300001124140exas:ScreeningMemberus-gaap:ProductAndServiceOtherMember2023-01-012023-09-300001124140exas:ScreeningMember2024-07-012024-09-300001124140exas:ScreeningMember2023-07-012023-09-300001124140exas:ScreeningMember2024-01-012024-09-300001124140exas:ScreeningMember2023-01-012023-09-300001124140exas:PrecisionOncologyMemberus-gaap:ProductMember2024-07-012024-09-300001124140exas:PrecisionOncologyMemberus-gaap:ProductMember2023-07-012023-09-300001124140exas:PrecisionOncologyMemberus-gaap:ProductMember2024-01-012024-09-300001124140exas:PrecisionOncologyMemberus-gaap:ProductMember2023-01-012023-09-300001124140exas:PrecisionOncologyMemberus-gaap:ServiceMember2024-07-012024-09-300001124140exas:PrecisionOncologyMemberus-gaap:ServiceMember2023-07-012023-09-300001124140exas:PrecisionOncologyMemberus-gaap:ServiceMember2024-01-012024-09-300001124140exas:PrecisionOncologyMemberus-gaap:ServiceMember2023-01-012023-09-300001124140exas:PrecisionOncologyMemberexas:InternationalSalesMember2024-07-012024-09-300001124140exas:PrecisionOncologyMemberexas:InternationalSalesMember2023-07-012023-09-300001124140exas:PrecisionOncologyMemberexas:InternationalSalesMember2024-01-012024-09-300001124140exas:PrecisionOncologyMemberexas:InternationalSalesMember2023-01-012023-09-300001124140exas:PrecisionOncologyMemberus-gaap:ProductAndServiceOtherMember2024-07-012024-09-300001124140exas:PrecisionOncologyMemberus-gaap:ProductAndServiceOtherMember2023-07-012023-09-300001124140exas:PrecisionOncologyMemberus-gaap:ProductAndServiceOtherMember2024-01-012024-09-300001124140exas:PrecisionOncologyMemberus-gaap:ProductAndServiceOtherMember2023-01-012023-09-300001124140exas:PrecisionOncologyMember2024-07-012024-09-300001124140exas:PrecisionOncologyMember2023-07-012023-09-300001124140exas:PrecisionOncologyMember2024-01-012024-09-300001124140exas:PrecisionOncologyMember2023-01-012023-09-300001124140exas:COVID19TestingMember2024-07-012024-09-300001124140exas:COVID19TestingMember2023-07-012023-09-300001124140exas:COVID19TestingMember2024-01-012024-09-300001124140exas:COVID19TestingMember2023-01-012023-09-300001124140exas:VariablePriceContractMember2024-07-012024-09-300001124140exas:VariablePriceContractMember2023-01-012023-09-300001124140us-gaap:ShortTermInvestmentsMember2024-09-300001124140us-gaap:ShortTermInvestmentsMember2023-12-310001124140us-gaap:CashEquivalentsMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300001124140us-gaap:CashEquivalentsMember2024-09-300001124140us-gaap:ShortTermInvestmentsMemberus-gaap:CorporateBondSecuritiesMember2024-09-300001124140us-gaap:ShortTermInvestmentsMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300001124140us-gaap:ShortTermInvestmentsMemberus-gaap:AssetBackedSecuritiesMember2024-09-300001124140us-gaap:CashEquivalentsMemberus-gaap:CommercialPaperMember2023-12-310001124140us-gaap:CashEquivalentsMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001124140us-gaap:CashEquivalentsMember2023-12-310001124140us-gaap:ShortTermInvestmentsMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001124140us-gaap:ShortTermInvestmentsMemberus-gaap:CorporateBondSecuritiesMember2023-12-310001124140us-gaap:ShortTermInvestmentsMemberus-gaap:AssetBackedSecuritiesMember2023-12-310001124140us-gaap:ShortTermInvestmentsMemberus-gaap:CommercialPaperMember2023-12-310001124140us-gaap:LandMember2024-09-300001124140us-gaap:LandMember2023-12-310001124140exas:BuildingsAndLeaseholdImprovementsMember2024-09-300001124140exas:BuildingsAndLeaseholdImprovementsMember2023-12-310001124140us-gaap:LandImprovementsMember2024-09-300001124140us-gaap:LandImprovementsMember2023-12-310001124140srt:MinimumMemberus-gaap:BuildingMember2024-09-300001124140srt:MaximumMemberus-gaap:BuildingMember2024-09-300001124140us-gaap:BuildingMember2024-09-300001124140us-gaap:BuildingMember2023-12-310001124140exas:OfficeEquipmentAndComputerSoftwareMember2024-09-300001124140exas:OfficeEquipmentAndComputerSoftwareMember2023-12-310001124140srt:MinimumMemberus-gaap:EquipmentMember2024-09-300001124140srt:MaximumMemberus-gaap:EquipmentMember2024-09-300001124140us-gaap:EquipmentMember2024-09-300001124140us-gaap:EquipmentMember2023-12-310001124140srt:MinimumMemberus-gaap:FurnitureAndFixturesMember2024-09-300001124140srt:MaximumMemberus-gaap:FurnitureAndFixturesMember2024-09-300001124140us-gaap:FurnitureAndFixturesMember2024-09-300001124140us-gaap:FurnitureAndFixturesMember2023-12-310001124140us-gaap:AssetUnderConstructionMember2024-09-300001124140us-gaap:AssetUnderConstructionMember2023-12-310001124140us-gaap:ComputerSoftwareIntangibleAssetMember2024-09-300001124140us-gaap:TradeNamesMember2024-09-300001124140us-gaap:CustomerRelationshipsMember2024-09-300001124140us-gaap:PatentsMember2024-09-300001124140us-gaap:DevelopedTechnologyRightsMember2024-09-300001124140us-gaap:TradeNamesMember2023-12-310001124140us-gaap:CustomerRelationshipsMember2023-12-310001124140us-gaap:PatentsMember2023-12-310001124140us-gaap:DevelopedTechnologyRightsMember2023-12-310001124140exas:ResolutionBioscienceMember2023-01-012023-12-3100011241402023-01-012023-12-310001124140exas:ResolutionBioscienceMember2024-01-012024-09-300001124140us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001124140us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001124140us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001124140us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001124140us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001124140us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001124140us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001124140us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001124140us-gaap:FairValueMeasurementsRecurringMember2024-09-300001124140us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001124140us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001124140us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001124140us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2024-09-300001124140us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2024-09-300001124140us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2024-09-300001124140us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2024-09-300001124140us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300001124140us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300001124140us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300001124140us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300001124140us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2024-09-300001124140us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2024-09-300001124140us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2024-09-300001124140us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2024-09-300001124140us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001124140us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001124140us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001124140us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001124140us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001124140us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001124140us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001124140us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001124140us-gaap:FairValueMeasurementsRecurringMember2023-12-310001124140us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001124140us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001124140us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001124140us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001124140us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001124140us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001124140us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001124140us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001124140us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001124140us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001124140us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001124140us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2023-12-310001124140us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2023-12-310001124140us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2023-12-310001124140us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2023-12-310001124140us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2023-12-310001124140us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2023-12-310001124140us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2023-12-310001124140us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2023-12-310001124140us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-12-310001124140us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-12-310001124140us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-12-310001124140us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-12-310001124140exas:ThriveAshionAndOmicEraMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300001124140exas:ThriveAshionAndOmicEraMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310001124140exas:ProductDevelopmentAndOtherMilestoneBasedPaymentsMemberexas:MeasurementInputProbabilityOfSuccessMembersrt:WeightedAverageMember2024-09-300001124140exas:ProductDevelopmentAndOtherMilestoneBasedPaymentsMemberexas:MeasurementInputProbabilityOfSuccessMembersrt:WeightedAverageMember2023-12-310001124140exas:ProductDevelopmentAndOtherMilestoneBasedPaymentsMemberexas:MeasurementInputPresentValueFactorMembersrt:WeightedAverageMember2024-09-300001124140exas:ProductDevelopmentAndOtherMilestoneBasedPaymentsMemberexas:MeasurementInputPresentValueFactorMembersrt:WeightedAverageMember2023-12-310001124140us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMember2023-12-310001124140exas:VentureCapitalInvestmentFundMember2024-01-012024-09-300001124140exas:VentureCapitalInvestmentFundMember2024-09-300001124140exas:VentureCapitalInvestmentFundMember2023-12-310001124140us-gaap:ForeignExchangeForwardMember2024-09-300001124140us-gaap:ForeignExchangeForwardMember2023-12-310001124140us-gaap:ForeignExchangeForwardMember2024-07-012024-09-300001124140us-gaap:ForeignExchangeForwardMember2023-01-012023-09-300001124140us-gaap:ForeignExchangeForwardMember2024-01-012024-09-300001124140us-gaap:ForeignExchangeForwardMember2023-07-012023-09-300001124140srt:MinimumMemberexas:SecuritizedReceivablesMember2022-06-290001124140exas:SecuritizedReceivablesMember2024-01-012024-06-300001124140exas:SecuritizedReceivablesMember2022-06-290001124140exas:SecuritizedReceivablesMember2023-12-310001124140exas:SecuritizedReceivablesMember2024-06-290001124140exas:RevolvingLoanAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2021-11-300001124140exas:RevolvingLoanAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2021-11-012021-11-300001124140exas:RevolvingLoanAgreementMemberus-gaap:LetterOfCreditMemberus-gaap:LineOfCreditMember2021-12-012021-12-310001124140exas:RevolvingLoanAgreementMemberus-gaap:LetterOfCreditMemberus-gaap:LineOfCreditMember2023-01-012023-01-310001124140exas:RevolvingLoanAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2023-12-310001124140exas:RevolvingLoanAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2024-09-300001124140exas:ConvertibleNotesPayable2031Member2024-09-300001124140us-gaap:FairValueInputsLevel2Memberexas:ConvertibleNotesPayable2031Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300001124140exas:ConvertibleNotesPayable2030Member2024-09-300001124140us-gaap:FairValueInputsLevel2Memberexas:ConvertibleNotesPayable2030Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300001124140exas:ConvertibleNotesPayable2028Member2024-09-300001124140us-gaap:FairValueInputsLevel2Memberexas:ConvertibleNotesPayable2028Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300001124140exas:ConvertibleNotesPayable2027Member2024-09-300001124140us-gaap:FairValueInputsLevel2Memberexas:ConvertibleNotesPayable2027Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300001124140exas:ConvertibleNotesPayable2025Member2024-09-300001124140us-gaap:FairValueInputsLevel2Memberexas:ConvertibleNotesPayable2025Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300001124140exas:ConvertibleNotesPayable2030Member2023-12-310001124140us-gaap:FairValueInputsLevel2Memberexas:ConvertibleNotesPayable2030Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310001124140exas:ConvertibleNotesPayable2028Member2023-12-310001124140us-gaap:FairValueInputsLevel2Memberexas:ConvertibleNotesPayable2028Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310001124140exas:ConvertibleNotesPayable2027Member2023-12-310001124140us-gaap:FairValueInputsLevel2Memberexas:ConvertibleNotesPayable2027Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310001124140exas:ConvertibleNotesPayable2025Member2023-12-310001124140us-gaap:FairValueInputsLevel2Memberexas:ConvertibleNotesPayable2025Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310001124140exas:ConvertibleNotesPayable2030Member2023-03-010001124140exas:ConvertibleNotesPayable2027Member2023-03-012023-03-310001124140exas:ConvertibleNotesPayable2028Member2023-03-012023-03-310001124140exas:ConvertibleNotesPayable2030Member2023-03-012023-03-3100011241402023-03-012023-03-310001124140exas:ConvertibleNotesPayable2030Memberexas:ConvertibleNotesPayable2025Member2023-03-060001124140exas:ConvertibleNotesPayable2025Member2023-03-012023-03-310001124140exas:ConvertibleNotesPayable2025Member2023-03-012023-03-310001124140exas:ConvertibleNotesPayable2031Member2024-04-170001124140exas:ConvertibleNotesPayable2028Member2024-04-012024-04-300001124140exas:ConvertibleNotesPayable2031Member2024-04-012024-04-3000011241402024-04-012024-04-300001124140exas:ConvertibleNotesPayable2025Member2024-01-012024-09-300001124140exas:ConvertibleNotesPayable2027Member2024-01-012024-09-300001124140exas:ConvertibleNotesPayable2028Member2024-01-012024-09-300001124140exas:ConvertibleNotesPayable2030Member2024-01-012024-09-300001124140exas:ConvertibleNotesPayable2031Member2024-01-012024-09-300001124140exas:ConvertibleNotesPayable2031Member2024-07-012024-09-300001124140exas:ConvertibleNotesPayable2031Member2023-07-012023-09-300001124140exas:ConvertibleNotesPayable2031Member2023-01-012023-09-300001124140exas:ConvertibleNotesPayable2030Member2024-07-012024-09-300001124140exas:ConvertibleNotesPayable2030Member2023-07-012023-09-300001124140exas:ConvertibleNotesPayable2030Member2023-01-012023-09-300001124140exas:ConvertibleNotesPayable2028Member2024-07-012024-09-300001124140exas:ConvertibleNotesPayable2028Member2023-07-012023-09-300001124140exas:ConvertibleNotesPayable2028Member2023-01-012023-09-300001124140exas:ConvertibleNotesPayable2027Member2024-07-012024-09-300001124140exas:ConvertibleNotesPayable2027Member2023-07-012023-09-300001124140exas:ConvertibleNotesPayable2027Member2023-01-012023-09-300001124140exas:ConvertibleNotesPayable2025Member2024-07-012024-09-300001124140exas:ConvertibleNotesPayable2025Member2023-07-012023-09-300001124140exas:ConvertibleNotesPayable2025Member2023-01-012023-09-300001124140exas:MAYOFoundationMemberus-gaap:LicensingAgreementsMember2017-10-310001124140exas:MAYOFoundationMemberus-gaap:LicensingAgreementsMember2024-01-012024-09-300001124140exas:ThriveEarlierDetectionCorporationMemberus-gaap:LicensingAgreementsMember2021-01-050001124140exas:TARDISTechnologyMember2021-01-110001124140exas:TARDISTechnologyMember2024-05-010001124140exas:TARDISTechnologyMember2024-01-012024-09-300001124140exas:TARDISTechnologyMember2024-09-300001124140exas:ProductDevelopmentAndOtherMilestoneBasedPaymentsMemberexas:TheBroadInstituteLLCMemberus-gaap:LicensingAgreementsMember2023-06-300001124140exas:SalesMilestoneRangeOneMemberexas:TheBroadInstituteLLCMemberus-gaap:LicensingAgreementsMember2023-06-302023-06-300001124140exas:WatchmakerGenomicsIncMemberus-gaap:LicensingAgreementsMember2023-07-310001124140exas:TwinStrandBiosciencesIncMember2024-07-012024-07-010001124140exas:TwinStrandBiosciencesIncMember2024-09-300001124140us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310001124140us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-12-310001124140us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-09-300001124140us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-01-012024-09-300001124140us-gaap:AccumulatedTranslationAdjustmentMember2024-09-300001124140us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-09-300001124140us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310001124140us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-12-310001124140us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-09-300001124140us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-01-012023-09-300001124140us-gaap:AccumulatedTranslationAdjustmentMember2023-09-300001124140us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-09-300001124140us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300001124140us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300001124140us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300001124140us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300001124140exas:StockBasedCompensationPlansMember2024-09-300001124140exas:StockBasedCompensationPlansMember2024-01-012024-09-300001124140exas:StockBasedCompensationPlansMember2023-12-310001124140exas:StockBasedCompensationPlansMember2023-12-312023-12-310001124140exas:StockBasedCompensationPlansMember2023-01-012023-09-300001124140exas:RestrictedStockAwardsAndRestrictedStockUnitsRSUMember2023-12-310001124140exas:RestrictedStockAwardsAndRestrictedStockUnitsRSUMember2024-01-012024-09-300001124140exas:RestrictedStockAwardsAndRestrictedStockUnitsRSUMember2024-09-300001124140us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001124140exas:RestrictedStockAwardsAndRestrictedStockUnitsRSUMember2023-01-012023-09-300001124140us-gaap:PerformanceSharesMember2023-12-310001124140us-gaap:PerformanceSharesMember2024-09-300001124140us-gaap:EmployeeStockMembersrt:MinimumMember2024-01-012024-09-300001124140us-gaap:EmployeeStockMembersrt:MinimumMember2023-01-012023-09-300001124140us-gaap:AssetsMember2024-01-012024-09-300001124140us-gaap:LeaseholdImprovementsMember2024-01-012024-09-300001124140exas:AmendedWisconsinEconomicDevelopmentTaxCreditAgreementMember2021-12-310001124140exas:AmendedWisconsinEconomicDevelopmentTaxCreditAgreementMember2021-12-012021-12-310001124140exas:AmendedWisconsinEconomicDevelopmentTaxCreditAgreementMember2024-09-300001124140us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberexas:AmendedWisconsinEconomicDevelopmentTaxCreditAgreementMember2024-09-300001124140us-gaap:OtherNoncurrentAssetsMemberexas:AmendedWisconsinEconomicDevelopmentTaxCreditAgreementMember2024-09-300001124140country:US2024-07-012024-09-300001124140country:US2023-07-012023-09-300001124140country:US2024-01-012024-09-300001124140country:US2023-01-012023-09-300001124140us-gaap:NonUsMember2024-07-012024-09-300001124140us-gaap:NonUsMember2023-07-012023-09-300001124140us-gaap:NonUsMember2024-01-012024-09-300001124140us-gaap:NonUsMember2023-01-012023-09-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2024
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number: 001-35092
EXACT SCIENCES CORPORATION
(Exact name of registrant as specified in its charter)
Delaware02-0478229
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification Number)
5505 Endeavor Lane, Madison WI
53719
(Address of principal executive offices)(Zip Code)
(608) 535-8815 (Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.01 par value per shareEXASThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically, if any, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☒Accelerated filer ☐
Non-accelerated filer☐Smaller reporting company ☐
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of November 4, 2024, the registrant had 185,076,293 shares of common stock outstanding.


EXACT SCIENCES CORPORATION
INDEX
Page
Number

2
EXACT SCIENCES CORPORATION
Condensed Consolidated Balance Sheets
(Amounts in thousands, except share data - unaudited)
Part I — Financial Information
September 30, 2024December 31, 2023
ASSETS
Current assets:
Cash and cash equivalents$588,830 $605,378 
Marketable securities432,301 172,266 
Accounts receivable, net264,819 203,623 
Inventory136,987 127,475 
Prepaid expenses and other current assets110,180 85,627 
Total current assets1,533,117 1,194,369 
Long-term Assets:
Property, plant and equipment, net690,332 698,354 
Operating lease right-of-use assets122,452 143,708 
Goodwill2,367,450 2,367,120 
Intangible assets, net1,864,399 1,890,396 
Other long-term assets, net170,821 177,387 
Total assets$6,748,571 $6,471,334 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable$97,653 $78,816 
Accrued liabilities313,997 341,683 
Operating lease liabilities, current portion27,170 29,379 
Convertible notes, net, current portion
249,038 — 
Debt, current portion— 50,000 
Other current liabilities35,804 14,823 
Total current liabilities723,662 514,701 
Long-term liabilities:
Convertible notes, net, less current portion
2,319,490 2,314,276 
Other long-term liabilities332,213 335,982 
Operating lease liabilities, less current portion162,695 161,070 
Total liabilities3,538,060 3,326,029 
Commitments and contingencies (Note 13)
Stockholders’ equity:
Preferred stock, $0.01 par value Authorized—5,000,000; shares issued and outstanding—no shares at September 30, 2024 and December 31, 2023
— — 
Common stock, $0.01 par value Authorized—400,000,000; shares issued and outstanding—185,054,760 and 181,364,180 shares at September 30, 2024 and December 31, 2023
1,852 1,815 
Additional paid-in capital6,837,476 6,611,237 
Accumulated other comprehensive income
4,630 1,428 
Accumulated deficit(3,633,447)(3,469,175)
Total stockholders’ equity3,210,511 3,145,305 
Total liabilities and stockholders’ equity$6,748,571 $6,471,334 
The accompanying notes are an integral part of these condensed consolidated financial statements.
3
EXACT SCIENCES CORPORATION
Condensed Consolidated Statements of Operations
(Amounts in thousands, except per share data - unaudited)
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Revenue$708,655 $628,338 $2,045,443 $1,852,881 
Operating expenses
Cost of sales (exclusive of amortization of acquired intangible assets)196,070 168,526 556,019 482,383 
Research and development100,101 111,446 331,593 310,960 
Sales and marketing194,653 173,159 572,288 536,613 
General and administrative217,201 217,393 662,174 672,653 
Amortization of acquired intangible assets24,435 22,992 71,057 68,849 
Impairment of long-lived assets18,698 — 31,296 621 
Total operating expenses751,158 693,516 2,224,427 2,072,079 
Other operating income3,100 72,027 6,632 72,027 
Income (loss) from operations(39,403)6,849 (172,352)(147,171)
Other income (expense)
Investment income, net
11,582 2,065 29,596 7,383 
Interest expense
(9,607)(7,871)(17,439)(11,582)
Total other income (expense)1,975 (5,806)12,157 (4,199)
Net income (loss) before tax(37,428)1,043 (160,195)(151,370)
Income tax expense
(808)(249)(4,077)(3,013)
Net income (loss)$(38,236)$794 $(164,272)$(154,383)
Net income (loss) per share—basic$(0.21)$0.00 $(0.89)$(0.86)
Net income (loss) per share—diluted $(0.21)$0.00 $(0.89)$(0.86)
Weighted average common shares outstanding—basic184,795 180,649 183,823 179,817
Weighted average common shares outstanding—diluted184,795 184,075 183,823 179,817 
The accompanying notes are an integral part of these condensed consolidated financial statements.
4
EXACT SCIENCES CORPORATION
Condensed Consolidated Statements of Comprehensive Loss
(Amounts in thousands - unaudited)
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Net income (loss)
$(38,236)$794 $(164,272)$(154,383)
Other comprehensive income (loss), net of tax:
Unrealized gain on available-for-sale investments
3,700 423 2,775 4,327 
Foreign currency adjustment
1,873 (1,235)427 (626)
Comprehensive loss$(32,663)$(18)$(161,070)$(150,682)
The accompanying notes are an integral part of these condensed consolidated financial statements.
5
EXACT SCIENCES CORPORATION
Condensed Consolidated Statements of Stockholders’ Equity
(Amounts in thousands, except share data - unaudited)
Common StockAdditional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated DeficitTotal Stockholders’ Equity
Number of Shares
$0.01
Par Value
Balance, January 1, 2024181,364,180 $1,815 $6,611,237 $1,428 $(3,469,175)$3,145,305 
Exercise of common stock options, net of shares withheld for taxes71,537 1 (1,409)— — (1,408)
Issuance of common stock upon settlement of restricted stock awards, net of shares withheld for taxes1,792,087 17 (61)— — (44)
Issuance of common stock to fund the Company’s 2023 401(k) match
617,384 6 40,544 — — 40,550 
Stock-based compensation expense— — 60,370 — — 60,370 
Net loss— — — — (110,228)(110,228)
Other comprehensive loss
— — — (1,927)— (1,927)
Balance, March 31, 2024183,845,188 $1,839 $6,710,681 $(499)$(3,579,403)$3,132,618 
Exercise of common stock options, net of shares withheld for taxes8,184 1 42 — — 43 
Issuance of common stock upon settlement of restricted stock awards, net of shares withheld for taxes210,590 2 (6)— — (4)
Stock-based compensation expense— — 56,555 — — 56,555 
Purchase of employee stock purchase plan shares604,226 6 19,396 — — 19,402 
Net loss— — — — (15,808)(15,808)
Other comprehensive loss
— — — (444)— (444)
Balance, June 30, 2024184,668,188 $1,848 $6,786,668 $(943)$(3,595,211)$3,192,362 
Exercise of common stock options, net of shares withheld for taxes
79,871 1 2,131 — — 2,132 
Issuance of common stock upon settlement of restricted stock awards, net of shares withheld for taxes
306,701 3 (80)— — (77)
Stock-based compensation expense— — 48,757 — — 48,757 
Net loss
— — — — (38,236)(38,236)
Other comprehensive income
— — — 5,573 — 5,573 
Balance, September 30, 2024185,054,760 $1,852 6,837,476 $4,630 (3,633,447)$3,210,511 

6
EXACT SCIENCES CORPORATION
Condensed Consolidated Statements of Stockholders’ Equity
(Amounts in thousands, except share data - unaudited)
Common StockAdditional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated DeficitTotal Stockholders’ Equity
Number of Shares
$0.01
Par Value
Balance, January 1, 2023177,925,631 $1,780 $6,311,644 $(5,236)$(3,265,026)$3,043,162 
Exercise of common stock options, net of shares withheld for taxes88,228 1 963 — — 964 
Issuance of common stock upon settlement of restricted stock awards, net of shares withheld for taxes1,299,071 13 (13)— — — 
Issuance of common stock to fund the Company’s 2022 401(k) match517,215 5 35,072 — — 35,077 
Stock-based compensation expense— — 49,139 — — 49,139 
Net loss— — — — (74,151)(74,151)
Other comprehensive income
— — — 3,517 — 3,517 
Balance, March 31, 2023179,830,145 $1,799 $6,396,805 $(1,719)$(3,339,177)$3,057,708 
Exercise of common stock options, net of shares withheld for taxes
36,728 1 851 — — 852 
Issuance of common stock upon settlement of restricted stock awards, net of shares withheld for taxes134,002 1 (1)— — — 
Issuance of common stock to fund the Company’s 2022 401(k) match335 — 23 — — 23 
Stock-based compensation expense— — 61,725 — — 61,725 
Purchase of employee stock purchase plan shares544,453 5 16,339 — — 16,344 
Net loss— — — — (81,026)(81,026)
Other comprehensive income— — — 996 — 996 
Balance, June 30, 2023180,545,663 $1,806 $6,475,742 $(723)$(3,420,203)$3,056,622 
Exercise of common stock options, net of shares withheld for taxes
51,262 1 1,076 — — 1,077 
Issuance of common stock upon settlement of restricted stock awards, net of shares withheld for taxes
217,482 2 (2)— — — 
Stock-based compensation expense— — 61,871 — — 61,871 
Issuance of common stock for business combinations— — 1,675 — — 1,675 
Net income— — — — 794 794 
Other comprehensive loss
— — — (812)— (812)
Balance, September 30, 2023180,814,407 $1,809 $6,540,362 $(1,535)$(3,419,409)$3,121,227 
The accompanying notes are an integral part of these condensed consolidated financial statements.
7
EXACT SCIENCES CORPORATION
Condensed Consolidated Statements of Cash Flows
(Amounts in thousands - unaudited)
Nine Months Ended September 30,
20242023
Cash flows from operating activities:
Net loss$(164,272)$(154,383)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation90,655 83,587 
Loss on non-marketable and marketable equity securities
1,772 10,264 
Deferred tax expense
1,827 (279)
Stock-based compensation165,682 172,735 
Gain on settlements of convertible notes, net(10,254)(10,324)
Amortization of acquired intangible assets71,057 68,849 
Impairment of long-lived assets31,296 621 
Remeasurement of contingent consideration from sale of asset
(6,632)(68,900)
Remeasurement of contingent consideration liabilities(2,326)(13,051)
Non-cash lease expense20,645 20,918 
Other(1,437)3,530 
Changes in assets and liabilities:
Accounts receivable, net(61,410)(40,306)
Inventory, net(9,516)(13,074)
Operating lease liabilities(19,345)(19,741)
Accounts payable and accrued liabilities38,258 51,084 
Other assets6,358 (3,686)
Other liabilities11,115 (1,274)
Net cash provided by operating activities
163,473 86,570 
Cash flows from investing activities:
Purchases of marketable securities(405,385)(75,096)
Maturities and sales of marketable securities150,916 328,054 
Purchases of property, plant and equipment(99,673)(89,268)
Business combination, net of cash acquired— (50,000)
Asset acquisition, net of cash acquired
(45,000)— 
Purchases of non-marketable securities
(916)(6,290)
Sales of investments in non-marketable securities
— 9,296 
Other investing activities(225)(250)
Net cash provided by (used in) investing activities
(400,283)116,446 
Cash flows from financing activities:
Proceeds from exercise of common stock options, net of cash paid for taxes767 2,893 
Proceeds in connection with the Company’s employee stock purchase plan19,402 16,344 
Proceeds from issuance of convertible notes266,750 137,976 
Payments on accounts receivable securitization facility(50,000)— 
Other financing activities(15,544)(7,484)
Net cash provided by financing activities
221,375 149,729 
Effects of exchange rate changes on cash and cash equivalents427 (626)
Net increase (decrease) in cash, cash equivalents and restricted cash(15,008)352,119 
Cash, cash equivalents and restricted cash, beginning of period609,675 242,790 
Cash, cash equivalents and restricted cash, end of period$594,667 $594,909 


8
EXACT SCIENCES CORPORATION
Condensed Consolidated Statements of Cash Flows
(Amounts in thousands - unaudited)
Nine Months Ended September 30,
20242023
Supplemental disclosure of non-cash investing and financing activities
Property, plant and equipment acquired but not paid$11,904 $14,422 
Supplemental disclosure of cash flow information:
Interest paid$21,109 $18,176 
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents$588,830 $594,612 
Restricted cash — included in other long-term assets, net
5,837 297 
Total cash, cash equivalents and restricted cash$594,667 $594,909 
The accompanying notes are an integral part of these condensed consolidated financial statements.
9
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)

(1) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Business
Exact Sciences Corporation (together with its subsidiaries, “Exact,” or the “Company”) was incorporated in February 1995. A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype DX® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis.
Basis of Presentation and Principles of Consolidation
The accompanying condensed consolidated financial statements, which include the accounts of the Company and those of its wholly owned subsidiaries and variable interest entities, are unaudited and have been prepared on a basis substantially consistent with the Company’s audited financial statements and notes as of and for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K (the “2023 Form 10-K”). All intercompany transactions and balances have been eliminated upon consolidation. These condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted (“GAAP”) in the United States of America (“U.S.”) and follow the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting only of adjustments of a normal and recurring nature) considered necessary for a fair statement of its financial position, operating results and cash flows for the periods presented. The condensed consolidated balance sheet at December 31, 2023 has been derived from audited financial statements, but does not contain all of the footnote disclosures from the 2023 Form 10-K. The results of the Company’s operations for any interim period are not necessarily indicative of the results of the Company’s operations for any other interim period or for a full fiscal year. The statements should be read in conjunction with the audited financial statements and related notes included in the 2023 Form 10-K.
Use of Estimates
The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Critical accounting policies are those that affect the Company’s financial statements materially and involve difficult, subjective or complex judgments by management, and actual results could differ from those estimates. These estimates include revenue recognition, valuation of intangible assets and goodwill, contingent consideration, and accounting for income taxes. The Company’s critical accounting policies and estimates are explained further in the notes to the condensed consolidated financial statements in this Quarterly Report on Form 10-Q and the 2023 Form 10-K.
Significant Accounting Policies
During the nine months ended September 30, 2024, there were no changes to the Company’s significant accounting policies as described in the Company’s 2023 Form 10-K, except as described in the Recently Adopted Accounting Pronouncements sections below.
Recent Accounting Pronouncements
Recently Adopted Accounting Pronouncements
In March 2024, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2024-02: Codification Improvement – Amendments to Remove References to the Concepts Statements. This update amends the Accounting Standards Codification (“ASC”) to remove references to various FASB Concepts Statements. The Company early adopted and prospectively applied the amendments in this update during the first quarter of fiscal year 2024. There was no significant impact to the Company’s condensed consolidated financial statements.
10
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Recently Issued Accounting Pronouncements Not Yet Adopted
In October 2023, the FASB issued ASU No. 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative. This update modifies the disclosure or presentation requirements of a variety of topics in the ASC to conform with certain SEC amendments in Release No. 33-10532, Disclosure Update and Simplification. The amendments in this update should be applied prospectively, and the effective date for each amendment will be the date on which the SEC’s removal of that related disclosure from Regulation S-X or S-K becomes effective. However, if the SEC has not removed the related disclosure from its regulations by June 30, 2027, the amendments will be removed from the Codification and not become effective. Early adoption is prohibited. The Company is currently evaluating the potential impact of this guidance on its condensed consolidated financial statements.
In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This update improves reportable segment disclosure requirements, primarily through enhanced disclosures of significant segment expenses. The amendments in this update should be applied retrospectively to all prior periods presented in the consolidated financial statements and are effective for fiscal years beginning after December 31, 2023 and interim periods within fiscal years beginning after December 31, 2024. Early adoption is permitted. The Company is currently evaluating the potential impact of this guidance on its condensed consolidated financial statements.
In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvement to Income Tax Disclosures. This update improves income tax disclosure requirements, primarily through enhanced transparency and decision usefulness of disclosures. The amendments in this update should be applied prospectively with the option to apply retrospectively and are effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the potential impact of this guidance on its condensed consolidated financial statements.
Net Income (Loss) Per Share
Basic net income (loss) per common share (“EPS”) was determined by dividing net income (loss) applicable to common stockholders by the weighted average common shares outstanding during the period. Diluted EPS is based on shares that are outstanding per the calculation of basic EPS and on potentially dilutive shares.
The following is a reconciliation of the numerator and denominator used to calculate basic EPS and diluted EPS for the periods indicated:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2024202320242023
Net income (loss) available to common shareholders
$(38,236)$794 $(164,272)$(154,383)
Weighted average common shares outstanding - basic
184,795 180,649 183,823 179,817 
Effect of dilutive shares:
Restricted stock awards
— 2,153 — — 
Stock options
— 646 — — 
Employee stock purchase plan
— 589 — — 
Performance share units
— 38 — — 
Dilutive potential common shares
— 3,426 — — 
Weighted average common shares outstanding - diluted
184,795 184,075 183,823 179,817 
Earnings per common share from net earnings - basic
$(0.21)$0.00 $(0.89)$(0.86)
Earnings per common share from net earnings - diluted
$(0.21)$0.00 $(0.89)$(0.86)
11
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
The following potentially issuable common shares were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect due to net losses for each period:
Three Months Ended September 30,
Nine Months Ended September 30,
(In thousands)2024202320242023
Shares issuable upon conversion of convertible notes26,526 23,231 26,526 23,231 
Shares issuable upon the release of restricted stock awards7,487 — 7,487 6,423 
Shares issuable upon the release of performance share units2,037 — 2,037 1,584 
Shares issuable upon exercise of stock options1,028 — 1,028 1,305 
37,078 23,231 37,078 32,543 

(2) REVENUE
The Company’s revenue is primarily generated by its laboratory testing services utilizing its Cologuard and Oncotype® tests. The services are considered completed upon release of a patient’s test result to the ordering healthcare provider.
The following table presents the Company’s revenues disaggregated by revenue source:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2024202320242023
Screening
Medicare Parts B & C$201,423 $173,624 $570,550 $521,370 
Commercial289,637 253,401 827,509 732,182 
Other53,841 44,988 153,246 124,443 
Total Screening544,901 472,013 1,551,305 1,377,995 
Precision Oncology
Medicare Parts B & C$47,080 $46,383 $142,597 $141,352 
Commercial47,685 44,430 143,572 135,574 
International49,433 38,599 140,688 111,453 
Other19,556 26,913 67,281 80,552 
Total Precision Oncology163,754 156,325 494,138 468,931 
COVID-19 Testing$— $— $— $5,955 
Total$708,655 $628,338 $2,045,443 $1,852,881 
Screening revenue primarily includes laboratory service revenue from Cologuard and Prevention Genetics, LLC (“PreventionGenetics”) tests while Precision Oncology revenue primarily includes laboratory service revenue from global Oncotype DX and therapy selection tests.
At each reporting period end, the Company conducts an analysis of the estimates used to calculate the transaction price to determine whether any new information available impacts those estimates made in prior reporting periods. Adjustments to revenue recognized during the period relating to prior period estimates were less than 1% of revenue recorded in the Company’s condensed consolidated statement of operations for the three and nine months ended September 30, 2024. Adjustments to revenue recognized during the period relating to prior period estimates were less than 2% of revenue recorded in the Company’s condensed consolidated statement of operations for the three and nine months ended September 30, 2023.
The Company’s deferred revenue, which is reported in other current liabilities in the Company’s condensed consolidated balance sheets, was not significant as of September 30, 2024 and December 31, 2023.
Revenue recognized for the three and nine months ended September 30, 2024 and 2023 that was included in the deferred revenue balance at the beginning of the period was not significant.
12
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)

(3) MARKETABLE SECURITIES
The following table sets forth the Company’s cash, cash equivalents, and marketable securities at September 30, 2024 and December 31, 2023:
(In thousands)September 30, 2024December 31, 2023
Cash and cash equivalents
Cash and money market$582,741 $530,100 
Cash equivalents6,089 75,278 
Total cash and cash equivalents588,830 605,378 
Marketable securities
Available-for-sale debt securities$427,072 $168,425 
Equity securities5,229 3,841 
Total marketable securities432,301 172,266 
Total cash, cash equivalents and marketable securities$1,021,131 $777,644 
Available-for-sale debt securities, including the classification within the condensed consolidated balance sheet at September 30, 2024, consisted of the following:
(In thousands)Amortized Cost
Gains in Accumulated Other Comprehensive Income (1)
Losses in Accumulated Other Comprehensive Income (1)
Estimated Fair Value
Cash equivalents
U.S. government agency securities$6,089 $— $— $6,089 
Total cash equivalents6,089 — — 6,089 
Marketable securities
Corporate bonds$212,590 $2,039 $(14)$214,615 
U.S. government agency securities126,676 436 (19)127,093 
Asset backed securities84,977 441 (54)85,364 
Total marketable securities424,243 2,916 (87)427,072 
Total available-for-sale securities$430,332 $2,916 $(87)$433,161 
______________
(1)There was no tax impact from the gains and losses in accumulated other comprehensive income (“AOCI”).
13
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Available-for-sale debt securities, including the classification within the condensed consolidated balance sheet at December 31, 2023, consisted of the following:
(In thousands)Amortized Cost
Gains in Accumulated Other Comprehensive Income (1)
Losses in Accumulated Other Comprehensive Income (1)
Estimated Fair Value
Cash equivalents
Commercial paper$72,243 $— $— $72,243 
U.S. government agency securities3,035 — — 3,035 
Total cash equivalents75,278 — — 75,278 
Marketable securities
U.S. government agency securities$56,594 $166 $(44)$56,716 
Corporate bonds55,712 175 (59)55,828 
Asset backed securities35,081 65 (249)34,897 
Commercial paper
20,984 — — 20,984 
Total marketable securities168,371 406 (352)168,425 
Total available-for-sale securities$243,649 $406 $(352)$243,703 
______________
(1)There was no tax impact from the gains and losses in AOCI.
The following table summarizes contractual underlying maturities of the Company’s available-for-sale debt securities at September 30, 2024:
Due one year or lessDue after one year through five years
(In thousands)CostFair ValueCostFair Value
Cash equivalents
U.S. government agency securities$6,089 $6,089 $— $— 
Total cash equivalents6,089 6,089 — — 
Marketable securities
U.S. government agency securities$89,800 $90,048 $36,876 $37,045 
Corporate bonds51,706 51,890 160,884 162,725 
Asset backed securities11,388 11,448 73,589 73,916 
Total marketable securities152,894 153,386 271,349 273,686 
Total available-for-sale securities$158,983 $159,475 $271,349 $273,686 
The following table summarizes the gross unrealized losses and fair values of available-for-sale debt securities in an unrealized loss position as of September 30, 2024 aggregated by investment category and length of time those individual securities have been in a continuous unrealized loss position:
Less than one yearOne year or greaterTotal
(In thousands)Fair ValueGross Unrealized LossFair ValueGross Unrealized LossFair ValueGross Unrealized Loss
Marketable securities
Corporate bonds$9,501 $(13)$3,290 $(1)$12,791 $(14)
U.S. government agency securities8,551 (16)3,963 (3)12,514 (19)
Asset backed securities3,399 (3)3,986 (51)7,385 (54)
Total available-for-sale securities$21,451 $(32)$11,239 $(55)$32,690 $(87)
14
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
The Company evaluates investments that are in an unrealized loss position for impairment as a result of credit loss. It was determined that no credit losses exist as of September 30, 2024 and December 31, 2023 because the change in market value for those securities in an unrealized loss position resulted from fluctuating interest rates rather than a deterioration of the credit worthiness of the issuers.
The gains and losses recorded on available-for-sale debt securities and equity securities are included in investment income, net in the Company’s condensed consolidated statements of operations. The gains and losses recorded were not material for the three and nine months ended September 30, 2024 and 2023.

(4) INVENTORY
Inventory consisted of the following:
(In thousands)September 30, 2024December 31, 2023
Raw materials$54,714 $58,593 
Semi-finished and finished goods82,273 68,882 
Total inventory$136,987 $127,475 
(5) PROPERTY, PLANT AND EQUIPMENT
The carrying value and estimated useful lives of property, plant and equipment are as follows:
(In thousands)Estimated Useful LifeSeptember 30, 2024December 31, 2023
Property, plant and equipment
Landn/a$4,716 $4,716 
Leasehold and building improvements(1)227,600 214,562 
Land improvements15 years6,747 6,729 
Buildings
30 - 40 years
290,777 290,777 
Computer equipment and computer software3 years199,715 168,131 
Machinery and equipment
3 - 10 years
324,129 290,294 
Furniture and fixtures
3 - 10 years
36,976 35,756 
Assets under constructionn/a80,063 104,592 
Property, plant and equipment, at cost1,170,723 1,115,557 
Accumulated depreciation(480,391)(417,203)
Property, plant and equipment, net$690,332 $698,354 
______________
(1)Lesser of remaining lease term, building life, or estimated useful life.
Depreciation expense for the three months ended September 30, 2024 and 2023 was $30.3 million and $29.3 million, respectively. Depreciation expense for the nine months ended September 30, 2024 and 2023 was $90.7 million and $83.6 million, respectively.
At September 30, 2024, the Company had $80.1 million of assets under construction, which consisted of $52.3 million in machinery and equipment, $12.7 million in capitalized costs related to software projects, $10.0 million in leasehold and building improvements, $5.1 million related to buildings, and minimal furniture and fixtures. Depreciation will begin on these assets once they are placed into service upon completion.

15
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
(6) INTANGIBLE ASSETS AND GOODWILL
Intangible Assets
The following table summarizes the net-book-value and estimated remaining life of the Company’s intangible assets as of September 30, 2024:
(In thousands)Weighted Average Remaining Life (Years)CostAccumulated Amortization
Net Balance at September 30, 2024
Finite-lived intangible assets
Trade name11.0$104,000 $(33,340)$70,660 
Customer relationships6.34,000 (1,222)2,778 
Patents and licenses9.756,542 (11,811)44,731 
Acquired developed technology (1)6.6887,708 (391,478)496,230 
Total finite-lived intangible assets1,052,250 (437,851)614,399 
In-process research and developmentn/a1,250,000 — 1,250,000 
Total intangible assets$2,302,250 $(437,851)$1,864,399 
The following table summarizes the net-book-value and estimated remaining life of the Company’s intangible assets as of December 31, 2023:
(In thousands)Weighted Average Remaining Life (Years)CostAccumulated Amortization
Net Balance at December 31, 2023
Finite-lived intangible assets
Trade name11.6$104,000 $(27,903)$76,097 
Customer relationships7.04,000 (889)3,111 
Patents and licenses4.511,542 (9,600)1,942 
Acquired developed technology (1)7.3887,789 (328,543)559,246 
Total finite-lived intangible assets1,007,331 (366,935)640,396 
In-process research and developmentn/a1,250,000 — 1,250,000 
Total intangible assets$2,257,331 $(366,935)$1,890,396 
______________
(1)The gross carrying amount includes an insignificant foreign currency translation adjustment related to the intangible asset acquired as a result of the acquisition of OmicEra Diagnostics GmbH (“OmicEra”).
As of September 30, 2024, the estimated future amortization expense associated with the Company’s finite-lived intangible assets for each of the five succeeding fiscal years is as follows:
(In thousands)
2024 (remaining three months)$24,100 
202596,361 
202695,300 
202795,300 
202895,300 
Thereafter208,038 
$614,399 
16
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
The Company’s acquired intangible assets are being amortized on a straight-line basis over their estimated useful lives.
There were no impairment losses recorded on finite-lived intangible assets during the three and nine months ended September 30, 2024 and 2023. Updates to key assumptions used to calculate the fair value of the Company’s in-process research and development asset (“IPR&D”) could change the Company’s estimate that it will recover the carrying amount of the IPR&D asset in the near term.
Goodwill
The change in the carrying amount of goodwill for the periods ended September 30, 2024 and December 31, 2023 is as follows:
(In thousands)
Balance, January 1, 2023
$2,346,040 
Resolution Bioscience acquisition
20,692 
Effects of changes in foreign currency exchange rates (1)388 
Balance, December 31, 2023
2,367,120 
Resolution Bioscience acquisition adjustments225 
Effects of changes in foreign currency exchange rates (1)105 
Balance September 30, 2024
$2,367,450 
______________
(1)Represents the impact of foreign currency translation related to the goodwill acquired as a result of the acquisition of OmicEra.
There were no impairment losses for the three and nine months ended September 30, 2024 and 2023.

(7) FAIR VALUE MEASUREMENTS
The three levels of the fair value hierarchy established are as follows:
Level 1    Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2    Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
Level 3    Unobservable inputs that reflect the Company’s assumptions about the assumptions that market participants would use in pricing the asset or liability. Unobservable inputs shall be used to measure fair value to the extent that observable inputs are not available.
17
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
The following table presents the Company’s fair value measurements as of September 30, 2024 along with the level within the fair value hierarchy in which the fair value measurements, in their entirety, fall.
(In thousands)Fair Value at September 30, 2024Quoted Prices in Active Markets for Identical Assets (Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)
Cash, cash equivalents, and restricted cash
Cash and money market$582,741 $582,741 $— $— 
U.S. government agency securities6,089 — 6,089 — 
Restricted cash (1)
5,837 5,837 — — 
Marketable securities
Corporate bonds$214,615 $— $214,615 $— 
U.S. government agency securities127,093 — 127,093 — 
Asset backed securities85,364 — 85,364 — 
Equity securities5,229 5,229 — — 
Non-marketable securities$686 $— $— $686 
Liabilities
Contingent consideration$(283,231)$— $— $(283,231)
Total$744,423 $593,807 $433,161 $(282,545)
The following table presents the Company’s fair value measurements as of December 31, 2023 along with the level within the fair value hierarchy in which the fair value measurements, in their entirety, fall.
(In thousands)Fair Value at December 31, 2023Quoted Prices in Active Markets for Identical Assets (Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)
Cash, cash equivalents and restricted cash
Cash and money market$530,100 $530,100 $— $— 
Commercial paper72,243 — 72,243 — 
Restricted cash (1)
4,297 4,297 — — 
U.S. government agency securities3,035 — 3,035 — 
Marketable securities
U.S. government agency securities$56,716 $— $56,716 $— 
Corporate bonds55,828 — 55,828 — 
Asset backed securities34,897 — 34,897 — 
Commercial paper20,984 — 20,984 — 
Equity securities3,841 3,841 — — 
Non-marketable securities$7,650 $— $— $7,650 
Liabilities
Contingent consideration$(288,657)$— $— $(288,657)
Total$500,934 $538,238 $243,703 $(281,007)
_________________________________
(1)Restricted cash primarily represents cash held by a third-party financial institution as part of a cash collateral agreement related to the Company’s credit card program. The restrictions will lapse upon the termination of the agreements or the removal of the cash collateral requirement by the third-parties.
18
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
There have been no material changes in valuation techniques or transfers between fair value measurement levels during the three and nine months ended September 30, 2024. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities are valued using a third-party pricing agency where the valuation is based on observable inputs including pricing for similar assets and other observable market factors.
The Company has elected the fair value option under the income approach to measure certain Level 3 non-marketable securities. Gains and losses recorded on non-marketable securities are included in investment income, net in the condensed consolidated statement of operations. The following table provides a reconciliation of the beginning and ending balances of non-marketable securities valued using the fair value option:
(In thousands)Non-Marketable Securities
Beginning balance, January 1, 2024
$7,650 
Changes in fair value(714)
Settlement of non-marketable securities(6,250)
Ending balance, September 30, 2024
$686 
Contingent Consideration Liabilities
The fair value of the contingent consideration liabilities was $283.2 million and $288.7 million as of September 30, 2024 and December 31, 2023, respectively, of which $19.4 million was included in other current liabilities and $263.8 million was included in other long-term liabilities in the condensed consolidated balance sheet as of September 30, 2024. The contingent consideration liabilities were included in other long-term liabilities as of December 31, 2023.
The following table provides a reconciliation of the beginning and ending balances of contingent consideration:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2024202320242023
Beginning balance
$277,921 $302,141 $288,657 $306,927 
Changes in fair value (1)5,310 (8,364)(2,326)(13,051)
Payments (2)
— — (3,100)(99)
Ending balance
$283,231 $293,777 $283,231 $293,777 
______________
(1)The change in fair value of the contingent consideration liability is included in general and administrative expenses in the condensed consolidated statement of operations for the three and nine months ended September 30, 2024 and 2023.
(2)Payment was made in the second quarter of 2024 to settle the contingent consideration liability previously recorded related to the Company’s acquisition of OmicEra.
This fair value measurement of contingent consideration is categorized as a Level 3 liability, as the measurement amount is based primarily on significant inputs not observable in the market.
19
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
The fair value of the contingent consideration liabilities recorded from the Company’s acquisitions of Thrive Earlier Detection Corporation (“Thrive”), Ashion Analytics, LLC (“Ashion”), and OmicEra related to regulatory and product development milestones was $283.2 million and $288.7 million as of September 30, 2024 and December 31, 2023, respectively. The Company estimates the fair value of the contingent consideration liabilities related to the regulatory and product development milestones using the probability-weighted scenario based discounted cash flow model, which is consistent with the initial measurement of the contingent consideration liabilities. Probabilities of success are applied to each potential scenario and the resulting values are discounted using a present-value factor. The passage of time in addition to changes in projected milestone achievement timing, present-value factor, the degree of achievement, if applicable, and probabilities of success may result in adjustments to the fair value measurement. The fair value of the contingent consideration liability recorded related to regulatory and product development milestones was determined using a weighted average probability of success of 90% and 89% as of September 30, 2024 and December 31, 2023, respectively, and a weighted average present-value factor of 6.0% and 5.8% as of September 30, 2024 and December 31, 2023, respectively. The projected fiscal year of payment range is from 2025 to 2031. Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities.
The revenue milestone associated with the Ashion acquisition is not expected to be achieved and therefore no liability has been recorded for this milestone.
Non-Marketable Equity Securities
Non-marketable equity securities without readily determinable fair values, which are classified as a component of other long-term assets, net, had the following cumulative upward and downward adjustments and aggregate carrying amounts:
(In thousands)
September 30, 2024September 30, 2023
Cumulative upward adjustments (1)
$5,102 $779 
Cumulative downward adjustments and impairments (2)
15,071 15,071 
Aggregate carrying value (3)
52,227 31,654 
_________________________________
(1)    There were no material upward adjustments recorded on non-marketable equity securities held for the three and nine months ended September 30, 2024 and 2023.
(2)    There were no material downward adjustments or impairments recorded on non-marketable equity securities held for the three and nine months ended September 30, 2024 and 2023, respectively.
(3)    The aggregate carrying value of non-marketable equity securities was $46.0 million as of December 31, 2023.
There were no material realized gains or losses recorded during the three and nine months ended September 30, 2024 and 2023.
The Company has committed capital to venture capital investment funds of $18.0 million, of which $11.7 million remains callable through 2033 as of September 30, 2024. The aggregate carrying amount of these funds, which are classified as a component of other long-term assets, net in the Company’s condensed consolidated balance sheets, was $6.7 million and $5.2 million as of September 30, 2024 and December 31, 2023, respectively.
Derivative Financial Instruments
The Company enters into foreign currency forward contracts on the last day of each month to mitigate the impact of adverse movements in foreign exchange rates related to the remeasurement of monetary assets and liabilities and hedge the Company’s foreign currency exchange rate exposure. As of September 30, 2024 and December 31, 2023 the Company had open foreign currency forward contracts with notional amounts of $47.7 million and $39.5 million, respectively. The Company's foreign exchange derivative instruments are classified as Level 2 within the fair value hierarchy as they are valued using inputs that are observable in the market or can be derived principally from or corroborated by observable market data. The fair value of the open foreign currency forward contracts was zero at September 30, 2024 and December 31, 2023 and there were no gains or losses recorded to adjust the fair value of the open foreign currency contract held as of September 30, 2024. The contracts are closed subsequent to each month-end, and the gains and losses recorded from the contracts were not significant for the three and nine months ended September 30, 2024 and 2023.
20
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)

(8) LONG-TERM DEBT
Accounts Receivable Securitization Facility
On June 29, 2022, the Company, through a wholly-owned special purpose entity, Exact Receivables LLC (“Exact Receivables”) entered into an accounts receivable securitization program (the “Securitization Facility”) with PNC Bank, National Association (“PNC”), with a scheduled maturity date of June 29, 2024. The Securitization Facility required the Company to maintain minimum borrowings under the facility of $50.0 million. Upon the maturity of the Securitization Facility in June 2024, the Company repaid the previously outstanding balance of $50.0 million in full. The Securitization Facility provided Exact Receivables with a revolving line-of-credit of up to $150.0 million of borrowing capacity, subject to certain borrowing base requirements, by collateralizing a security interest in the domestic customer accounts receivable of certain wholly-owned subsidiaries of the Company. The amount available under the Securitization Facility fluctuated over time based on the total amount of eligible customer accounts receivable generated by the Company during the normal course of operations. The debt issuance costs incurred related to the Securitization Facility were not significant and were amortized over the life of the Securitization Facility through interest expense within the condensed consolidated statements of operations.
In connection with the Securitization Facility, the Company also entered into two Receivables Purchase Agreements (“Receivable Purchase Agreements”) on June 29, 2022. The Receivable Purchase Agreements were among the Company and certain wholly-owned subsidiaries of the Company, and between the Company and Exact Receivables. Under the agreements, the wholly-owned subsidiaries sold all of their right, title and interest in their accounts receivables to Exact Receivables. The receivables were used to collateralize borrowings made under the Securitization Facility. The Company retained the responsibility of servicing the accounts receivable balances pledged as collateral under the Securitization Facility and provided a performance guaranty.
As of December 31, 2023, the Company had an outstanding balance of $50.0 million, which was included in debt, current portion on the Company’s condensed consolidated balance sheet. Prior to the repayment, the outstanding balance accrued interest at a rate equal to a daily secured overnight financing rate (“SOFR”) plus a SOFR adjustment and an applicable margin. The interest rate was 6.89% as of the maturity date.
Revolving Loan Agreement
During November 2021, the Company entered into a revolving loan agreement (the “Revolving Loan Agreement”) with PNC. The Revolving Loan Agreement provides the Company with a revolving line of credit of up to $150.0 million (the “Revolver”). The Revolver is collateralized by the Company’s marketable securities held by PNC, which must continue to maintain a minimum market value of $150.0 million. The Revolver is available for general working capital purposes and all other lawful corporate purposes. In addition, the Company may request, in lieu of cash advances, letters of credit with an aggregate stated amount outstanding not to exceed $20.0 million. The availability of advances under the line of credit will be reduced by the stated amount of each letter of credit issued and outstanding.
Borrowings under the Revolving Loan Agreement accrue interest at an annual rate equal to the sum of the daily Bloomberg Short-Term Bank Yield Index Rate plus the applicable margin of 0.60%. Loans under the Revolving Loan Agreement may be prepaid at any time without penalty. In October 2022, the Revolving Loan Agreement was amended to extend the maturity date from November 5, 2023 to November 5, 2025. There were no other amendments to the Revolver.
The Company has agreed to various financial covenants under the Revolving Loan Agreement, and as of September 30, 2024, the Company is in compliance with all covenants.
In December 2021 and January 2023, PNC issued letters of credit of $2.9 million and $1.5 million, respectively, which reduced the amount available for cash advances under the line of credit to $145.6 million as of September 30, 2024 and December 31, 2023. As of September 30, 2024 and December 31, 2023, the Company has not drawn funds from, nor are any amounts outstanding under, the Revolving Loan Agreement.

21
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
(9) CONVERTIBLE NOTES
Convertible note obligations included in the condensed consolidated balance sheet consisted of the following as of September 30, 2024:
Fair Value (1)
(In thousands)Principal AmountUnamortized Debt Discount and Issuance CostsNet Carrying AmountAmountLeveling
2031 Convertible Notes - 1.750%
$620,709 $(14,090)$606,619 $623,558 2
2030 Convertible Notes - 2.000%
572,993 (3,820)569,173 652,244 2
2028 Convertible Notes - 0.375%
589,380 (5,346)584,034 546,650 2
2027 Convertible Notes - 0.375%
563,822 (4,158)559,664 547,668 2
2025 Convertible Notes - 1.000% (2)
249,172 (134)249,038 254,155 2
Convertible note obligations included in the condensed consolidated balance sheet consisted of the following as of December 31, 2023:
Fair Value (1)
(In thousands)Principal AmountUnamortized Debt Discount and Issuance CostsNet Carrying AmountAmountLeveling
2030 Convertible Notes - 2.000%
$572,993 $(4,349)$568,644 $684,475 2
2028 Convertible Notes - 0.375%
949,042 (10,499)938,543 887,354 2
2027 Convertible Notes - 0.375%
563,822 (5,429)558,393 549,839 2
2025 Convertible Notes - 1.000%
249,172 (476)248,696 293,300 2
______________
(1)The fair values are based on observable market prices for this debt, which is traded in less active markets and therefore is classified as a Level 2 fair value measurement.
(2)The Company’s convertible notes due in 2025 (the “2025 Notes”) mature on January 15, 2025 and are included in convertible notes, net, current portion on the condensed consolidated balance sheet as of September 30, 2024. The 2025 Notes were included in convertible notes, net, less current portion as of December 31, 2023.
Issuances and Settlements
In February 2023, the Company entered into a privately negotiated exchange and purchase agreement with a single holder of certain of the Company’s convertible notes due in 2027 (the “2027 Notes”) and 2028 (the “2028 Notes”). The Company issued the holder $500.0 million aggregate principal amount of 2.0% Convertible Notes due in 2030 (the “2030 Notes”) in exchange for $183.7 million of aggregate principal of 2027 Notes, $201.0 million of aggregate principal of 2028 Notes, and $138.0 million of cash. The extinguishment resulted in a gain on settlement of convertible notes of $17.7 million, which is included in interest expense in the condensed consolidated statement of operations for the nine months ended September 30, 2023. The gain represents the difference between (i) the fair value of the consideration transferred and (ii) the carrying value of the debt at the time of exchange.
In March 2023, the Company entered into a privately negotiated exchange agreement with two holders of certain of the 2025 Notes. The Company issued the holder $73.0 million aggregate principal amount of 2030 Notes in exchange for $65.8 million of aggregate principal of 2025 Notes. The extinguishment resulted in a loss on settlement of convertible notes of $7.4 million, which is included in interest expense in the condensed consolidated statement of operations for the nine months ended September 30, 2023. The loss represents the difference between (i) the fair value of the consideration transferred and (ii) the carrying value of the debt at the time of exchange.
22
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
The net proceeds from the issuance of the 2030 Notes were approximately $133.0 million, after deducting commissions and offering expenses payable by the Company.
The 2030 Notes will mature on March 1, 2030 and bear interest at a rate of 2.0% per year, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2023.
In April 2024, the Company entered into a privately negotiated exchange and purchase agreement with certain holders of the Company’s 2028 Notes. The Company issued $620.7 million aggregate principal amount of 1.75% Convertible Notes due in 2031 (the “2031 Notes” and, collectively with the 2025 Notes, 2027 Notes, 2028 Notes, and 2030 Notes, the “Notes”) in exchange for $359.7 million of aggregate principal of 2028 Notes, and $266.8 million of cash after deducting underwriting discounts. The extinguishment resulted in a gain on settlement of convertible notes of $10.3 million, which is included in interest expense in the condensed consolidated statement of operations for the nine months ended September 30, 2024. The gain represents the difference between (i) the fair value of the consideration transferred and (ii) the carrying value of the debt at the time of exchange.
The net proceeds from the issuance of the 2031 Notes were approximately $259.8 million, after deducting commissions and offering expenses payable by the Company.
The 2031 Notes will mature on April 15, 2031 and bear interest at a rate of 1.75% per year, payable semi-annually in arrears on October 15 and April 15 of each year, beginning on October 15, 2024. The Company has the ability to repurchase the 2031 Notes after April 17, 2029 upon the occurrence of certain events and during certain periods, as set forth in the Indenture filed at the time of the offering.
Summary of Conversion Features
Until the six-months immediately preceding the maturity date of the applicable series of the Company’s convertible notes, each series of Notes is convertible only upon the occurrence of certain events and during certain periods, as set forth in the Indentures filed at the time of the original offerings. On or after the date that is six-months immediately preceding the maturity date of the applicable series of Notes until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may elect to convert such Notes at any time, and if elected, the conversion would occur on the maturity date. The Notes will be convertible into cash, shares of the Company’s common stock (plus, if applicable, cash in lieu of any fractional share), or a combination of cash and shares of the Company’s common stock, at the Company’s election. If the Notes are not converted prior to the maturity date, the principal amount will be settled in cash upon maturity.
It is the Company’s intent to settle all conversions through combination settlement. The initial conversion rate is 13.26, 8.96, 8.21, 12.37, and 10.06 shares of common stock per $1,000 principal amount for the 2025 Notes, 2027 Notes, 2028 Notes, 2030 Notes, and 2031 Notes, respectively, which is equivalent to an initial conversion price of approximately $75.43, $111.66, $121.84, $80.83, and $99.36 per share of the Company’s common stock for the 2025 Notes, 2027 Notes, 2028 Notes, 2030 Notes, and 2031 Notes, respectively. The 2025 Notes, 2027 Notes, 2028 Notes, 2030 Notes, and 2031 Notes are potentially convertible into up to 3.3 million, 5.0 million, 4.8 million, 7.1 million, and 6.2 million shares, respectively. The conversion rate is subject to adjustment upon the occurrence of certain specified events as set forth in the Indentures filed at the time of the original offerings but will not be adjusted for accrued and unpaid interest. In addition, holders of the Notes who convert their Notes in connection with a “make-whole fundamental change” (as defined in the Indentures), will, under certain circumstances, be entitled to an increase in the conversion rate.
If the Company undergoes a “fundamental change” (as defined in the Indentures), holders of the Notes may require the Company to repurchase for cash all or part of their Notes at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest.
Based on the closing price of the Company’s common stock of $68.12 on September 30, 2024, the if-converted values on the Notes do not exceed the principal amount.
The Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness, or the issuance or repurchase of securities by the Company.
23
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Ranking of Convertible Notes
The Notes are the Company’s senior unsecured obligations and (i) rank senior in right of payment to all of its future indebtedness that is expressly subordinated in right of payment to the Notes; (ii) rank equal in right of payment to each outstanding series thereof and to all of the Company’s future liabilities that are not so subordinated, unsecured indebtedness; (iii) are effectively junior to all of the Company’s existing and future secured indebtedness and other secured obligations, to the extent of the value of the assets securing that indebtedness and other secured obligations; and (iv) are structurally subordinated to all indebtedness and other liabilities of the Company’s subsidiaries.
Issuance Costs
Issuance costs are amortized to interest expense over the term of the Notes. The following table summarizes the original issuance costs at the time of issuance for each set of Notes:
(In thousands)
2031 Convertible Notes
$6,820 
2030 Convertible Notes4,938 
2028 Convertible Notes24,453 
2027 Convertible Notes14,285 
2025 Convertible Notes17,646 
Interest Expense
Interest expense on the Notes includes the following:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2024202320242023
Debt issuance costs amortization$1,334 $1,329 $3,965 $4,021 
Debt discount amortization322 25 611 81 
Gain on settlements of convertible notes— — (10,254)(10,324)
Coupon interest expense7,285 4,906 19,054 13,166 
Total interest expense (income) on convertible notes$8,941 $6,260 $13,376 $6,944 
The following table summarizes the effective interest rates of the Notes:
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
2031 Convertible Notes
2.10 %— %2.06 %— %
2030 Convertible Notes2.12 %2.12 %2.09 %2.09 %
2028 Convertible Notes0.64 %0.64 %0.63 %0.63 %
2027 Convertible Notes0.68 %0.68 %0.67 %0.67 %
2025 Convertible Notes1.18 %1.18 %1.17 %1.17 %
The remaining period over which the unamortized debt discount will be recognized as non-cash interest expense is 0.29, 2.45, 3.42, 5.42, and 6.54 years for the 2025 Notes, 2027 Notes, 2028 Notes, 2030 Notes, and 2031 Notes, respectively.

24
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
(10) LICENSE AND COLLABORATION AGREEMENTS
The Company licenses certain technologies that are, or may be, incorporated into its technology under several license agreements, as well as the rights to commercialize certain diagnostic tests through collaboration agreements. Generally, the license agreements require the Company to pay single-digit royalties based on net revenues received using the technologies and may require minimum royalty amounts, milestone payments, or maintenance fees.
Mayo Foundation for Medical Education and Research
In June 2009, the Company entered into an exclusive, worldwide license agreement with the Mayo Foundation for Medical Education and Research (“Mayo”), under which Mayo granted the Company an exclusive, worldwide license to certain Mayo patents and patent applications, as well as a non-exclusive, worldwide license with regard to certain Mayo know-how. The scope of the license covers any screening, surveillance or diagnostic test or tool for use in connection with any type of cancer, pre-cancer, disease or condition. The Company’s license agreement with Mayo was most recently amended and restated in September 2020.
The licensed Mayo patents and patent applications contain both method and composition claims that relate to sample processing, analytical testing and data analysis associated with nucleic acid screening for cancers and other diseases. The jurisdictions covered by these patents and patent applications include the U.S., Australia, Canada, the European Union, China, Japan and Korea. Under the license agreement, the Company assumed the obligation and expense of prosecuting and maintaining the licensed Mayo patents and is obligated to make commercially reasonable efforts to bring to market products using the licensed Mayo intellectual property.
Pursuant to the Company’s agreement with Mayo, the Company is required to pay Mayo a low-single-digit royalty on the Company’s net sales of current and future products using the licensed Mayo intellectual property each year during the term of the Mayo agreement.
The Company is also required to pay Mayo up to $3.0 million in sales-based milestone payments upon cumulative net sales of each product using the licensed Mayo intellectual property reaching specified levels.
The license agreement will remain in effect, unless earlier terminated by the parties in accordance with the agreement, until the last of the licensed patents expires in 2039 (or later, if certain licensed patent applications are issued). However, if the Company is still using the licensed Mayo know-how or certain Mayo-provided biological specimens or their derivatives on such expiration date, the term shall continue until the earlier of the date the Company stops using such know-how and materials and the date that is five years after the last licensed patent expires. The license agreement contains customary termination provisions and permits Mayo to terminate the license agreement if the Company sues Mayo or its affiliates, other than any such suit claiming an uncured material breach by Mayo of the license agreement.
In addition to granting the Company a license to the covered Mayo intellectual property, Mayo provides the Company with product development and research and development assistance pursuant to the license agreement and other collaborative arrangements. In September 2020, Mayo also agreed to make available certain personnel to provide such assistance through January 2025. In connection with this collaboration, the Company has incurred insignificant charges for the three months ended September 30, 2024 and 2023, respectively. The charges incurred in connection with this collaboration are recorded in research and development expenses in the Company’s condensed consolidated statements of operations.
Johns Hopkins University
Through the acquisition of Thrive, the Company acquired a worldwide exclusive license agreement with Johns Hopkins University (“JHU”) for use of several JHU patents and licensed know-how. The license is designed to enable the Company to leverage JHU intellectual property in the development and commercialization of a blood-based, multi-cancer screening test. The agreement terms would require the Company to pay single-digit sales-based royalties and up to $45.0 million in sales-based milestone payments for each JHU licensed product that reaches specified net sales levels. The Company will record the sales-based royalties once sales of licensed products have occurred and sales-based milestones once achievement is deemed probable. The Company has not incurred charges related to the achievement of any sales-based royalties or sales-based milestones as of September 30, 2024.
25
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Targeted Digital Sequencing (“TARDIS”) License Agreement
In January 2021, the Company entered into an exclusive, worldwide license to the proprietary TARDIS technology from The Translational Genomics Research Institute (“TGen”). Under the agreement, the Company acquired a royalty-free, worldwide exclusive license to proprietary TARDIS patents and know-how. Under the agreement, the Company was obligated to make milestone payments to TGen of up to $45.0 million in sales-based milestone payments upon cumulative net sales related to molecular residual disease (“MRD”) detection and/or treatment reaching specified levels. These payments were contingent upon achievement of these cumulative revenues on or before December 31, 2030, which was not achieved prior to the termination.
Effective May 1, 2024, the Company entered into termination agreements (the “Termination Agreements”) with TGen for the purpose of terminating the license and sponsored research agreement relating to the TARDIS technology and an additional sponsored research agreement with a broader scope (collectively, the “Original Agreements”). As part of the Termination Agreements, the Company will pay TGen $27.6 million in compensation for the termination of the Original Agreements, which will be allocated into three annual installments of $9.2 million per year beginning in the second quarter of 2024. The fair value of the termination payments as of the date of the Termination Agreements was $25.8 million, which was recorded as research and development expense in the condensed consolidated statement of operations in the second quarter of 2024. The remaining $1.8 million in expense is being recognized ratably through the date of the final payment in the second quarter of 2026. The Company has recorded a liability of $17.1 million representing the fair value of the remaining payments, of which $8.8 million is included in accrued liabilities and $8.3 million is included in other long-term liabilities on the condensed consolidated balance sheet as of September 30, 2024. The termination payments eliminate the Company’s obligation to pay TGen any further payments, equities, fees, costs, or other amounts that would have been due under the Original Agreements, including the milestone payments. The Company’s ongoing development efforts for its pipeline tests are not impacted by the Termination Agreements.
Broad Institute, Inc.
In June 2023, the Company entered into an exclusive license agreement with Broad Institute, Inc. (“Broad Institute”) to utilize the Minor Allele Enriched Sequencing Through Recognition Oligonucleotides (“MAESTRO”) technology in the Company’s MRD testing. Under the license agreement, the Company is obligated to make development milestone payments to Broad Institute of up to $6.5 million upon achievement of certain development milestones related to prospective MRD tests that use the MAESTRO technology. In addition, the Company is obligated to make sales-based milestone payments to Broad Institute that equate up to a mid-single-digit royalty upon the achievement of certain cumulative net sales targets of licensed products using the MAESTRO technology beginning at $500.0 million. The Company will record the development milestones once achieved and the sales milestones once achievement is deemed probable. The Company has not incurred charges related to the achievement of development milestones or sales milestones as of September 30, 2024.
Watchmaker Genomics, Inc.
In July 2023, the Company entered into a co-exclusive development and license agreement with Watchmaker Genomics, Inc. (“Watchmaker”) under which the Company granted Watchmaker a co-exclusive license to the non-bisulfite technology for the detection of methylated DNA and other epigenetic modifications (“TAPS”). TAPS is based on patents obtained by the Company through an exclusive license agreement with the Ludwig Institute for Cancer Research. Under the agreement, both parties have the right to use and develop TAPS for commercial purposes. The Company has the potential to receive up to $82.0 million in sales-based milestone payments and mid-single-digit royalties based on future Watchmaker net sales of licensed products including TAPS. Additionally, Watchmaker has the right to sublicense TAPS, and the Company has the potential to receive royalties based on future Watchmaker sublicense receipts.
26
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
TwinStrand Biosciences, Inc.
On July 1, 2024, the Company entered into an agreement with TwinStrand Biosciences, Inc. (“TwinStrand”), under which TwinStrand licensed to the Company intellectual property related to the error correction technology in next-generation sequencing. The Company’s rights are broadly exclusive with respect to cell-free nucleic acid sequencing, subject to certain non-exclusive relationships in the field. Under the license agreement, the Company made upfront payments to TwinStrand totaling $45.0 million in July 2024. The upfront payments were capitalized as a patent and license intangible asset in the condensed consolidated balance sheet, which is amortized through amortization of acquired intangible assets in the condensed consolidated statement of operations over its estimated useful life of 10 years. In addition, the Company agreed to pay TwinStrand a low-single-digit royalty on the Company’s net sales of certain licensed products and services. The Company will record the sales-based royalties once sales using relevant licensed products and services have occurred. The Company has not incurred charges related to the sales-based royalties as of September 30, 2024.

(11) STOCKHOLDERS’ EQUITY
Changes in Accumulated Other Comprehensive Income
The amounts recognized in AOCI for the nine months ended September 30, 2024 were as follows:
(In thousands)Cumulative Translation Adjustment
Unrealized Gain on Securities (1)
AOCI
Balance at December 31, 2023$1,374 $54 $1,428 
Other comprehensive loss before reclassifications
427 2,723 3,150 
Amounts reclassified from accumulated other comprehensive income
— 52 52 
Net current period change in accumulated other comprehensive income
427 2,775 3,202 
Balance at September 30, 2024$1,801 $2,829 $4,630 
______________
(1)There was no tax impact from the amounts recognized in AOCI for the three and nine months ended September 30, 2024.
The amounts recognized in AOCI for the nine months ended September 30, 2023 were as follows:
(In thousands)Cumulative Translation AdjustmentUnrealized Gain (Loss) on Securities (1)
AOCI
Balance at December 31, 2022$53 $(5,289)$(5,236)
Other comprehensive income before reclassifications
(626)748 122 
Amounts reclassified from accumulated other comprehensive income
— 3,579 3,579 
Net current period change in accumulated other comprehensive income
(626)4,327 3,701 
Balance at September 30, 2023$(573)$(962)$(1,535)
______________
(1)There was no tax impact from the amounts recognized in AOCI for the nine months ended September 30, 2023.
Amounts reclassified from AOCI for the nine months ended September 30, 2024 and 2023 were as follows:
Affected Line Item in the
Statements of Operations		Nine Months Ended September 30,
Details about AOCI Components (In thousands)20242023
Change in value of available-for-sale investments
Sales and maturities of available-for-sale investments
Investment income, net
$52 $3,579 
Total reclassifications$52 $3,579 

27
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
(12) STOCK-BASED COMPENSATION
Stock-Based Compensation Plans
The Company maintains the following plans for which awards were granted from or had awards outstanding in 2023: the 2010 Omnibus Long-Term Incentive Plan (as Amended and Restated effective July 27, 2017), the 2019 Omnibus Long-Term Incentive Plan, and the 2010 Employee Stock Purchase Plan. These plans are collectively referred to as the “Stock Plans” and are administered in conjunction with the Company’s Equity Award Death, Disability and Retirement Policy, which was adopted in February 2023. Refer to the Company’s 2023 Form 10-K for further information regarding this policy.
Stock-Based Compensation Expense
The Company records stock-based compensation expense in connection with the amortization of restricted stock and restricted stock unit awards (“RSUs”), performance share units (“PSUs”), stock purchase rights granted under the Company’s employee stock purchase plan (“ESPP”) and stock options granted to employees, non-employee consultants and non-employee directors. The Company recorded $48.8 million and $61.9 million in stock-based compensation expense during the three months ended September 30, 2024 and 2023, respectively. The Company recorded $165.7 million and $172.7 million in stock-based compensation expense during the nine months ended September 30, 2024 and 2023, respectively.
As of September 30, 2024, there was approximately $383.8 million of expected total unrecognized compensation cost related to non-vested stock-based compensation arrangements granted under all equity compensation plans. The Company expects to recognize that cost over a weighted average period of 2.6 years.
Stock Options
A summary of stock option activity under the Stock Plans is as follows:
Option SharesWeighted Average Exercise PriceWeighted Average Remaining Contractual Term (Years)Aggregate Intrinsic Value (1)
(Aggregate intrinsic value in thousands)
Outstanding, January 1, 20241,286,173 $47.67 3.8
Exercised(221,374)19.50 
Forfeited(36,575)91.37 
Outstanding, September 30, 20241,028,224 $52.18 3.3$26,970 
Vested and expected to vest, September 30, 2024
1,028,224 $52.18 3.3$26,970 
Exercisable, September 30, 20241,028,224 $52.18 3.3$26,970 
______________
(1)The total intrinsic value of options exercised, net of shares withheld for taxes, during the nine months ended September 30, 2024 and 2023 was $6.2 million and $10.6 million, respectively, determined as of the date of exercise.
Restricted Stock and Restricted Stock Units
The fair value of restricted stock and RSUs is determined on the date of grant using the closing stock price on that day.
28
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
A summary of restricted stock and RSU activity during the nine months ended September 30, 2024 is as follows:
Restricted SharesWeighted Average Grant Date Fair Value (1)
Outstanding, January 1, 20246,272,763 $73.39 
Granted4,227,223 56.67 
Released (2)(2,232,590)77.62 
Forfeited(780,430)61.93 
Outstanding, September 30, 20247,486,966 $63.07 
______________
(1)The weighted average grant date fair value of the RSUs granted during the nine months ended September 30, 2023 was $62.28.
(2)The fair value of RSUs vested and converted to shares of the Company’s common stock was $173.3 million and $146.7 million during the nine months ended September 30, 2024 and 2023, respectively.
Performance Share Units
The Company has issued performance-based equity awards to certain employees which vest upon the achievement of certain performance goals, including financial performance targets and operational milestones.
A summary of PSU activity during the nine months ended September 30, 2024 is as follows:
Performance Share Units (1)Weighted Average Grant Date Fair Value (2)
Outstanding, January 1, 20241,597,801 $92.73 
Granted913,533 63.68 
Released (3)(70,662)140.20 
Forfeited(403,454)92.47 
Outstanding, September 30, 20242,037,218 $75.47 
______________
(1)The PSUs listed above assumes attainment of maximum payout rates as set forth in the performance criteria. Applying actual or expected payout rates, the number of outstanding PSUs as of September 30, 2024 was 820,015.
(2)The weighted average grant date fair value of the PSUs granted during the nine months ended September 30, 2023 was $79.11.
(3)The fair value of PSUs vested and converted to shares of the Company’s common stock was $9.9 million and $1.0 million for the nine months ended September 30, 2024 and 2023, respectively.
Employee Stock Purchase Plan
The fair value of shares purchased during the three and nine months ended September 30, 2024 and 2023 under the ESPP is based on the assumptions in the following table:
29
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
ESPP Shares
Risk-free interest rates
(1)
(1)
4.71% - 5.30%
4.68%
Expected term (in years)
(1)
(1)
1.171.25
Expected volatility
(1)
(1)
55.67% - 63.13%
67.30%
Dividend yield
(1)
(1)
—%—%
______________
(1)The Company did not issue stock purchase rights under its 2010 Employee Stock Purchase Plan during the period indicated.
(13) COMMITMENTS AND CONTINGENCIES
Leases
Supplemental disclosure of cash flow information related to the Company’s cash and non-cash activities with its leases are as follows:
Nine Months Ended September 30,
(In thousands)20242023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$28,658$29,212
Operating cash flows from finance leases991559
Finance cash flows from finance leases4,8902,545
Non-cash investing and financing activities:
Right-of-use assets obtained in exchange for new operating lease liabilities
$17,860$2,097
Right-of-use assets obtained in exchange for new finance lease liabilities15,9954,940
Weighted-average remaining lease term - operating leases (in years)7.587.00
Weighted-average remaining lease term - finance leases (in years)3.082.99
Weighted-average discount rate - operating leases6.55 %6.50 %
Weighted-average discount rate - finance leases6.71 %7.32 %
As of September 30, 2024 and December 31, 2023, the Company’s right-of-use assets from operating leases are $122.5 million and $143.7 million, respectively, which are reported in operating lease right-of-use assets in the Company’s condensed consolidated balance sheets. As of September 30, 2024, the Company has outstanding operating lease obligations of $189.9 million, of which $27.2 million is reported in operating lease liabilities, current portion and $162.7 million is reported in operating lease liabilities, less current portion in the Company’s condensed consolidated balance sheets. As of December 31, 2023, the Company had outstanding operating lease obligations of $190.4 million, of which $29.4 million is reported in operating lease liabilities, current portion and $161.1 million is reported in operating lease liabilities, less current portion in the Company’s condensed consolidated balance sheets.
In the third quarter of 2024, the Company recorded an impairment charge of $18.7 million, which consisted of a right-of-use asset of $11.8 million and associated leasehold improvements of $6.9 million relating to one of its domestic facilities that will be vacated in the fourth quarter of 2024 as a result of a change in strategic priorities. The Company used the income approach, under which the recoverability of the assets was measured by comparing the carrying amount of the asset to future undiscounted, pre-tax cash flows generated by the assets held. The fair value of the assets was determined using discounted cash flows, and the impairment charge recorded represents the difference between the carrying value and fair value of the impaired assets. The impairment charge recorded is included in impairment of long-lived assets in the Company’s condensed consolidated statement of operations for the three and nine months ended September 30, 2024.
30
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
As of September 30, 2024 and December 31, 2023, the Company’s right-of-use assets from finance leases are $21.6 million and $11.3 million, respectively, which are reported in other long-term assets, net in the Company’s condensed consolidated balance sheets. As of September 30, 2024, the Company has outstanding finance lease obligations of $22.7 million, of which $7.9 million is reported in other current liabilities and $14.8 million is reported in other long-term liabilities in the Company’s condensed consolidated balance sheets. As of December 31, 2023, the Company had outstanding finance lease obligations of $11.9 million, of which $4.4 million is reported in other current liabilities and $7.5 million is reported in other long-term liabilities in the Company’s condensed consolidated balance sheets.

Legal Matters
In addition to commitments and obligations incurred in the ordinary course of business, from time to time the Company may be subject to a variety of claims and legal proceedings, including legal actions for damages, governmental investigations and other matters. The Company has also instituted, and may in the future institute, additional legal proceedings to enforce its rights and seek remedies, such as monetary damages, injunctive relief and declaratory relief.
The Company accrues costs for certain legal proceedings and regulatory matters to the extent that it determines an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. While such accrued costs reflect the Company’s best estimate of the probable loss for such matters, the recorded amounts may differ materially from the actual amount of any such losses. In some cases, no estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made because of the inherently unpredictable nature of legal and regulatory proceedings, which may be exacerbated by various factors, including but not limited to, that they may involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or legal uncertainties; involve disputed facts; represent a shift in regulatory policy; involve a large number of parties, claimants or regulatory bodies; are in the early stages of the proceedings; involve a number of separate proceedings and/or a wide range of potential outcomes; or result in a change of business practices.
As of the date of this Quarterly Report on Form 10-Q, amounts accrued for legal proceedings and regulatory matters were not material. The Company believes that the ultimate outcome of any of the regulatory and legal proceedings that are currently pending against it should not have a material adverse effect on financial condition, results of operations, cash flow or liquidity. However, it is possible that in a particular quarter or annual period the Company’s financial condition, results of operations, cash flow and/or liquidity could be materially adversely affected by an ultimate unfavorable resolution of, or development in, legal and/or regulatory proceedings.
Refer to the Company’s 2023 Form 10-K for detailed disclosures on legal matters that were settled in 2023.
Intellectual Property Litigation Matters
In May 2023, after receiving a cease-and-desist letter from the Company regarding its patent infringement, Geneoscopy Inc. (“Geneoscopy”) requested a reexamination of the Company’s U.S. Patent No. 11,634,781 (the “’781 Patent”) by the United States Patent and Trademark Office (the “USPTO”). Upon completion of the reexamination in October 2023, the USPTO rejected Geneoscopy’s challenge. In November 2023, the Company filed suit against Geneoscopy in the United States District Court for the District of Delaware, alleging that certain of Geneoscopy’s products infringe the ‘781 Patent and seeking unspecified monetary damages and injunctive relief (the “’781 Action”) and in May 2024, the Company filed a second complaint against Geneoscopy alleging infringement of the Company’s U.S. Patent No. 11,970,746 (the “’746 Patent”), which has been consolidated with the ’781 Action. On June 28, 2024, Geneoscopy filed counterclaims against the Company challenging the validity of the patents at issue and alleging breach of contract, misappropriation of trade secrets, unfair competition, and other violations of state and federal law seeking unspecified monetary damages and injunctive relief, which were amended on August 16, 2024. On July 16, 2024, the Company filed a motion for preliminary injunction seeking an order prohibiting Geneoscopy from selling its infringing Colosense test in the United States. On August 8, 2024, Geneoscopy filed a motion to stay pending inter partes review of the ‘781 Patent, which is fully briefed. On August 30, 2024, the Company filed a motion to dismiss the amended counterclaim, which is fully briefed. On September 3, 2024, the Court entered a stipulated order for briefing and expedited discovery for the Company’s preliminary injunction motion. On September 27, 2024, Geneoscopy filed its opposition to the Company’s motion for preliminary injunction, and the parties are currently engaged in expedited discovery. Briefing for the Company’s motion for preliminary injunction will be complete by the end of November 2024.
31
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
In January 2024, Geneoscopy petitioned the USPTO to institute an inter partes review (“IPR”) challenging the validity of the ‘781 Patent before the Patent Trial and Appeals Board (“PTAB”). On July 26, 2024, the PTAB notified the Company that it decided to institute review. The Company filed its Patent Owner Response on October 25, 2024, and the parties are currently engaged in discovery. The Company intends to defend the validity of the ‘781 Patent, and a final decision of that review will be made on or before July 30, 2025.
On August 20, 2024, Geneoscopy filed a petition for inter partes review of the ‘746 Patent before the PTAB. The Company’s Patent Owner Preliminary Response is due November 27, 2024. The PTAB is expected to decide on or before February 27, 2025, whether it will institute the IPR. If the IPR is instituted, the Company intends to defend the validity of the ‘746 Patent, and a final decision of that review will be made on or before February 27, 2026.

(14) WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS
During December 2021, the Company entered into an amended agreement (“Amended WEDC Agreement”) with the Wisconsin Economic Development Corporation (“WEDC”) to earn an additional $18.5 million in refundable tax credits on the condition that the Company expends $350.0 million in capital investments and establishes and maintains 1,300 additional full-time positions over a five-year period. The capital investment credits are earned at a rate of 10% of eligible capital investments up to a maximum of $7.0 million, while the jobs creation credits are earned annually pursuant to the Amended WEDC Agreement.
The tax credits earned are first applied against the tax liability otherwise due, and if there is no such liability present, the claim for tax credits will be reimbursed in cash to the Company. The maximum amount of the refundable tax credit to be earned for each year is fixed, and the Company earns the credits by meeting certain capital investment and job creation thresholds over the term of the Amended WEDC Agreement. Should the Company earn and receive the job creation tax credits but not maintain those full-time positions through the end of the agreement, the Company may be required to pay those credits back to the WEDC.
The Company records the earned tax credits as job creation and capital investments occurs. The tax credits earned from capital investment are recognized as a reduction to capital expenditures at the time the costs are incurred, and then as an offset to depreciation expense over the expected life of the acquired capital assets. The tax credits earned related to job creation are recognized as an offset to operational expenses in the period in which the credits are earned.
As of September 30, 2024, the Company has earned $14.3 million of the refundable tax credits under the Amended WEDC Agreement. The unpaid portion is $8.8 million, of which $4.2 million is reported in prepaid expenses and other current assets and $4.6 million is reported in other long-term assets, net in the Company’s condensed consolidated balance sheets reflecting when collection of the refundable tax credits is expected to occur. During the three and nine months ended September 30, 2024 and 2023, the amounts recorded as an offset to capital expenditures and operating expenses for the tax credits earned were not significant.
(15) ACQUISITIONS AND DIVESTITURES
Business Combinations
Resolution Bioscience, Inc.
On September 12, 2023, the Company completed the acquisition of all of the outstanding capital stock of Resolution Bioscience, Inc. (“Resolution Bioscience”) from Agilent Technologies, Inc. The acquisition provides the Company with a high-quality blood-based therapy selection platform, complementing its comprehensive, tissue-based OncoExTra® test.
Refer to the Company’s 2023 Form 10-K for detailed disclosures on the combination, including the fair value of the consideration transferred, purchase price allocation, and goodwill and intangible assets identified in the transaction. During the three and nine months ended September 30, 2024, there were no significant changes to the purchase price and purchase price allocation, and the measurement period has closed.
32
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Divestitures
Oncotype DX Genomic Prostate Score Test
On August 2, 2022, pursuant to an asset purchase agreement (the “Asset Purchase Agreement”) with MDxHealth SA (“MDxHealth”), the Company completed the sale of the intellectual property and know-how related to the Company’s Oncotype DX Genomic Prostate Score test (“GPS test”). On August 23, 2023, the Company and MDxHealth executed the Second Amendment to the Asset Purchase Agreement (the “Second Amendment”). Under the Second Amendment, the Company agreed to allow MDxHealth to defer the 2023 contingent consideration payment by three years in exchange for additional consideration and more favorable contingent consideration terms, including elimination of the minimum revenue thresholds previously required to be met under the Asset Purchase Agreement. Refer to the Company’s 2023 Form 10-K for additional details on the agreements.
As of September 30, 2024 and December 31, 2023, a portion of the contingent consideration is classified as a contract asset. As of September 30, 2024, the contract asset was $48.3 million, of which $25.8 million is included in prepaid expenses and other current assets and $22.5 million is included in other long-term assets, net on the condensed consolidated balance sheet. As of December 31, 2023, the contract asset was $41.7 million, which is included in other long-term assets on the condensed consolidated balance sheet. The contract asset was estimated using historical GPS test revenues by MDxHealth under the most likely amount method. The remaining consideration balance as of September 30, 2024 and December 31, 2023 was $31.6 million, which includes the amount earned during the 2023 earnout year and is classified as a receivable within other long-term assets, net on the condensed consolidated balance sheet. The Company recorded an insignificant contingent consideration gain for the three and nine months ended September 30, 2024, which is included in other operating income in the condensed consolidated statement of operations.
(16) SEGMENT INFORMATION
Management determined that the Company functions as a single operating segment, and thus reports as a single reportable segment. This operating segment is focused on the development and global commercialization of clinical laboratory services allowing healthcare providers and patients to make individualized treatment decisions. Management assessed the financial information routinely reviewed by the Company's Chief Operating Decision Maker, its President and Chief Executive Officer, to monitor the Company's operating performance and support decisions regarding allocation of resources to its operations. Performance is continuously monitored at the consolidated level to timely identify deviations from expected results.
The following table summarizes total revenue from customers by geographic region. Product revenues are attributed to countries based on ship-to location.
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2024202320242023
United States$659,222 $589,739 $1,904,755 $1,741,428 
Outside of United States49,433 38,599 140,688 111,453 
Total revenues$708,655 $628,338 $2,045,443 $1,852,881 
Long-lived assets located in countries outside of the U.S. are not significant.

(17) INCOME TAXES
The Company recorded income tax expense of $0.8 million and $0.2 million for the three months ended September 30, 2024 and 2023, respectively. The Company recorded income tax expense of $4.1 million and $3.0 million for the nine months ended September 30, 2024 and 2023, respectively. The Company’s income tax expense recorded during the three and nine months ended September 30, 2024 is primarily related to current foreign and state tax expense. A deferred tax liability of $19.3 million and $17.3 million was recorded as of September 30, 2024 and December 31, 2023, respectively, which is included in other long-term liabilities on the Company’s condensed consolidated balance sheet. The Company continues to maintain a full valuation allowance against its deferred tax assets based on management’s determination that it is more likely than not the benefit will not be realized.
33
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
The Company had $42.0 million and $36.4 million of unrecognized tax benefits at September 30, 2024 and December 31, 2023, respectively. These amounts have been recorded as a reduction to the Company’s deferred tax asset, if recognized they would not have an impact on the effective tax rate due to the existing valuation allowance. Certain of the Company's unrecognized tax benefits could change due to activities of various tax authorities, including possible settlement of audits, or through normal expiration of various statutes of limitations. The Company does not expect a material change in unrecognized tax benefits in the next twelve months.
As of September 30, 2024, due to the carryforward of unutilized net operating losses and research and development credits, the Company is subject to U.S. federal income tax examinations for the tax years 2000 through 2024, and to state income tax examinations for the tax years 2000 through 2024. No interest or penalties related to income taxes have been accrued or recognized as of September 30, 2024.
The Organization for Economic Co-operation and Development has endorsed a framework (“Pillar Two”) with model rules introducing a global minimum corporate tax rate via a system where multinational groups with consolidated revenue over €750.0 million are subject to a minimum effective tax rate of 15% on income arising in low-tax jurisdictions on a country-by-country basis. Many countries have implemented laws based on these model rules, with effective dates beginning January 1, 2024. These rules do not have a material impact on the Company for the current period and, as currently designed, are not expected to materially increase the Company’s global tax costs. The Company will continue to monitor U.S. and global legislative action related to Pillar Two for potential impacts.

34

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Objective
The purpose of this Management’s Discussion and Analysis is to better allow our investors to understand and view our Company from management’s perspective. We are providing an overview of our business and strategy including a discussion of our financial condition and results of operations. The following discussion of our financial condition and results of operations should be read in conjunction with the condensed consolidated financial statements and the related notes thereto included elsewhere in this Quarterly Report on Form 10-Q and the audited financial statements and notes thereto and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Form 10-K”), which has been filed with the U.S. Securities and Exchange Commission (“SEC”).

Forward-Looking Statements
This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate” or other comparable terms. All statements other than statements of historical facts included in this Quarterly Report on Form 10-Q regarding our strategies, prospects, expectations, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results; expectations for development of new or improved products and services and their impact on patients; our strategies, positioning, resources, capabilities and expectations for future events or performance; and the anticipated benefits of our acquisitions, including estimated synergies and other financial impacts. Forward-looking statements are neither historical facts nor assurances of future performance or events. Instead, they are based only on current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results, conditions and events may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; our ability to meet demand for our products and services; our reliance upon certain suppliers, including suppliers that are the sole source of certain supplies and products used in our tests and operations; approval and maintenance of adequate reimbursement rates for our products and services within and outside of the U.S.; the amount and nature of competition for our products and services; the effects of any judicial, executive or legislative action affecting us or the healthcare system; recommendations, guidelines and quality metrics issued by various organizations regarding cancer screening or our products and services; our ability to successfully develop and commercialize new products and services and assess potential market opportunities; our ability to effectively enter into and utilize strategic partnerships and acquisitions; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to obtain and maintain regulatory approvals and comply with applicable regulations; our ability to protect and enforce our intellectual property; the results of our validation studies and clinical trials, including the risks that the results of future studies and trials may differ materially from the results of previously completed studies and trials; our ability to manage an international business and our expectations regarding our international expansion and opportunities; our ability to raise the capital necessary to support our operations or meet our payment obligations under our indebtedness; the potential effects of changing macroeconomic conditions, including the effects of inflation, interest rate and foreign currency exchange rate fluctuations, and geopolitical conflict; the possibility that the anticipated benefits from our business acquisitions will not be realized in full or at all or may take longer to realize than expected; the possibility that costs or difficulties related to the integration of acquired businesses’ operations or the divestiture of business operations will be greater than expected and the possibility that integration or divestiture efforts will disrupt our business and strain management time and resources; the outcome of any litigation, government investigations, enforcement actions or other legal proceedings; and our ability to retain and hire key personnel. The risks included above are not exhaustive. Other important risks and uncertainties are described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of the 2023 Form 10-K and subsequently filed Quarterly Reports on Form 10-Q. You are further cautioned not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
35
Overview
A leading provider of cancer screening and diagnostic tests, Exact Sciences Corporation (together with its subsidiaries, “Exact,” “we,” “us,” “our” or the “Company”) gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype DX® tests, we are investing in our pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis.
During the third quarter of 2024, we achieved many critical milestones, including:
•delivering tests results to 1.2 million people including a record number for Cologuard and Oncotype DX,
•growing total revenue 13% year-over-year while leveraging efficiencies in our operating expenses,
•generating cash provided by operating activities of $138.7 million for the three months ended September 30, 2024, an improvement of $114.4 million in comparison to the three months ended September 30, 2023,
•increasing customer satisfaction and brand awareness to all-time highs,
•receiving U.S. Food and Drug Administration (“FDA”) approval for Cologuard PlusTM, our next-generation Cologuard test,
•showcasing data at the European Society for Medical Oncology (“ESMO”) 2024 congress for our liquid biopsy colon cancer screening and multi-cancer screening tests, and
•gaining acceptance from a top-tier journal for the first publication of OncodetectTM, our molecular residual disease (“MRD”) test.

Our Screening Tests
Cologuard Test
Colorectal cancer is the second leading cause of cancer deaths in the United States (“U.S.”) and the leading cause of cancer deaths in the U.S. among non-smokers. Each year in the U.S., there are approximately 153,000 new cases of colorectal cancer and approximately 53,000 deaths. It is widely accepted that colorectal cancer is among the most preventable, yet least prevented cancers.
Our flagship screening product, the Cologuard test, is a patient-friendly, non-invasive stool-based DNA (“sDNA”) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Upon approval by the FDA in August 2014, our Cologuard test became the first and only FDA-approved sDNA non-invasive colorectal cancer screening test. Our Cologuard test is now indicated for average risk adults 45 years of age and older. In October 2024, the FDA approved Cologuard Plus, our next-generation Cologuard test, which we expect to launch with Medicare coverage and guideline inclusion in 2025.
Genetic Testing
We provide more than 5,000 predefined genetic tests for nearly all clinically relevant genes, additional custom panels, and comprehensive germline, whole exome (“PGxome®”), and whole genome (“PGnome®”) sequencing tests.
RiskguardTM, our hereditary cancer test, helps people understand their inherited risk of cancer, arming them with critical information to make more informed treatment decisions.

Our Precision Oncology Tests
Our precision oncology portfolio delivers actionable genomic insights to inform prognosis and cancer treatment after a diagnosis. In breast cancer, the Oncotype DX Breast Recurrence Score® test is the only test shown to predict the likelihood of chemotherapy benefit as well as the chance of cancer recurrence in the most common sub-type of early-stage breast cancer. As the only test proven to predict both the likelihood of chemotherapy benefit and cancer recurrence, the Oncotype DX test is recognized globally as standard of care and is included in all major breast cancer treatment guidelines. The OncoExTra® test applies comprehensive tumor profiling, utilizing whole exome and whole transcriptome sequencing, to aid in therapy selection for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer. With an extensive panel of approximately 20,000 genes and 169 introns, the OncoExTra test is one of the most comprehensive genomic (DNA) and transcriptomic (RNA) panels available today. We enable patients to take a more active role in their cancer care and make it easy for providers to order tests, interpret results, and personalize medicine.
36

International Business Background and Products
We commercialize or plan to commercialize our Oncotype® tests internationally through employees in Canada, Japan and a number of European countries, as well as through exclusive distribution agreements. We have provided our Oncotype tests in approximately 120 countries outside of the U.S. We do not offer our Cologuard test outside of the U.S.

Upcoming Test Launches
We are preparing to launch in 2025 new screening and diagnostic tests to address unmet patient needs and enhance our existing products.
•Cologuard Plus - Our Cologuard Plus test sets a new performance standard in non-invasive colorectal cancer screening. Our Cologuard Plus test detects cancers and precancerous polyps with even greater sensitivity than our Cologuard test while reducing false positives by more than 30 percent. In October 2024, the FDA approved our Cologuard Plus test for adults ages 45 and older of average risk for colorectal cancer. This approval was based on results from our pivotal BLUE-C study, which showed 95% overall cancer sensitivity and 43% sensitivity for advanced precancerous lesions at 94% specificity when age-weighted to the U.S. population with no findings on colonoscopy. We expect to launch our Cologuard Plus test with Medicare coverage and guideline inclusion in 2025.
•Oncodetect - We expect to launch our Oncodetect MRD test for patients with colorectal cancer, supported by forthcoming data releases and medical journal publications. We recently completed clinical validation of our tumor-informed platform utilizing colorectal cancer samples. Results will be submitted to MolDx for approval and subsequent Medicare reimbursement. Our tumor-informed Oncodetect test is designed to detect small amounts of tumor DNA that may remain in patients’ blood after they have undergone initial colorectal cancer treatment. This test will help patients and oncologists understand the success of initial treatment, guide further treatment, and monitor for cancer recurrence.
Pipeline Research and Development
We are continuing to advance our pipeline of future screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and patient monitoring.
Through our collaboration with Mayo Foundation for Medical Education and Research (“Mayo”), we have successfully performed validation studies involving multiple types of cancer using tissue, blood, and other sample types. Our research and development programs are also powered by technologies we have exclusively licensed from The Johns Hopkins University, Broad Institute, Inc. (“Broad Institute”), Oxford University, the Ludwig Institute for Cancer Research, and TwinStrand Biosciences, Inc. (“TwinStrand”).
We are focusing our research and development efforts on three main areas:
•Colorectal Cancer Screening. Over the past decade, together with Mayo, we have been seeking to develop even better colorectal cancer screening tests. Beyond Cologuard Plus, we are also working to develop a blood-based screening test for colorectal cancer. In September 2024, we presented performance data for our blood-based colorectal cancer screening test at the ESMO Congress, showing sensitivities of 88% for colorectal cancer and 31% for advanced precancerous lesions at specificity of 90% for negative samples confirmed by colonoscopy. BLUE-C pivotal study results for our blood-based colorectal cancer screening test are expected in the first half of 2025.
37
•MRD Test Development. In addition to our expected 2025 launch of Oncodetect for patients with colorectal cancer, we plan to validate Oncodetect for other cancer types, including breast cancer, and continually enhance the performance characteristics of our MRD test offerings over time. We recently completed clinical validation of our tumor-informed platform utilizing colorectal cancer samples. Results will be submitted to MolDx for approval and subsequent Medicare reimbursement. In June 2023, we entered into a sponsored research agreement and exclusive license agreement with Broad Institute to utilize their Minor Allele Enriched Sequencing Through Recognition Oligonucleotides (“MAESTRO”) diagnostic testing technology to further our ability to develop and launch impactful MRD tests. We are developing the MAESTRO platform for use in certain future MRD tests.
•Multi-cancer Screening Test Development. We are currently seeking to develop a multi-cancer screening test, which will be branded as CancerguardTM, to help detect many different types of cancer from a single blood draw. ASCEND-2, a multi-center, prospective, case-control study of over 11,000 clinically characterized participants, validates the sensitivity and specificity of our multi-biomarker class approach across a broad range of cancer types, including the most aggressive cancers and cancers with no current standard of care for screening. We presented initial ASCEND-2 data in April 2024 at the American Association for Cancer Research (“AACR”) annual meeting, which demonstrated the ability to detect cancer signals from 21 cancer types with a mean sensitivity of 50.9% with 98.5% specificity and 56.8% sensitivity when breast and prostate cancer were excluded from the analysis. We plan to share additional analyses from ASCEND-2 at an upcoming scientific conference. Our multi-cancer screening test was recently approved by the FDA to be used within a real-world evidence study, providing an opportunity to test 25,000 people over the next three years. The first patient was enrolled within this study at Baylor Scott & White, the primary study site, in August 2024. In the future, we plan to begin recruiting patients for the FDA registrational Study of All comeRs (“SOAR”) trial, which we expect to be the largest prospective, interventional multi-cancer screening trial ever conducted in the U.S.
Research and development, which includes our clinical study programs, accounts for a material portion of our operating expenses. As we seek to enhance our product portfolio and advance our pipeline, we expect that our research and development expenditures will continue to be a significant portion of our operating expenditures.

2024 Priorities
Our top priorities for 2024 are to (1) focus on our people and customers, (2) bring our portfolio to life, and (3) magnify our impact.
Focus on our People and Customers
We want to continue to provide an exceptional experience for our patients and team members. We plan to improve customer relations by delivering simple and smooth workflows, providing communication that is clear and easy to understand, and providing results that are fast and accurate. We will also strive to ensure that Exact Sciences remains a great place to work by taking care of our people.
Bring our Portfolio to Life
We will focus on advancing new tests in our highest priority programs including colorectal cancer screening, MRD, and multi-cancer screening. We plan to continue investing in our clinical trials to enhance existing products and bring new products to patients and providers, including obtaining FDA approval and securing coverage for our next generation Cologuard test, Cologuard Plus.
Magnify our Impact
We are committed to improving lives through testing more people with our laboratory testing services in 2024 including expanding screening access to underserved populations. By testing more people, we will continue to expand our business in a cost-efficient manner allowing us to generate sustainable profits and increase shareholder value. Generating sustained profits will put the company in a better position to continue investing in life-changing cancer diagnostics to help achieve our mission.
38
Recent Developments and Trends
We estimate there are up to 60 million Americans that are not up to date with their colon cancer screenings. The capacity for screening colonoscopies in the U.S. is relatively fixed because it is dependent on the number of gastroenterologists available to perform the procedures. Health systems, payers, and health care providers are motivated to increase screening rates because they are measured as part of the Healthcare Effectiveness Data and Information Set (“HEDIS”) and Medicare Stars quality measure systems. More health systems and payers are recognizing the opportunity to partner with Exact Sciences to address their screening rates and related quality measures through large, organized screening programs. We aim to partner with them to implement our Cologuard test within these programs as a solution for patients who infrequently visit their health care provider. Cologuard utilization is increasing in this setting, helping us screen more Americans.
We have an opportunity to impact even more lives by increasing adoption of Oncotype DX tests internationally. In 2023, we secured reimbursement for the Oncotype DX test in Japan. Breast cancer is the most common cancer among Japanese women, with about 45,000 new diagnoses of early-stage HR+, HER2- breast cancer each year. With reimbursement in place, we estimate our Oncotype DX test could help more than 100 women per day understand if their cancer is likely to recur and whether chemotherapy should be used in their treatment plan.

Results of Operations
We have incurred losses since our inception and, as of September 30, 2024, we had an accumulated deficit of approximately $3.63 billion. While our operating results have continued to improve, we expect to incur net losses for the near future, and it is possible we may never become profitable or sustain profitability.
Revenue. Our Screening revenue primarily includes laboratory service revenue from our Cologuard and Prevention Genetics, LLC (“PreventionGenetics”) tests while our Precision Oncology revenue primarily includes laboratory service revenue from global Oncotype DX and therapy selection tests.
Three Months Ended September 30,
Amounts in millions20242023Change
Screening$544.9 $472.0 $72.9 
Precision Oncology163.8 156.3 7.4 
Total$708.7 $628.3 $80.3 
Nine Months Ended September 30,
Amounts in millions20242023Change
Screening$1,551.3 $1,378.0 $173.3 
Precision Oncology494.1 468.9 25.2 
COVID-19 Testing— 6.0 (6.0)
Total$2,045.4 $1,852.9 $192.5 
The increase in Screening revenue was mainly due to an increase in the number of completed Cologuard tests. The increase in completed Cologuard tests for the three and nine months ended September 30, 2024 was due to growth across all customer segments, more patients rescreening with our Cologuard test, and expansion of organized screening programs run by payers and health systems. The increase in Precision Oncology revenue was mainly due to an increase in the number of completed Oncotype DX breast cancer tests, both domestically and internationally, led by an increased number of ordering providers outside the U.S., specifically in Japan. We discontinued our COVID-19 testing business in the second quarter of 2023 due to lower demand, which led to the decrease in COVID-19 testing revenue. A discussion on our COVID-19 testing business was provided in our Annual Report on Form 10-K for the year ended December 31, 2023.
39
Adjustments to revenue recognized during the period relating to prior period estimates were less than 1% of revenue recorded in our condensed consolidated statement of operations for the three and nine months ended September 30, 2024. Adjustments to revenue recognized during the period relating to prior period estimates were less than 2% of revenue recorded in our condensed consolidated statement of operations for the three and nine months ended September 30, 2023. The impact to revenue for the three and nine months ended September 30, 2023 was due to improvements made in our billing systems and processes, including international contracting and collections.
We expect continuing revenue growth for our Cologuard and Oncotype tests subject to seasonal variability. Our revenues are affected by the test volume of our products, patient adherence rates, payer mix, the levels of reimbursement, our order to cash operations, and payment patterns of payers and patients.
Cost of sales (exclusive of amortization of acquired intangible assets). The increase in cost of sales for the three and nine months ended September 30, 2024 was primarily due to an increase in production costs, personnel expenses, and facility and support services, which was a result of an increase in completed Cologuard and Oncotype tests and the corresponding increase in headcount to support the increase in tests completed. Cost of sales (exclusive of amortization of acquired intangible assets) as a percentage of revenue increased for the three and nine months ended September 30, 2024 compared to the same periods in 2023, primarily due to higher Cologuard test volume from organized screening programs run by payers and health systems. We expect that cost of sales will generally continue to increase in future periods as a result of an increase in our existing laboratory testing services and as we launch our pipeline products. We also expect to see a corresponding increase in personnel and support services associated with this growth.
Three Months Ended September 30,
Amounts in millions20242023Change
Production costs$125.6 $102.6 $23.0 
Personnel expenses48.2 45.8 2.4 
Facility and support services17.3 13.6 3.7 
Stock-based compensation4.9 5.3 (0.4)
Other cost of sales expenses0.1 1.2 (1.1)
Total cost of sales expense$196.1 $168.5 $27.6 
Nine Months Ended September 30,
Amounts in millions20242023Change
Production costs$341.6 $289.2 $52.4 
Personnel expenses146.4 134.4 12.0 
Facility and support services50.4 40.3 10.1 
Stock-based compensation15.7 15.6 0.1 
Other cost of sales expenses1.9 2.9 (1.0)
Total cost of sales expense$556.0 $482.4 $73.6 
40
Research and development expenses. The decrease in research and development expenses for the three months ended September 30, 2024 was primarily due to a decrease in resources needed to support our ongoing clinical studies as discussed in further detail above. The increase in research and development expenses for the nine months ended September 30, 2024 was primarily due to the termination of a license agreement with The Translational Genomics Research Institute (“TGen”) resulting in the recognition of an expense of $25.8 million in the second quarter of 2024. In addition, personnel expenses grew for the nine months ended September 30, 2024 is primarily due to an increase in average headcount during the year. This was partially offset by a decrease in direct research and development costs as discussed above. We expect that research and development expenses will generally continue to increase in future periods as we continue to invest to advance new tests.
Three Months Ended September 30,
Amounts in millions20242023Change
Personnel expenses$43.7 $44.3 $(0.6)
Direct research and development28.4 36.6 (8.2)
Facility and support services14.4 17.0 (2.6)
Stock-based compensation9.3 10.5 (1.2)
Professional fees3.2 2.3 0.9 
Other research and development1.1 0.7 0.4 
Total research and development expenses$100.1 $111.4 $(11.3)
Nine Months Ended September 30,
Amounts in millions20242023Change
Personnel expenses$141.0 $129.9 $11.1 
Direct research and development81.2 96.1 (14.9)
Facility and support services43.0 46.5 (3.5)
Stock-based compensation31.1 31.0 0.1 
License agreement termination25.8 — 25.8 
Professional fees7.7 5.5 2.2 
Other research and development1.8 2.0 (0.2)
Total research and development expenses$331.6 $311.0 $20.6 
Sales and marketing expenses. Sales and marketing expenses increased for the three and nine months ended September 30, 2024 compared to the three and nine months ended September 30, 2023 due to continued investment in high impact sales and marketing opportunities. We anticipate sales and marketing expenses will generally increase in future periods as we reinvest in sales and marketing to meet demand for current products and the launch of new products, while continuing to decrease as a percentage of revenue over time, driven by the growth of Cologuard and Oncotype testing services.
Three Months Ended September 30,
Amounts in millions20242023Change
Personnel expenses$110.6 $99.7 $10.9 
Direct marketing costs49.3 39.4 9.9 
Professional and legal fees15.4 12.1 3.3 
Stock-based compensation14.5 17.5 (3.0)
Facility and support services4.5 4.0 0.5 
Other sales and marketing expenses0.4 0.5 (0.1)
Total sales and marketing expenses$194.7 $173.2 $21.5 
41
Nine Months Ended September 30,
Amounts in millions20242023Change
Personnel expenses$326.9 $310.8 $16.1 
Direct marketing costs 145.2 131.3 13.9 
Stock-based compensation44.8 48.8 (4.0)
Professional and legal fees44.3 30.7 13.6 
Facility and support services10.0 12.6 (2.6)
Other sales and marketing expenses1.1 2.4 (1.3)
Total sales and marketing expenses$572.3 $536.6 $35.7 
General and administrative expenses. The decrease in general and administrative expenses for the three months ended September 30, 2024 was primarily due to a reduction in certain incentive-based compensation arrangements and a reduction in other discretionary spend including professional and legal fees as a result of our cost savings measures that were implemented. The decrease in general and administrative expenses for the nine months ended September 30, 2024 was primarily due to the settlement of certain legal matters in 2023, as further described in Note 15 of our Annual Report on Form 10-K for the year ended December 31, 2023.These reductions were partially offset by increases in other general and administrative expense as a result of the change in fair value of our outstanding contingent consideration liabilities. Refer to Note 7 of our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for further discussion of our outstanding contingent consideration liabilities. We expect general and administrative expenses throughout the remainder of 2024 will remain relatively consistent with costs incurred thus far in 2024. We expect general and administrative expenses will decrease over time as we leverage efficiencies in our personnel and information technology systems.
Three Months Ended September 30,
Amounts in millions20242023Change
Personnel expenses$98.1 $101.3 $(3.2)
Facility and support services48.8 45.9 2.9 
Professional and legal fees30.8 34.5 (3.7)
Stock-based compensation20.1 28.6 (8.5)
Other general and administrative19.4 7.1 12.3 
Total general and administrative expenses$217.2 $217.4 $(0.2)
Nine Months Ended September 30,
Amounts in millions20242023Change
Personnel expenses$312.2 $294.0 $18.2 
Facility and support services138.0 133.2 4.8 
Professional and legal fees98.1 136.2 (38.1)
Stock-based compensation74.1 77.3 (3.2)
Other general and administrative39.8 32.0 7.8 
Total general and administrative expenses$662.2 $672.7 $(10.5)
Amortization of acquired intangible assets. Amortization of acquired intangible assets increased to $24.4 million for the three months ended September 30, 2024 compared to $23.0 million for the three months ended September 30, 2023. Amortization of acquired intangible assets increased to $71.1 million for the nine months ended September 30, 2024 compared to $68.8 million for the nine months ended September 30, 2023. The increase was primarily due to amortization of the intangible asset acquired as part of our acquisition of Resolution Bioscience in September 2023 and our acquisition of intellectual property through a license from TwinStrand in July 2024.
Impairment of long-lived assets. Impairment of long-lived assets was $18.7 million and $31.3 million for the three and nine months ended September 30, 2024, respectively, compared to zero and $0.6 million for the three and nine months ended September 30, 2023. The impairment charges recorded during the three and nine months ended September 30, 2024 and 2023 related to the closure of certain of our domestic facilities.
42
Other operating income. Other operating income was $3.1 million and $6.6 million for the three and nine months ended September 30, 2024 compared to $72.0 million for the three and nine months ended September 30, 2023. The income recorded for the three and nine months ended September 30, 2024 represents the remeasurement of the contingent consideration asset from the sale of the Oncotype DX Genomic Prostate Score test to MDxHealth SA (“MDxHealth”). The income recorded for the three and nine months ended September 30, 2023 included a $68.9 million contingent consideration gain and $3.1 million in additional consideration received from MDxHealth.
Investment income, net. Investment income, net increased to $11.6 million for the three months ended September 30, 2024 compared to $2.1 million for the three months ended September 30, 2023. Investment income, net increased to $29.6 million for the nine months ended September 30, 2024 compared to $7.4 million for the nine months ended September 30, 2023. The investment income recorded for the three and nine months ended September 30, 2024 and 2023 was primarily due to gains recorded on our marketable securities.
Interest expense. Interest expense was $9.6 million for the three months ended September 30, 2024 compared to $7.9 million for the three months ended September 30, 2023. Interest expense recorded from our outstanding convertible notes totaled $8.9 million and $6.3 million for the three months ended September 30, 2024 and 2023, respectively. Interest expense increased to $17.4 million for the nine months ended September 30, 2024 compared to $11.6 million for the nine months ended September 30, 2023. Interest expense recorded from our outstanding convertible notes totaled $23.6 million and $17.3 million for the nine months ended September 30, 2024 and 2023, respectively. Interest expense included a net gain on settlement of convertible notes of $10.3 million and $10.3 million for the nine months ended September 30, 2024 and 2023, respectively. The convertible notes are further described in Note 9 of our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.
Income tax expense. Income tax expense increased to $0.8 million for the three months ended September 30, 2024 compared to $0.2 million for the three months ended September 30, 2023. Income tax expense increased to $4.1 million for the nine months ended September 30, 2024 compared to $3.0 million for the nine months ended September 30, 2023. Income tax expense for the three and nine months ended September 30, 2024 and 2023 was primarily related to current foreign and state tax expense.
Liquidity and Capital Resources
Overview
We have incurred losses since our inception, and have historically financed our operations primarily through public offerings of our common stock and convertible debt and through revenue generated by the sale of our laboratory testing services. We expect our operating expenditures to continue to increase to support future growth of our laboratory testing services, as well as an increase in research and development and clinical trial costs to support the advancement of our pipeline products and bringing new tests to market. We expect that cash, cash equivalents and marketable securities on hand at September 30, 2024, along with cash flows generated through our operations, will be sufficient to fund our current operations for at least the next twelve months based on current operating plans.
We have access to a revolving line-of-credit (the “Revolver”) of up to $150.0 million, which had its maturity date extended to November 2025 through an amended agreement in October 2022. The Revolver is collateralized by certain marketable securities which must continue to maintain a minimum market value of $150.0 million. PNC Bank, National Association has issued letters of credit totaling $4.4 million, which reduces the amount available for cash advances under the line of credit to $145.6 million. As of September 30, 2024, we had not drawn any funds under the Revolver. The Revolver is further described in Note 8 of our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.
We may raise additional capital to expand our business, to pursue strategic investments, to take advantage of financing opportunities or for other reasons. If we are unable to obtain sufficient additional funds to enable us to fund our business plans and strategic investments, our results of operations and financial condition could be materially adversely affected, and we may be required to delay the implementation of our plans or otherwise scale back our operations. There can be no certainty that we will ever be successful in generating sufficient cash flow from operations to achieve and maintain profitability and meet all of our obligations as they come due.
43
Cash, Cash Equivalents and Marketable Securities
As of September 30, 2024, we had approximately $588.8 million in unrestricted cash and cash equivalents and approximately $432.3 million in marketable securities.
The majority of our investments in marketable securities consist of fixed income investments, and all are deemed available-for-sale. The objectives of this portfolio are to provide liquidity and safety of principal while striving to achieve the highest rate of return. Our investment policy limits investments to certain types of instruments issued by institutions with investment grade credit ratings and places restrictions on maturities and concentration by type and issuer.
Cash Flows
Nine Months Ended September 30,
Amounts In millions20242023
Net cash provided by operating activities$163.5 $86.6 
Net cash provided by (used in) investing activities(400.3)116.4 
Net cash provided by financing activities221.4 149.7 
Operating activities
The increase in cash provided by operating activities for the nine months ended September 30, 2024 was primarily due to an increase in revenue. This was partially offset by an increase in operating expenses and cost of sales to support the increase in revenue as discussed in the Results of Operations section above and timing of payments on our accounts payable and accrued expenses and collections of our accounts receivable.
Investing activities
The increase in cash used in investing activities for the nine months ended September 30, 2024 compared to cash provided by investing activities for the nine months ended September 30, 2023 was due to a net increase of $507.4 million in cash used for purchases, maturities and sales of marketable securities as a result of a change in investing strategy towards more fixed income securities compared to money market funds as money market yields have decreased. We also increased our purchases of property, plant and equipment by $10.4 million due to additional investments in information technology infrastructure and lab automation. The increase in cash used in investing activities was partially offset by a decrease in cash used related to business combinations and asset acquisitions. We made payments of $45.0 million for our license of intellectual property from TwinStrand during the third quarter of 2024 compared to a cash payment of $50.0 for our acquisition of Resolution Bioscience, Inc. in the third quarter of 2023.
Financing activities
The increase in cash provided by financing activities during the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023 was primarily due to proceeds of $266.8 million from the issuance of convertible notes in the second quarter of 2024 compared to proceeds of $138.0 million from the issuance of convertible notes in the first quarter of 2023. This was partially offset by a payment of $50.0 million in settlement of our previously outstanding accounts receivable securitization facility (“Securitization Facility”) upon maturity in June 2024.
Material Cash Requirements
A discussion of our material cash requirements as of December 31, 2023 was provided in the Management’s Discussion and Analysis of Financial Condition and Results of Operation of our 2023 Form 10-K. Other than the matters described below, there were no material changes outside the ordinary course of our business in our specified material cash requirements during the nine months ended September 30, 2024.
44
In April 2024, we entered into privately negotiated agreements (the “Agreements”) with certain holders of our convertible notes due in 2028 (“2028 Notes”). Pursuant to the Agreements, we issued $620.7 million aggregate principal amount of a new series of Convertible Notes due in 2031 (the “2031 Notes”) in exchange for (i) the retirement of $359.7 million in aggregate principal amount of 2028 Notes, and (ii) payment to the Company of $266.8 million in cash. The net proceeds from the issuance of the Notes were approximately $259.8 million, after deducting commissions and the offering expenses payable by the Company. The 2031 Notes mature on April 15, 2031 and bear interest at a fixed rate of 1.75% per year, payable semiannually in arrears on October 15 and April 15 of each year, beginning on October 15, 2024.
As of September 30, 2024, we had outstanding aggregate principal of $249.2 million on our convertible notes with a maturity date of January 15, 2025 (the “2025 Notes”), which are classified as convertible notes, net, current portion on the condensed consolidated balance sheet. Beginning July 15, 2024, which is six months prior to the maturity date of the 2025 Notes, holders of the 2025 Notes may elect to convert such notes at any time. In accordance with the terms of the 2025 Notes, any 2025 Notes that are converted after July 15, 2024 will be settled through a combination settlement under which the par value will be settled in cash and any amount in excess of par value will be settled in shares of our common stock. 2025 Notes that are not converted prior to the maturity date will be settled in cash upon maturity.
In June 2024, we repaid the previously outstanding balance of $50.0 million in full upon maturity of the Securitization Facility. Prior to maturity, the Securitization Facility accrued interest at a rate equal to a daily secured overnight financing rate (“SOFR”) plus a SOFR adjustment and an applicable margin. The interest rate was 6.87% as of the maturity date.
As of September 30, 2024, we had no off-balance sheet arrangements.

Critical Accounting Policies and Estimates
Management’s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these financial statements requires us to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments. We base our estimates on historical experience and on various other factors that are believed to be appropriate under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
For a discussion of our critical accounting policies and estimates, refer to our Management’s Discussion and Analysis of Financial Condition and Results of Operations in our 2023 Form 10-K. There have been no material changes to our critical accounting policies and estimates since our 2023 Form 10-K.
Recent Accounting Pronouncements
See Note 1 of our condensed consolidated financial statements for the discussion of Recent Accounting Pronouncements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk
Interest Rate Risk
Our exposure to market risk is principally confined to our cash, cash equivalents and marketable securities and our outstanding variable-rate debt. We invest our cash, cash equivalents, and marketable securities in securities of the U.S. governments and its agencies and in investment-grade, highly liquid investments consisting of commercial paper, bank certificates of deposit, and corporate bonds, which as of September 30, 2024 and December 31, 2023 were classified as available-for-sale. We place our cash, cash equivalents, restricted cash, and marketable securities with high-quality financial institutions, limit the amount of credit exposure to any one institution, and have established investment guidelines relative to diversification and maturities designed to maintain safety and liquidity.
Based on a hypothetical 100 basis point decrease in market interest rates, the potential losses in future earnings, fair value of risk-sensitive financial instruments, and cash flows are immaterial, although the actual effects may differ materially from the hypothetical analysis. While we believe our cash, cash equivalents, restricted cash, and marketable securities do not contain excessive risk, we cannot provide absolute assurance that, in the future, our investments will not be subject to adverse changes
45
in market value. In addition, we maintain significant amounts of cash, cash equivalents, restricted cash, and marketable securities at one or more financial institutions that are in excess of federally insured limits. Given the potential instability of financial institutions, we cannot provide assurance that we will not experience losses on these deposits. We do not utilize interest rate hedging agreements or other interest rate derivative instruments.
As of September 30, 2024, we had no outstanding variable rate debt. If we were to draw down amounts under our Revolving Loan, we would be impacted by increases in prevailing market interest rates. All of our other significant interest-bearing liabilities bear interest at fixed rates and therefore are not subject to fluctuations in market interest rates; however, because these interest rates are fixed, we may be paying a higher interest rate, relative to market, in the future if circumstances change.
Foreign Currency Risk
The functional currency for most of our international subsidiaries is the U.S. dollar, and as a result we are not subject to material gains and losses from foreign currency translation of the subsidiary financial statements. Substantially all of our revenues are recognized in U.S. dollars, although a small portion is denominated in foreign currency as we continue to expand into markets outside of the U.S. Certain expenses related to our international activities are payable in foreign currencies. As a result, factors such as changes in foreign currency exchange rates or weak economic conditions in foreign markets will affect our financial results.
We enter into forward contracts to mitigate the impact of adverse movements in foreign exchange rates related to the re-measurement of monetary assets and liabilities and hedge our foreign currency exchange rate exposure. As of September 30, 2024, we had open foreign currency forward contracts with notional amounts of $47.7 million. Although the impact of currency fluctuations on our financial results has been immaterial in the past, there can be no guarantee that the impact of currency fluctuations related to our international activities will not be material in the future.

Item 4. Controls and Procedures
As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and our principal financial officer, of the effectiveness of our disclosure controls and procedures, as defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based upon that evaluation, our principal executive officer and our principal financial officer concluded that, as of September 30, 2024, our disclosure controls and procedures were effective. Disclosure controls and procedures enable us to record, process, summarize and report information required to be included in our Exchange Act filings within the required time period. Our disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed by us in the periodic reports filed with the SEC is accumulated and communicated to our management, including our principal executive, financial and accounting officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
There have been no significant changes in internal control over financial reporting during the quarter ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
46
Part II - Other Information

Item 1. Legal Proceedings
From time to time we are a party to various legal proceedings arising in the ordinary course of our business. Legal proceedings, including litigation, government investigations and enforcement actions could result in material costs, occupy significant management resources and entail civil and criminal penalties. The information called for by this item is incorporated by reference to the information in Note 13 of our condensed consolidated financial statements included in Part I of this Quarterly Report on Form 10-Q.

Item 1A. Risk Factors
We operate in a rapidly changing environment that involves a number of risks that could materially affect our business, financial condition or future results, some of which are beyond our control. In addition to the other information set forth in this report, the risks and uncertainties that we believe are most important for you to consider are discussed in Part I, “Item 1A. Risk Factors” in the 2023 Form 10-K and in Part II, “Item 1A. Risk Factors” in our subsequently filed Quarterly Reports on Form 10-Q. There have been no material changes to the risk factors described in the 2023 Form 10-K and subsequently filed Quarterly Report on Form 10-Q.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Not applicable.

Item 3. Defaults Upon Senior Securities
Not applicable.

Item 4. Mine Safety Disclosures
Not applicable.

Item 5. Other Information
Rule 10b5-1 Trading Plans
During the third quarter of 2024, none of the Company’s directors or executive officers adopted or terminated any “Rule 10b5-1 trading arrangement” or any “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K.
47
Item 6. Exhibits
The following documents are filed as part of this Form 10-Q.
Exhibit
Number		Exhibit DescriptionFiled
with
This
Report		Incorporated
by Reference
herein from
Form or
Schedule		Filing
Date		SEC File /
Registration
Number
Sixth Amended and Restated Certificate of Incorporation of the RegistrantS-1 (Exhibit 3.3)12/4/2000333-48812
Certificate of Amendment, dated July 23, 2020, to the Sixth Amended and Restated Certificate of Incorporation of the Registrant8-K (Exhibit 3.1)7/24/2020001-35092
Certificate of Amendment, dated June 9, 2023, to the Sixth Amended and Restated Certificate of Incorporation of the Registrant8-K (Exhibit 3.1)6/12/2023001-35092
Seventh Amended and Restated By-Laws of the Registrant8-K (Exhibit 3.2)6/12/2023001-35092
First Amendment to Employment Agreement, dated July 31, 2024, by and between Aaron Bloomer and the Registrant
X
First Amendment to Employment Agreement, dated July 31, 2024, by and between Jake Orville and the Registrant
X
First Amendment to Employment Agreement, dated July 31, 2024, by and between Brian Baranick and the Registrant
X
Second Amendment to Employment Agreement, dated July 31, 2024, by and between Sarah Condella and the Registrant
X
The Registrant’s 2010 Employee Stock Purchase Plan (as amended and restated on July 31, 2024)
X
Certification Pursuant to Rule 13(a)-14(a) or Rule 15d-14(a) of Securities Exchange Act of 1934X
Certification Pursuant to Rule 13(a)-14(a) or Rule 15d-14(a) of Securities Exchange Act of 1934X
Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002X
101
The following materials from the Quarterly Report on Form 10-Q of Exact Sciences Corporation for the quarter ended September 30, 2024 filed on November 5, 2024, formatted in Inline eXtensible Business Reporting Language (“iXBRL”): (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations, (iii) Condensed Consolidated Statement of Changes in Stockholders’ Equity, (iv) Condensed Consolidated Statements of Cash Flows and (v) related notes to these financial statements
X
104
The cover page from our Quarterly Report for the period ended September 30, 2024, filed with the Securities and Exchange Commission on November 5, 2024, is formatted in Inline Extensible Business Reporting Language (“iXBRL”)
X
(*) Indicates a management contract or any compensatory plan, contract or arrangement.

48
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
EXACT SCIENCES CORPORATION
Date: November 5, 2024
By:/s/ Kevin T. Conroy
Kevin T. Conroy
President and Chief Executive Officer
(Principal Executive Officer)
Date: November 5, 2024
By:
/s/ Aaron Bloomer
Aaron Bloomer
Executive Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)

49

EXHIBIT 10.1
FIRST AMENDMENT TO
EMPLOYMENT AGREEMENT
This First Amendment to Employment Agreement (this “Amendment”) is entered into as of July 31, 2024, by and between Exact Sciences Corporation, a Delaware corporation (the “Company”), and Aaron Bloomer. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Employment Agreement (as defined below).
RECITALS
    A.    WHEREAS, the Company and Employee are Parties to that certain Employment Agreement entered into effective as of April 15, 2024 (the “Employment Agreement”); and
    B.    WHEREAS, the Parties desire to amend certain provisions of the Employment Agreement, as more particularly set forth herein.
AGREEMENT
    In consideration of the foregoing and the mutual covenants and agreements herein contained, and intending to be legally bound hereby, the Parties agree as follows:
1.Addition of Section 7.2(c). Section 7 of the Employment Agreement is hereby amended by adding the following new Section 7.2(c):
    “(c)    Separation from Service in connection with a Change in Control. If within four (4) months before or twelve (12) months after a Change in Control, Employee incurs a Separation from Service initiated by the Company (or a successor) without Cause or initiated by Employee for Good Reason, then subject to the conditions described in Section 7.3 below, the Company shall provide Employee the following payments and other benefits:
(i)(A) A lump-sum payment equal to eighteen (18) months of Employee’s then current Base Salary; and (B) any accrued but unpaid Base Salary as of the day of the Separation from Service.
(ii)To the extent not duplicative with any bonus policy, plan, or program that provides for a prorated bonus following a Separation from Service, a lump-sum cash payment equal to Employee’s Year-End Bonus, at target performance, for the year of the Separation from Service, prorated based on the number of days elapsed in the performance period corresponding to such Year-End Bonus through the date of the Separation from Service, divided by the number of days in such performance period.
(iii)A lump-sum cash payment equal to 150% of Employee’s Year-End Bonus, at target performance, for the year of Separation from Service.
(iv)A lump-sum cash payment that is equal to twelve (12) months of premium payments for COBRA coverage for health, dental, and vision coverage based on the Company-provided health, dental, and vision coverage in which the Employee and the Employee’s dependents are enrolled at the time of the Employee’s Separation from Service. This lump-sum cash payment may be used for any purpose, including but not limited to continuation coverage under COBRA.


(v)Ten Thousand Dollars ($10,000) towards the cost of an outplacement consulting package for Employee.
(vi)The cash payments described above will be made on the first payroll date that is on or that immediately follows the sixtieth (60th) day following the Separation from Service. If a Separation from Service covered by this Section 7.2(c) occurs prior to a Change in Control, then the installment payments referenced in Section 7.1 will commence thereunder, and the lump sum payment of any additional amount provided under this Section 7.2(c) will be made as soon as administratively practicable (not more than ten (10) days) after the date of the Change in Control, reduced by any amounts already provided under Section 7.1 in order to avoid duplication of benefits.”
2.Amendment and Ratification. Except as specifically amended hereby, all terms, conditions, covenants, representations, and warranties contained in the Employment Agreement shall remain in full force and effect and shall be binding upon the Parties.
3.Entire Agreement. The Employment Agreement, as amended hereby, together with the documents incorporated therein, constitute the entire agreement (and supersede all prior written agreements, arrangements, communications and understandings and all prior and contemporaneous oral agreements, arrangements, communications and understandings) between the Parties with respect to the subject matter thereof and hereof.
4.Counterparts. This Amendment may be executed in two or more counterparts, all of which shall be considered one and the same instrument and shall become effective when one or more counterparts have been signed by each of the Parties and delivered to the other Party.
5.Facsimile or .pdf Signature. This Amendment may be executed by facsimile or .pdf signature and a facsimile or .pdf signature shall constitute an original for all purposes.


[Signature page follows]
2


IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed as of the date first written above.
EXACT SCIENCES CORPORATION
By:
Name: Kevin Conroy
Title: CEO
EXECUTIVE
Aaron Bloomer
[SIGNATURE PAGE TO FIRST AMENDMENT TO EMPLOYMENT AGREEMENT]
EXHIBIT 10.2

FIRST AMENDMENT TO
EMPLOYMENT AGREEMENT
This First Amendment to Employment Agreement (this “Amendment”) is entered into as of July 31, 2024, by and between Exact Sciences Corporation, a Delaware corporation (the “Company”), and Jacob Orville. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Employment Agreement (as defined below).
RECITALS
    A.    WHEREAS, the Company and Employee are Parties to that certain Employment Agreement entered into effective as of February 18, 2019 (the “Employment Agreement”); and
    B.    WHEREAS, the Parties desire to amend certain provisions of the Employment Agreement, as more particularly set forth herein.
AGREEMENT
    In consideration of the foregoing and the mutual covenants and agreements herein contained, and intending to be legally bound hereby, the Parties agree as follows:
1.Addition of Section 7.2(c). Section 7 of the Employment Agreement is hereby amended by adding the following new Section 7.2(c):
    “(c).    Separation from Service in connection with a Change in Control. If within four (4) months before or twelve (12) months after a Change in Control, Employee incurs a Separation from Service initiated by the Company (or a successor) without Cause or initiated by Employee for Good Reason, then subject to the conditions described in Section 7.c below, the Company shall provide Employee the following payments and other benefits:
(i)(A) A lump-sum payment equal to eighteen (18) months of Employee’s then current Base Salary; and (B) any accrued but unpaid Base Salary as of the day of the Separation from Service.
(ii)To the extent not duplicative with any bonus policy, plan, or program that provides for a prorated bonus following a Separation from Service, a lump-sum cash payment equal to Employee’s target annual bonus set forth in Section 3.b, for the year of the Separation from Service, prorated based on the number of days elapsed in the performance period corresponding to such target annual bonus through the date of the Separation from Service, divided by the number of days in such performance period.
(iii)A lump-sum cash payment equal to 150% of Employee’s target annual bonus set forth in Section 3.b, for the year of Separation from Service.
(iv)A lump-sum cash payment that is equal to twelve (12) months of premium payments for COBRA coverage for health, dental, and vision coverage based on the Company-provided health, dental, and vision coverage in which the Employee and the Employee’s dependents are enrolled at the time of the Employee’s Separation from Service. This lump-sum cash payment may be used for any purpose, including but not limited to continuation coverage under COBRA.


(v)Ten Thousand Dollars ($10,000) towards the cost of an outplacement consulting package for Employee.
(vi)The cash payments described above will be made on the first payroll date that is on or that immediately follows the sixtieth (60th) day following the Separation from Service. If a Separation from Service covered by this Section 7.b(iii) occurs prior to a Change in Control, then the installment payments referenced in Section 7.a will commence thereunder, and the lump sum payment of any additional amount provided under this Section 7.b(iii) will be made as soon as administratively practicable (not more than ten (10) days) after the date of the Change in Control, reduced by any amounts already provided under Section 7.a in order to avoid duplication of benefits.”
2.Amendment and Ratification. Except as specifically amended hereby, all terms, conditions, covenants, representations, and warranties contained in the Employment Agreement shall remain in full force and effect and shall be binding upon the Parties.
3.Entire Agreement. The Employment Agreement, as amended hereby, together with the documents incorporated therein, constitute the entire agreement (and supersede all prior written agreements, arrangements, communications and understandings and all prior and contemporaneous oral agreements, arrangements, communications and understandings) between the Parties with respect to the subject matter thereof and hereof.
4.Counterparts. This Amendment may be executed in two or more counterparts, all of which shall be considered one and the same instrument and shall become effective when one or more counterparts have been signed by each of the Parties and delivered to the other Party.
5.Facsimile or .pdf Signature. This Amendment may be executed by facsimile or .pdf signature and a facsimile or .pdf signature shall constitute an original for all purposes.


[Signature page follows]

2


IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed as of the date first written above.
EXACT SCIENCES CORPORATION
By:
Name: Kevin Conroy
Title: CEO
EXECUTIVE
Jacob Orville
[SIGNATURE PAGE TO FIRST AMENDMENT TO EMPLOYMENT AGREEMENT]
EXHIBIT 10.3

FIRST AMENDMENT TO
EMPLOYMENT AGREEMENT
This First Amendment to Employment Agreement (this “Amendment”) is entered into as of July 31, 2024, by and between Exact Sciences Corporation, a Delaware corporation (the “Company”), and Brian Baranick. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Employment Agreement (as defined below).
RECITALS
    A.    WHEREAS, the Company and Employee are Parties to that certain Employment Agreement entered into effective as of September 2, 2022 (the “Employment Agreement”); and
    B.    WHEREAS, the Parties desire to amend certain provisions of the Employment Agreement, as more particularly set forth herein.
AGREEMENT
    In consideration of the foregoing and the mutual covenants and agreements herein contained, and intending to be legally bound hereby, the Parties agree as follows:
1.Addition of Section 7.2(c). Section 7 of the Employment Agreement is hereby amended by adding the following new Section 7.2(c):
    “(c)    Separation from Service in connection with a Change in Control. If within four (4) months before or twelve (12) months after a Change in Control, Employee incurs a Separation from Service initiated by the Company (or a successor) without Cause or initiated by Employee for Good Reason, then subject to the conditions described in Section 7.3 below, the Company shall provide Employee the following payments and other benefits:
(i)(A) A lump-sum payment equal to eighteen (18) months of Employee’s then current Base Salary; and (B) any accrued but unpaid Base Salary as of the day of the Separation from Service.
(ii)To the extent not duplicative with any bonus policy, plan, or program that provides for a prorated bonus following a Separation from Service, a lump-sum cash payment equal to Employee’s Year-End Bonus, at target performance, for the year of the Separation from Service, prorated based on the number of days elapsed in the performance period corresponding to such Year-End Bonus through the date of the Separation from Service, divided by the number of days in such performance period.
(iii)A lump-sum cash payment equal to 150% of Employee’s Year-End Bonus, at target performance, for the year of Separation from Service.
(iv)A lump-sum cash payment that is equal to twelve (12) months of premium payments for COBRA coverage for health, dental, and vision coverage based on the Company-provided health, dental, and vision coverage in which the Employee and the Employee’s dependents are enrolled at the time of the Employee’s Separation from Service. This lump-sum cash payment may be used for any purpose, including but not limited to continuation coverage under COBRA.


(v)Ten Thousand Dollars ($10,000) towards the cost of an outplacement consulting package for Employee.
(vi)The cash payments described above will be made on the first payroll date that is on or that immediately follows the sixtieth (60th) day following the Separation from Service. If a Separation from Service covered by this Section 7.2(c) occurs prior to a Change in Control, then the installment payments referenced in Section 7.1 will commence thereunder, and the lump sum payment of any additional amount provided under this Section 7.2(c) will be made as soon as administratively practicable (not more than ten (10) days) after the date of the Change in Control, reduced by any amounts already provided under Section 7.1 in order to avoid duplication of benefits.”
2.Amendment and Ratification. Except as specifically amended hereby, all terms, conditions, covenants, representations, and warranties contained in the Employment Agreement shall remain in full force and effect and shall be binding upon the Parties.
3.Entire Agreement. The Employment Agreement, as amended hereby, together with the documents incorporated therein, constitute the entire agreement (and supersede all prior written agreements, arrangements, communications and understandings and all prior and contemporaneous oral agreements, arrangements, communications and understandings) between the Parties with respect to the subject matter thereof and hereof.
4.Counterparts. This Amendment may be executed in two or more counterparts, all of which shall be considered one and the same instrument and shall become effective when one or more counterparts have been signed by each of the Parties and delivered to the other Party.
5.Facsimile or .pdf Signature. This Amendment may be executed by facsimile or .pdf signature and a facsimile or .pdf signature shall constitute an original for all purposes.


[Signature page follows]

2


IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed as of the date first written above.
EXACT SCIENCES CORPORATION
By:
Name: Kevin Conroy
Title: CEO
EXECUTIVE
Jacob Orville
[SIGNATURE PAGE TO FIRST AMENDMENT TO EMPLOYMENT AGREEMENT]
EXHIBIT 10.4

SECOND AMENDMENT TO
EMPLOYMENT AGREEMENT
This Second Amendment to Employment Agreement (this “Amendment”) is entered into as of July 31, 2024, by and between Exact Sciences Corporation, a Delaware corporation (the “Company”), and Sarah Condella. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Employment Agreement (as defined below).
RECITALS
    A.    WHEREAS, the Company and Employee are Parties to that certain Employment Agreement entered into effective as of August 22, 2017 as amended by that certain Amendment to 2017 Employment Agreement dated March 23, 2021 (the “Employment Agreement”); and
    B.    WHEREAS, the Parties desire to amend certain provisions of the Employment Agreement, as more particularly set forth herein.
AGREEMENT
    In consideration of the foregoing and the mutual covenants and agreements herein contained, and intending to be legally bound hereby, the Parties agree as follows:
1.Addition of Section 7.2(c). Section 7 of the Employment Agreement is hereby amended by adding the following new Section 7.2(c):
    “(c)    Separation from Service in connection with a Change in Control. If within four (4) months before or twelve (12) months after a Change in Control, Employee incurs a Separation from Service initiated by the Company (or a successor) without Cause or initiated by Employee for Good Reason, then subject to the conditions described in Section 7.3 below, the Company shall provide Employee the following payments and other benefits:
(i)(A) A lump-sum payment equal to eighteen (18) months of Employee’s then current Base Salary; and (B) any accrued but unpaid Base Salary as of the day of the Separation from Service.
(ii)To the extent not duplicative with any bonus policy, plan, or program that provides for a prorated bonus following a Separation from Service, a lump-sum cash payment equal to Employee’s target annual bonus set forth in Section 3.2, for the year of the Separation from Service, prorated based on the number of days elapsed in the performance period corresponding to such target annual bonus through the date of the Separation from Service, divided by the number of days in such performance period.
(iii)A lump-sum cash payment equal to 150% of Employee’s target annual bonus set forth in Section 3.2, for the year of Separation from Service.
(iv)A lump-sum cash payment that is equal to twelve (12) months of premium payments for COBRA coverage for health, dental, and vision coverage based on the Company-provided health, dental, and vision coverage in which the Employee and the Employee’s dependents are enrolled at the time of the Employee’s Separation from Service. This lump-sum cash payment may be used for any purpose, including but not limited to continuation coverage under COBRA.


(v)Ten Thousand Dollars ($10,000) towards the cost of an outplacement consulting package for Employee.
(vi)The cash payments described above will be made on the first payroll date that is on or that immediately follows the sixtieth (60th) day following the Separation from Service. If a Separation from Service covered by this Section 7.2(c) occurs prior to a Change in Control, then the installment payments referenced in Section 7.1 will commence thereunder, and the lump sum payment of any additional amount provided under this Section 7.2(c) will be made as soon as administratively practicable (not more than ten (10) days) after the date of the Change in Control, reduced by any amounts already provided under Section 7.1 in order to avoid duplication of benefits.”
2.Amendment and Ratification. Except as specifically amended hereby, all terms, conditions, covenants, representations, and warranties contained in the Employment Agreement shall remain in full force and effect and shall be binding upon the Parties.
3.Entire Agreement. The Employment Agreement, as amended hereby, together with the documents incorporated therein, constitute the entire agreement (and supersede all prior written agreements, arrangements, communications and understandings and all prior and contemporaneous oral agreements, arrangements, communications and understandings) between the Parties with respect to the subject matter thereof and hereof.
4.Counterparts. This Amendment may be executed in two or more counterparts, all of which shall be considered one and the same instrument and shall become effective when one or more counterparts have been signed by each of the Parties and delivered to the other Party.
5.Facsimile or .pdf Signature. This Amendment may be executed by facsimile or .pdf signature and a facsimile or .pdf signature shall constitute an original for all purposes.


[Signature page follows]
2


IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed as of the date first written above.
EXACT SCIENCES CORPORATION
By:
Name: Kevin Conroy
Title: CEO
EXECUTIVE
Sarah Condella
[SIGNATURE PAGE TO SECOND AMENDMENT TO EMPLOYMENT AGREEMENT]
EXHIBIT 10.5
EXACT SCIENCES CORPORATION
2010 EMPLOYEE STOCK PURCHASE PLAN
(As amended and restated on July 31, 2024)
Article 1—Purpose.
This 2010 Employee Stock Purchase Plan, as amended and restated (the "Plan"), is intended to encourage stock ownership by all eligible employees of Exact Sciences Corporation (the "Company"), a Delaware corporation, and its Participating Subsidiaries (as defined in Article 17) so that they may share in the growth of the Company by acquiring or increasing their proprietary interest in the Company through the purchase of shares of the Company's common stock ("Common Stock"). The Plan is designed to encourage eligible employees to remain in the employ of the Company and its Participating Subsidiaries.
It is intended that a component of the Plan constitutes an “employee stock purchase plan” within the meaning of Section 423(b) of the U.S. Internal Revenue Code of 1986, as amended (the “Code” and such component, the “423 Component”) and the 423 Component shall be interpreted in accordance with that intent (although the Company makes no undertaking or representation to maintain such qualification).
In addition, this Plan authorizes the grant of Options (as defined in Article 5) under a component of the Plan that does not qualify as an “employee stock purchase plan” under Section 423 of the Code (such component, the “Non-423 Component”). Such Options granted under the Non-423 Component shall be granted pursuant to such sub-plans, appendices, rules or procedures as may be adopted by the Committee (as defined in Article 2) to achieve tax, securities laws or other objectives for the eligible employees and the Participating Subsidiaries designated for participation in the Non-423 Component. Except as otherwise provided herein or by the Committee, the Non-423 Component will operate and be administered in the same manner as the 423 Component.
For purposes of this Plan, the Committee may designate separate offerings under the Plan in which eligible employees will participate, the terms of which need not be identical even if the dates of the applicable Offering Periods of such offerings are identical, provided that the terms of participation are the same within each separate offering under the 423 Component as determined under Section 423 of the Code. Unless otherwise determined by the Committee, each offering under the Plan in which employee of one or more Participating Subsidiaries may participate shall be deemed a separate offering for purposes of Section 423 of the Code, even if the dates of the applicable Offering Periods of each such offering are identical, and the provisions of the Plan shall separately apply to each offering.
Article 2—Administration of the Plan.
The Plan may be administered by a committee appointed by the Board of Directors of the Company (the "Committee"). The Board of Directors may from time to time remove members from, or add members to, the Committee. Vacancies on the Committee, howsoever caused, shall be filled by the Board of Directors. The Committee may select one of its members as Chairman, and shall hold meetings at such times and places as it may determine. Acts by a majority of the Committee, or acts reduced to or approved in writing by a majority of the members of the Committee, shall be the valid acts of the Committee.
The Committee has authority at any time to: (i) adopt, alter and repeal such rules, guidelines and practices for the administration of the Plan and for its own acts and proceedings as it shall deem advisable; (ii) interpret the terms and provisions of the Plan; (iii) determine when and how Options shall be granted and the provisions and terms of each offering (which need not be identical between offerings); (iv) determine eligibility for participation in the Plan, including which subsidiaries of the Company will be Participating Subsidiaries and whether such Participating Subsidiaries participate in the 423 Component or the Non-423 Component (within the limits of the Plan); (v) make all determinations it deems advisable for the administration of the Plan; (vi) decide all disputes arising in connection with the Plan; and (vii) otherwise supervise the administration of the Plan. Further, the

1


Committee may adopt sub-plans, appendices, rules or procedures relating to the operation and administration of the Plan to accommodate the specific requirements of local laws and procedures, provided that the adoption and implementation of any such sub-plans, appendices rules and/or procedures would not cause the 423 Component to violate Section 423 of the Code.
All interpretations and decisions of the Committee shall be binding on all persons, including the Company and the participants. No member of the Board of Directors or individual exercising administrative authority with respect to the Plan shall be liable for any action or determination made in good faith with respect to the Plan or any Option granted hereunder.
In the event the Board of Directors fails to appoint or refrains from appointing a Committee, the Board of Directors or the Compensation Committee of the Board of Directors shall have all power and authority to administer the Plan. In such event, the word "Committee" wherever used herein shall be deemed to mean the Board of Directors or the Compensation Committee of the Board of Directors.
To the extent not prohibited by applicable law, the Committee may, from time to time, delegate some or all of its authority under the Plan to a subcommittee or subcommittees of the Committee, to one or more of the Company’s officers or management team, or to other persons or groups of persons as it deems necessary, appropriate or advisable under conditions or limitations that it may set at or after the time of the delegation. For purposes of the Plan, reference to the Committee will be deemed to include any subcommittee, subcommittees, or other persons or groups of persons to whom the Committee delegates authority pursuant to this provision.
Article 3—Eligible Employees.
All employees of the Company or any of its Participating Subsidiaries who are employed on or before the forty-fifth (45th) day (or such other period of time not to exceed two (2) years) prior to the beginning of an Offering Period and whose customary employment at such time is more than 20 hours per week and for more than five months in any calendar year shall be eligible to receive Options under the Plan to purchase shares of Common Stock, provided that the Committee may allow employees whose customary employment is below these thresholds to be considered as eligible employees, including where applicable law requires that such employees be considered as eligible employees, subject in all cases to the provisions of this Article 3 and the requirements set forth in Article 7 hereof.
An employee who works for a Participating Subsidiary and is a citizen or resident of a jurisdiction other than the United States (without regard to whether such individual also is a citizen or resident of the United States or is a resident alien (within the meaning of Section 7701(b)(1)(A) of the Code)) may be excluded from participation in the Plan or an offering if the participation of such employee is prohibited under the laws of the applicable jurisdiction or if complying with the laws of the applicable jurisdiction would cause the Plan or an offering under the 423 Component to violate Section 423 of the Code. In the case of the Non-423 Component, an employee (or group of employees) may be excluded from participation in the Plan if the Committee has determined, in its sole discretion, that participation of such employee(s) is not advisable or practicable for any reason.
In no event may an employee be granted an Option if such employee, immediately after the Option was granted, would be treated as owning stock possessing five percent or more of the total combined voting power or value of all classes of stock of the Company or of any parent corporation or subsidiary corporation, as the terms "parent corporation" and "subsidiary corporation" are defined in Section 424(e) and (f) of the Code. For purposes of determining stock ownership under this paragraph, the rules of Section 424(d) of the Code shall apply, and stock which the employee may purchase under outstanding Options shall be treated as stock owned by the employee.
Article 4—Stock Subject to the Plan.
The stock subject to the Options under the Plan shall be shares of the Company's authorized but unissued common stock, par value $.01 per share (the "Common Stock"), or shares of Common Stock reacquired by the Company, including shares purchased in the open market. The aggregate number of shares of Common Stock which

2


may be issued pursuant to the Plan is 5,800,000 subject to adjustment as provided in Article 12. If any Option granted under the Plan shall expire or terminate for any reason without having been exercised in full or shall cease for any reason to be exercisable in whole or in part, the unpurchased shares subject thereto shall again be available under the Plan. For avoidance of doubt, up to the maximum number of Shares reserved under this Article 4 may be used to satisfy purchases of shares of Common Stock under the 423 Component and any remaining portion of such maximum number of shares of Common Stock may be used to satisfy purchases of shares of Common Stock under the Non-423 Component.
Article 5—Offering Period and Stock Options.
The Plan shall be implemented by consecutive or overlapping Offering Periods, with a new Offering Period commencing on the first day of the relevant Offering Period and terminating on the last day of the relevant Offering Period (an “Offering Period”). The Offering Periods shall: (a) consist of one or more dates within each Offering Period on which shares of Common Stock may be purchased by participants in an Offering Period specified by the Committee prior to the scheduled beginning of the applicable Offering Period, to the extent they differ from the Exercise Dates set forth below ("Exercise Date(s)"); and (b) be of a duration, and commence on the dates, specified by the Committee prior to the scheduled beginning of the applicable Offering Period, to the extent they differ from the Offering Periods set forth below, provided that each Offering Period may not have a duration exceeding twenty-seven (27) months. Offering Periods under the Plan that began prior to November 1, 2024, shall consist of twenty-four-month periods commencing on November 1 and May 1 of each calendar year. For Offering Periods that began prior to November 1, 2024, there shall be four Exercise Dates occurring on each April 30 and October 31 (or, if such date is not a trading day, the first trading day thereafter) within each such Offering Period. Unless and until otherwise determined by the Committee, Offering Periods that begin on or after November 1, 2024, shall consist of six-month periods commencing on November 1 and May 1 of each calendar year. Unless and until otherwise determined by the Committee, for Offering Periods beginning on or after November 1, 2024, there shall be one Exercise Date per Offering Period, occurring on April 30 for Offering Periods that begin on November 1 and on October 31 for Offering Periods that begin on May 1 (or, if such Exercise Date is not a trading day, the first trading day thereafter). For the avoidance of any doubt, the Committee is vested with the authority to establish alternative sequential or overlapping Offering Periods, a different number of Exercise Dates within an Offering Period, a different duration for one or more Offering Periods or different commencement or ending dates for such Offering Periods with respect to future Offering Periods in accordance with the provisions contemplated in this Article 5 without stockholder approval.
On the first business day at the beginning of each Offering Period, the Company will grant to each eligible employee who is then a participant in the Plan an Option to purchase shares on the Exercise Dates (the "Option"), at the Option Price hereinafter provided for, a maximum of 10,000 shares of Common Stock or such other smaller maximum number of shares of Common Stock that may be specified by the Committee prior to the scheduled beginning of the applicable Offering Period, on condition that such employee remains eligible to participate in the Plan on each Exercise Date. If the participant's accumulated payroll deductions on the last date of the Offering Period would enable the participant to purchase more than the maximum number of shares provided herein except for the share limitation set forth herein, the excess of the amount of the accumulated payroll deductions over the aggregate purchase price of the maximum number of Shares of Common Stock that may be purchased in accordance with this Article 5 shall be promptly refunded to the participant by the Company, without interest. The participant shall be entitled to exercise the Option so granted only to the extent of the participant's accumulated payroll deductions on the Exercise Date. The option price per share of Common Stock for each Exercise Date within an Offering Period shall be the lesser of (i) 85% of the average market price of the Common Stock on the first business day of the Offering Period and (ii) 85% of the average market price of the Common Stock on the applicable Exercise Date, in either event rounded up to the nearest cent (the "Option Price"). The foregoing limitation on the number of shares subject to Option and the Option Price shall be subject to adjustment as provided in Article 12.
Unless a participant files a new authorization or withdraws from the Plan, the deductions and purchases under the authorization the participant has on file under the Plan will continue from one Offering Period to succeeding (but not overlapping) Offering Periods as long as the Plan remains in effect. Notwithstanding any of the foregoing, to the extent that the Committee establishes multiple Exercise Dates within an Offering Period or

3


overlapping Offering Periods with an Exercise Date based (in part) on the average market price of the Common Stock on the first business day of an Offering Period, the Committee shall have discretion to structure an Offering Period such that if the average market price of the Common Stock on an Exercise Date is less than or equal to the average market price of the Common Stock on the first business day of the Offering Period to which such Exercise Date relates, all participants shall be automatically withdrawn from such Offering Period immediately after the acquisition of shares of Common Stock for such Exercise Date and automatically enrolled in the immediately following Offering Period as of the first day thereof.
For purposes of the Plan, the term "average market price" on any date means (i) the average (on that date) of the high and low prices of the Common Stock on the principal national securities exchange on which the Common Stock is traded, if the Common Stock is then traded on a national securities exchange; or (ii) the average of the closing bid and asked prices last quoted (on that date) by an established quotation service for over-the-counter securities, if the Common Stock is not reported on the NASDAQ; or (iii) if the Common Stock is not publicly traded, the fair market value of the Common Stock as determined by the Committee after taking into consideration all factors which it deems appropriate, including, without limitation, recent sale and offer prices of the Common Stock in private transactions negotiated at arm's length.
For purposes of the Plan, the term "business day" means a day on which there is trading on the NASDAQ Capital Market or the aforementioned national securities exchange, whichever is applicable pursuant to the preceding paragraph; and if neither is applicable, a day that is not a Saturday, Sunday or legal holiday in State of Wisconsin.
Notwithstanding the foregoing, no participant may be granted an Option which permits his or her rights to purchase shares under the Plan, and any other employee stock purchase plan of the Company or Subsidiaries, to accrue at a rate which exceeds $25,000 of the fair market value of such shares (determined on the Option grant date or dates) for each calendar year in which the Option is outstanding at any time. The purpose of the limitation in the preceding sentence is to comply with Section 423(b)(8) of the Code and shall be applied taking Options into account in the order in which they were granted. Solely with respect to the 423 Component, for Offering Periods beginning on or after May 1, 2023, once the participant's accumulated payroll deductions would enable the participant to purchase the maximum amount of Common Stock permitted under the Section 423(b)(8) limitation described in this paragraph, payroll deductions will cease until the first day after the last Exercise Date in the calendar year in which accumulated payroll deductions reached such maximum amount. For both the 423 Component and the Non-423 Component, on any Exercise Date, if the participant’s accumulated payroll deductions would otherwise enable the participant to purchase Common Stock in excess of the Section 423(b)(8) limitation described in this paragraph, the excess of the amount over the accumulated payroll deductions over the aggregate purchase price of the shares actually purchased shall be promptly refunded to the participant by the Company, without interest.
Article 6—Exercise of Option.
Each eligible employee who continues to be a participant in the Plan on an Exercise Date within an Offering Period shall be deemed to have exercised his or her Option on such date and shall be deemed to have purchased from the Company such number of full shares of Common Stock reserved for the purpose of the Plan as the participant's accumulated payroll deductions on such date will pay for at the Option Price, subject to the 10,000 maximum share limit (or other maximum share limit, as applicable) of the Option and the Section 423(b)(8) limitation described in Article 5. Only full shares of Common Stock may be purchased under the Plan, unless the Committee determines, in its sole discretion, that fractional shares may be purchased under the Plan. Unless otherwise determined by the Committee in advance of any Offering Period, unused payroll deductions remaining in a participant's account at the end of either an Exercise Date or an Offering Period, by reason of the inability to purchase a fractional share, shall be promptly refunded to the participant by the Company, without interest.

4


Article 7—Authorization for Entering the Plan.
An employee may elect to enter the Plan by filling out, signing and delivering an authorization to the Company (in such form and according to such procedures determined by the Committee which may include by electronic or other delivery). Such authorization shall:
A.State the percentage to be deducted regularly from the employee's Compensation;
B.Authorize the purchase of stock for the employee in each Offering Period in accordance with the terms of the Plan;
C.Specify the exact name or names in which stock purchased for the employee is to be issued as provided under Article 11 hereof; and
D.Include the employee's agreement any other terms and conditions for participation in the Plan that the Committee determines to be advisable.
Such authorization must be received by the Company at least ten days before the first day of the next Offering Period, or within such other time frame as determined by the Company and communicated to eligible employees, and shall take effect only if the employee is an eligible employee on the first business day of such Offering Period.
An employee cannot participate in more than one Offering Period at any time.
Unless a participant files a new authorization or withdraws from the Plan, the deductions and purchases under the authorization the participant has on file under the Plan will continue from one Offering Period to succeeding (but not overlapping) Offering Periods as long as the Plan remains in effect. The terms and conditions applicable to participation in the Plan in such successive Offering Periods shall be those in effect at the commencement of such successive Offering Periods, as set forth in the Plan and the authorization documentation available to eligible employees at such time.
The Company will accumulate and hold for each participant's account the amounts deducted from his or her Compensation. No interest will be paid on these amounts, unless required by applicable law. For purposes of the Plan, the term “Compensation” means the amount of base pay or wages (including 13th/14th month payments or similar concepts under local law), including, in the interest of clarity, paid time off, paid leaves of absence (including statutory paid leave) paid by the Company, and overtime (including on-call payments and shift differentials), quarterly sales incentive payments, and corporate year-end and quarter-end bonus awards, but excluding any other one-time payments, allowances, and reimbursements for expenses such as relocation allowances or travel expenses, income or gains related to other Company share-based awards, and similar items. For U.S. participants, Compensation will include elective amounts that are not includible in the participant’s gross income by reason of Sections 125, 132(f), or 401(k) of the Code. The Committee shall have the discretion to determine the application of this definition to participants on payrolls outside of the United States.
Article 8—Maximum Amount of Payroll Deductions.
An employee may authorize payroll deductions in an amount (expressed as a whole percentage) not less than one percent (1%) but not more than fifteen percent (15%) of the employee's total Compensation.
Notwithstanding any other provisions of the Plan to the contrary, in non-U.S. jurisdictions where participation in the Plan through payroll deductions is prohibited or otherwise problematic under applicable laws (as determined by the Committee in its sole discretion), the Committee may provide that an eligible employee may elect to participate through other contributions in a form acceptable to the Committee in lieu of or in addition to payroll deductions, provided that, for any offering under the 423 Component, the Committee must determine that any alternative method of contribution is applied on an equal and uniform basis to all eligible employees in the offering.

5


Any reference to “payroll deductions” in this Article 8 (or in any other section of the Plan) will similarly cover contributions by other means made pursuant to this Article 8.
Article 9—Change in Payroll Deductions.
Payroll deductions may not be increased or decreased during an Offering Period. However, a participant may withdraw in full from the Plan (as described in Article 10). The Committee may, in advance of any Offering Period, establish rules, procedures and deadlines permitting a participant to increase, decrease or terminate his or her payroll deductions during an Offering Period.
Article 10—Withdrawal from the Plan.
A participant may withdraw from the Plan (in whole but not in part), within such time prior to the Exercise Date for such Offering Period as may be established by the Committee, by delivering a withdrawal notice to the Company (in such form and according to such procedures determined by the Committee which may include by electronic or other delivery). In the event a participant elects to withdraw from the Plan, amounts then credited to such participant's account shall be returned to the participant as soon as practicable after such election is received by the Company (without any interest thereon except as may be required by applicable local laws), the participant shall cease to participate in the Plan and the participant’s Option for such Offering Period shall terminate. 
To re-enter the Plan, an employee who has previously withdrawn must file a new authorization at least ten days before the first day of the next Offering Period in which he or she wishes to participate, or within such other time frame as determined by the Company and communicated to eligible employees. The employee's re-entry into the Plan becomes effective at the beginning of such Offering Period, provided that he or she is an eligible employee on the first business day of the Offering Period.
Article 11—Issuance of Stock.
Certificates for stock issued to participants (or other indicia of ownership of such stock) shall be delivered as soon as practicable after each Exercise Date by the Company's transfer agent.
Stock purchased under the Plan shall be issued only in the name of the participant, or if the participant's authorization so specifies and if and to the extent permitted by the Company, in the name of the participant and another person of legal age as joint tenants with rights of survivorship.
Article 12—Adjustments.
Upon the happening of any of the following described events, a participant's rights under Options granted under the Plan shall be adjusted as hereinafter provided:
A.In the event that the shares of Common Stock shall be subdivided or combined into a greater or smaller number of shares or if, upon a reorganization, split-up, liquidation, recapitalization or the like of the Company, the shares of Common Stock shall be exchanged for other securities of the Company, each participant shall be entitled, subject to the conditions herein stated, to purchase such number of shares of Common Stock or amount of other securities of the Company as were exchangeable for the number of shares of Common Stock that such participant would have been entitled to purchase except for such action, and appropriate adjustments shall be made in the purchase price per share to reflect such subdivision, combination or exchange; and
B.In the event the Company shall issue any of its shares or other securities, including any of the shares of any of its subsidiaries, as a stock dividend upon or with respect to the shares of stock of the class which shall at the time be subject to Option hereunder, each participant upon exercising such an Option shall be entitled to receive (for the purchase price paid upon such exercise) the shares as to which the participant is exercising his or her Option and, in addition thereto (at no additional cost), such number of

6


shares of the class or classes in which such stock dividend or dividends were declared or paid, and such amount of cash in lieu of fractional shares, as is equal to the number of shares thereof and the amount of cash in lieu of fractional shares, respectively, which the participant would have received if the participant had been the holder of the shares as to which the participant is exercising his or her Option at all times between the date of the granting of such Option and the date of its exercise.
Upon the happening of any of the foregoing events (or in the event of an extraordinary cash dividend or other distribution that affects the shares of Common Stock), the class and aggregate number of shares set forth in Article 4 hereof which are subject to Options which have been or may be granted under the Plan and the limitations set forth in the second paragraph of Article 5 shall also be appropriately adjusted to reflect the events specified in paragraphs A and B above. Notwithstanding the foregoing, any adjustments made pursuant to paragraphs A or B shall be made only after the Committee, based on advice of counsel for the Company, determines whether such adjustments would constitute a "modification" (as that term is defined in Section 424 of the Code). If the Committee determines that such adjustments would constitute a modification, it may refrain from making such adjustments.
If the Company is to be consolidated with or acquired by another entity in a merger, a sale of all or substantially all of the Company's assets or otherwise (an "Acquisition"), the Committee or the board of directors of any entity assuming the obligations of the Company hereunder (the "Successor Board") shall, with respect to Options then outstanding under the Plan, either (i) make appropriate provision for the continuation of such Options by arranging for the substitution on an equitable basis for the shares then subject to such Options either (a) the consideration payable with respect to the outstanding shares of the Common Stock in connection with the Acquisition, (b) shares of stock of the successor corporation, or a parent or subsidiary of such corporation, or (c) such other securities as the Successor Board deems appropriate, the fair market value of which shall not materially exceed the fair market value of the shares of Common Stock subject to such Options immediately preceding the Acquisition; (ii) shorten the Offering Period with respect to which such Options relate by setting a new Exercise Date on which such Offering Period will end, with such new Exercise Date occurring before the effective date of the Acquisition, and provided that each participant shall be notified of the new Exercise Date on which the Options will be exercised as provided in Article 6 hereof, unless prior to such date the participant has withdrawn from the Offering Period as provided in Article 10 hereof or the participant has ceased to be an eligible employee as provided in Article 14 hereof; or (iii) terminate each participant's Option in exchange for a cash payment equal to the excess of (a) the fair market value, on the date of the Acquisition, of the number of shares of Common Stock that the participant's accumulated payroll deductions as of the date of the Acquisition could purchase, at an Option Price determined with reference only to the first business day of the applicable Offering Period and subject to the maximum share limitation set forth in Article 5 hereof, Code Section 423(b)(8) and fractional-share limitations on the amount of stock a participant would be entitled to purchase, over (b) the result of multiplying such number of shares by such Option Price.
The Committee or Successor Board, as applicable, shall determine the adjustments to be made under this Article 12, and its determination shall be conclusive.
Article 13—No Transfer or Assignment of Employee's Rights.
An Option granted under the Plan may not be transferred or assigned, except by will or the laws of descent and distribution, and shall be exercised, during the participant's lifetime, only by the participant.
Article 14—Termination of Employee's Rights; Transfer of Employment.
Whenever a participant ceases to be an eligible employee because of retirement, voluntary or involuntary termination, resignation, layoff, discharge, death or for any other reason, his or her rights under the Plan shall immediately terminate, and the Company shall promptly refund, without interest (except where otherwise required by applicable law), the entire balance of his or her payroll deduction account under the Plan.
A participant will be deemed to have terminated employment, for this purpose, if the corporation that employs him or her, having been a Participating Subsidiary, ceases to be a subsidiary or to be designated as a

7


Participating Subsidiary, or if the employee is transferred to any corporation other than the Company or a Participating Subsidiary. A participant will not be deemed to have terminated employment for this purpose, if the participant is on an approved leave of absence for military service or sickness or for any other purpose approved by the Company for up to 90 days, or if the employee’s right to reemployment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Committee otherwise provides in writing, if longer than 90 days.
If a participant transfers employment from the Company or any Participating Subsidiary participating in the 423 Component to any Participating Subsidiary participating in the Non-423 Component, such transfer shall not be treated as a termination of employment, but the participant shall immediately cease to participate in the 423 Component; however, any contributions made for the Offering Period in which such transfer occurs shall be transferred to the Non-423 Component, and such participant shall immediately join the then-current offering under the Non-423 Component upon the same terms and conditions in effect for the participant’s participation in the 423 Component, except for such modifications otherwise applicable for participants in such offering. A participant who transfers employment from any Participating Subsidiary participating in the Non-423 Component to the Company or any Participating Subsidiary participating in the 423 Component shall not be treated as terminating the participant’s employment and shall remain a participant in the Non-423 Component until the earlier of (i) the end of the current Offering Period under the Non-423 Component, or (ii) the Offering Date of the first Offering Period in which the participant is eligible to participate following such transfer. Notwithstanding the foregoing, the Committee may establish different rules to govern transfers of employment between companies participating in the 423 Component and the Non-423 Component, consistent with the applicable requirements of Section 423 of the Code.
Article 15—Termination and Amendments to Plan.
Unless terminated sooner as provided below, the Plan shall terminate on October 31, 2030. The Plan may be terminated at any time by the Company's Board of Directors but such termination shall not affect Options then outstanding under the Plan. It will terminate in any case when all or substantially all of the unissued shares of stock reserved for the purposes of the Plan have been purchased. If at any time shares of stock reserved for the purpose of the Plan remain available for purchase but not in sufficient number to satisfy all then unfilled purchase requirements, the available shares shall be apportioned among participants in proportion to the amount of payroll deductions accumulated on behalf of each participant that would otherwise be used to purchase stock, and the Plan shall terminate. Upon such termination or any other termination of the Plan, all payroll deductions not used to purchase stock will be refunded, without interest (unless otherwise required under applicable law).
The Committee or the Board of Directors may from time to time adopt amendments to the Plan, provided that, without the approval of the stockholders of the Company, no amendment may (i) increase the number of shares that may be issued under the Plan; (ii) change the class of employees eligible to receive Options under the Plan, if such action would be treated as the adoption of a new plan for purposes of Section 423(b) of the Code; or (iii) cause Rule 16b-3 under the Securities Exchange Act of 1934 to become inapplicable to the Plan; (iv) otherwise be made to the extent stockholder approval is required under applicable law.
Article 16—Limits on Sale of Stock Purchased under the Plan.
The Plan is intended to provide shares of Common Stock for investment and not for resale. The Company does not, however, intend to restrict or influence any employee in the conduct of his or her own affairs. An employee may, therefore, sell stock purchased under the Plan at any time the employee chooses, subject to compliance with any applicable federal or state securities laws or other applicable securities or other laws and subject to any restrictions imposed under Article 23 to ensure that tax withholding obligations are satisfied. THE EMPLOYEE ASSUMES THE RISK OF ANY MARKET FLUCTUATIONS IN THE PRICE OF THE STOCK.

8


Article 17—Participating Subsidiaries.
The term "Participating Subsidiary" shall mean any present or future “subsidiary” of the Company, as that term is defined in Section 424(f) of the Code, that has been designated by the Committee from time to time, in its sole discretion, as eligible to participate in the Plan, such designation to specify whether such participation is in the 423 Component or Non-423 Component. A Participating Subsidiary may participate in either the 423 Component or Non-423 Component, but not both. Notwithstanding the foregoing, if any subsidiary is disregarded for U.S. tax purposes in respect of the Company or any Participating Subsidiary participating in the 423 Component, then such disregarded subsidiary shall automatically be a Participating Subsidiary participating in the 423 Component. If any subsidiary is disregarded for U.S. tax purposes in respect of any Participating Subsidiary participating in the Non-423 Component, the Committee may exclude such subsidiary from participating in the Plan, notwithstanding that the Participating Subsidiary in respect of which such subsidiary is disregarded may participate in the Plan. The Committee may so designate any subsidiary, or revoke any such designation, at any time and from time to time, either before or after the Plan is approved by the stockholders.
Article 18—Optionees Not Stockholders.
Neither the granting of an Option to an employee nor the deductions from an employee's Compensation shall constitute such employee a stockholder of the shares covered by an Option until such shares have been actually purchased by the employee.
Article 19—Section 409A.
The 423 Component of the Plan and the Options granted pursuant to an Offering Period are intended to be exempt from the application of Section 409A of the Code. Neither the Non-423 Component nor any Option granted pursuant to an Offering Period thereunder is intended to constitute or provide for “nonqualified deferred compensation” within the meaning of Section 409A of the Code. Notwithstanding any provision of the Plan to the contrary, if the Committee determines that any Option granted under the Plan may be or become subject to Section 409A of the Code or that any provision of the Plan may cause an Option granted under the Plan to be or become subject to Section 409A of the Code, the Committee may adopt such amendments to the Plan and/or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions as the Committee determines are necessary or appropriate to avoid the imposition of taxes under Section 409A of the Code, either through compliance with the requirements of Section 409A of the Code or with an available exemption therefrom.
Article 20—Application of Funds.
The proceeds received by the Company from the sale of Common Stock pursuant to Options granted under the Plan will be used for general corporate purposes.
Article 21—Notice to Company of Disposition.
By electing to participate in the Plan, each participant agrees to notify the Company in writing immediately after the participant transfers Common Stock acquired under the Plan. Each participant further agrees to provide any information about such a transfer as may be requested by the Company or any subsidiary corporation in order to assist it in complying with the tax laws. Without limitation to the foregoing, the Company reserves the right to require participants to hold any shares of Common Stock acquired under the Plan with a designated broker or other third party to facilitate compliance with the applicable reporting and other compliance requirements.
Article 22—Withholding of Additional Income Taxes.
By electing to participate in the Plan, each participant acknowledges that the Company and its Participating Subsidiaries are required to withhold any Tax-Related Items with respect to the amounts deducted from the participant's Compensation and accumulated for the benefit of the participant under the Plan, and each participant

9


agrees that the Company and Participating Subsidiaries may deduct additional amounts from the participant's Compensation, when amounts are added to the participant's account, used to purchase shares of Common Stock or refunded, in order to satisfy such withholding obligations.
At the time a participant’s Option is exercised, in whole or in part, or at the time a participant disposes of some or all of the shares of Common Stock acquired under the Plan (or any other time that a taxable event related to the Plan occurs), the participant will make adequate provision for the payment and/or withholding of any Tax-Related Items. In their sole discretion, and except as otherwise determined by the Committee, the Company or a Participating Subsidiary that employs the participant may satisfy their obligations to withhold Tax-Related Items by (a) withholding from the participant’s wages or other cash compensation, (b) withholding a number of shares of Common Stock otherwise issuable following the exercise of the Option, (c) withholding from proceeds from the sale of shares of Common Stock issued upon exercise, either through a voluntary sale or a mandatory sale arranged by the Company, or (d) withholding by any other means determined by the Committee, in its sole discretion, and in compliance with applicable law.
For purposes of this Article 23, “Tax-Related Items” means any U.S. and non-U.S. federal, provincial, state and/or local taxes (including, without limitation, income tax, social insurance contributions, fringe benefit tax, employment tax, stamp tax and any employer tax liability which has been transferred to a participant) for which a participant is liable in connection with participation in the Plan.
Article 23—Governmental Regulations.
The Company's obligation to sell and deliver shares of Common Stock under the Plan is subject to the approval of any governmental authority required in connection with the authorization, issuance or sale of such shares.
Government regulations may impose reporting or other obligations on the Company with respect to the Plan. For example, the Company may be required to identify shares of Common Stock issued under the Plan on its stock ownership records and send tax information statements to employees and former employees who transfer title to such shares.
Article 24—Rules Particular to Specific Jurisdictions.
Without limitation to and notwithstanding any other provision in this Plan, the Committee may adopt such sub-plans or rules relating to the operation and administration of the Plan to accommodate local laws, customs and procedures for jurisdictions outside of the United States, the terms of which may take precedence over other provisions of this Plan, with the exception of Article 4 hereof, but unless otherwise superseded by the terms of such sub-plan or rules, the provisions of this Plan will govern the operation of such sub-plan or rules. To the extent inconsistent with the requirements of Section 423, any such sub-plan or rules will be considered part of a Non-423 Offering, and Options granted thereunder will not be required by the terms of the Plan to comply with Section 423 of the Code. Without limiting the generality of the foregoing, the Committee is authorized to adopt sub-plans or rules for particular non-U.S. jurisdictions that modify the terms of the Plan to meet applicable local requirements, customs or procedures regarding, without limitation, (i) eligibility to participate, (ii) the definition of Compensation, (iii) the dates and duration of Offering Periods or other periods during which participants may contribute payroll deductions towards the purchase of shares of Common Stock, (iv) the method of determining the Option Price and the discount from fair market value at which shares may be purchased, (v) any minimum or maximum amount of payroll deductions a participant may contribute in an Offering Period or other specified period under the applicable sub-plan or rules, (vi) the treatment of Options upon an Acquisition or adjustment event described in Article 12, (vii) the handling of payroll deductions and the methods for contributing to the Plan by means other than payroll deductions, (viii) establishment of bank, building society or trust accounts to hold payroll deductions, (ix) payment of interest or waivers therefrom, (x) conversion of local currency, (xi) obligations to pay payroll tax, (xii)

10


determination of beneficiary designation requirements, (xiii) withholding procedures, and (xiv) handling of share issuances.
Article 25—Governing Law.
The validity and construction of the Plan shall be governed by the laws of Delaware, without giving effect to the principles of conflict of laws thereof.
Article 26—Approval of Board of Directors and Stockholders of the Company and Subsequent Restatements.
The Plan was initially adopted by the Board of Directors on April 15, 2010, and was initially approved by the stockholders of the Company on July 16, 2010. The Plan, as amended and restated, was adopted by the Committee on March 11, 2022. The Plan, as further amended and restated, was adopted by the Board of Directors on April 13, 2022, and was approved by the stockholders of the Company on June 9, 2022. Subsequent amendments and restatements were adopted by the Committee on March 22, 2023, and July 31, 2024.



11

EXHIBIT 31.1
Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Kevin T. Conroy, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Exact Sciences Corporation (the “registrant”);
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 5, 2024
By:/s/ Kevin T. Conroy
Kevin T. Conroy
President and Chief Executive Officer
(Principal Executive Officer)

EXHIBIT 31.2
Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Aaron Bloomer, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Exact Sciences Corporation (the “registrant”);
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 5, 2024
By:/s/ Aaron Bloomer
Aaron Bloomer
Executive Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)

EXHIBIT 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 
In connection with the Quarterly Report of Exact Sciences Corporation (the “Company”) on Form 10-Q for the quarter ended September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Kevin T. Conroy, President and Chief Executive Officer of the Company and Aaron Bloomer, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to our knowledge, that:
(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. 
Dated: November 5, 2024
/s/ Kevin T. Conroy
Name:Kevin T. Conroy
Title:President and Chief Executive Officer
(Principal Executive Officer)
Dated: November 5, 2024
/s/ Aaron Bloomer
Name:Aaron Bloomer
Title:Executive Vice President and Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)


v3.24.3
Cover Page - shares
 9 Months Ended
Sep. 30, 2024
Nov. 04, 2024
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2024  
Document Transition Report false  
Entity File Number 001-35092  
Entity Registrant Name EXACT SCIENCES CORPORATION  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 02-0478229  
Entity Address, Address Line One 5505 Endeavor Lane  
Entity Address, City or Town Madison  
Entity Address, State or Province WI  
Entity Address, Postal Zip Code 53719  
City Area Code 608  
Local Phone Number 535-8815  
Title of 12(b) Security Common Stock, $0.01 par value per share  
Trading Symbol EXAS  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   185,076,293
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q3  
Entity Central Index Key 0001124140  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
v3.24.3
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 588,830 $ 605,378
Marketable securities 432,301 172,266
Accounts receivable, net 264,819 203,623
Inventory 136,987 127,475
Prepaid expenses and other current assets 110,180 85,627
Total current assets 1,533,117 1,194,369
Long-term Assets:    
Property, plant and equipment, net 690,332 698,354
Operating lease right-of-use assets 122,452 143,708
Goodwill 2,367,450 2,367,120
Intangible assets, net 1,864,399 1,890,396
Other long-term assets, net 170,821 177,387
Total assets 6,748,571 6,471,334
Current liabilities:    
Accounts payable 97,653 78,816
Accrued liabilities 313,997 341,683
Operating lease liabilities, current portion 27,170 29,379
Convertible Notes Payable, Current 249,038 0
Loans Payable, Current 0 50,000
Other current liabilities 35,804 14,823
Total current liabilities 723,662 514,701
Long-term liabilities:    
Convertible notes, net, less current portion 2,319,490 2,314,276
Other long-term liabilities 332,213 335,982
Operating lease liabilities, less current portion 162,695 161,070
Total liabilities 3,538,060 3,326,029
Commitments and contingencies (Note 13)
Stockholders’ equity:    
Preferred stock, $0.01 par value Authorized—5,000,000; shares issued and outstanding—no shares at September 30, 2024 and December 31, 2023 0 0
Common stock, $0.01 par value Authorized—400,000,000; shares issued and outstanding—185,054,760 and 181,364,180 shares at September 30, 2024 and December 31, 2023 1,852 1,815
Additional paid-in capital 6,837,476 6,611,237
Accumulated other comprehensive income 4,630 1,428
Accumulated deficit (3,633,447) (3,469,175)
Total stockholders’ equity 3,210,511 3,145,305
Total liabilities and stockholders’ equity $ 6,748,571 $ 6,471,334
v3.24.3
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, authorized (in shares) 5,000,000 5,000,000
Preferred stock, issued (in shares) 0 0
Preferred stock, outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, authorized (in shares) 400,000,000 400,000,000
Common stock, issued (in shares) 185,054,760 181,364,180
Common stock, outstanding (in shares) 185,054,760 181,364,180
v3.24.3
Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Statement [Abstract]        
Revenue $ 708,655 $ 628,338 $ 2,045,443 $ 1,852,881
Operating expenses        
Cost of sales (exclusive of amortization of acquired intangible assets) 196,070 168,526 556,019 482,383
Research and development 100,101 111,446 331,593 310,960
Sales and marketing 194,653 173,159 572,288 536,613
General and administrative 217,201 217,393 662,174 672,653
Amortization of acquired intangible assets 24,435 22,992 71,057 68,849
Impairment of long-lived assets 18,698 0 31,296 621
Total operating expenses 751,158 693,516 2,224,427 2,072,079
Other operating income 3,100 72,027 6,632 72,027
Income (loss) from operations (39,403) 6,849 (172,352) (147,171)
Other income (expense)        
Investment income, net 11,582 2,065 29,596 7,383
Interest expense (9,607) (7,871) (17,439) (11,582)
Total other income (expense) 1,975 (5,806) 12,157 (4,199)
Net income (loss) before tax (37,428) 1,043 (160,195) (151,370)
Income tax expense (808) (249) (4,077) (3,013)
Net income (loss) $ (38,236) $ 794 $ (164,272) $ (154,383)
Increase (decrease) in net loss per share (in usd per share) $ (0.21) $ 0.00 $ (0.89) $ (0.86)
Net loss per share—basic (in usd per share) $ (0.21) $ 0.00 $ (0.89) $ (0.86)
Weighted average common shares outstanding—diluted (in shares) 184,795 184,075 183,823 179,817
Weighted average common shares outstanding—basic (in shares) 184,795 180,649 183,823 179,817
v3.24.3
Condensed Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Statement of Comprehensive Income [Abstract]        
Net income (loss) $ (38,236) $ 794 $ (164,272) $ (154,383)
Other comprehensive income (loss), net of tax:        
Unrealized gain on available-for-sale investments 3,700 423 2,775 4,327
Foreign currency adjustment 1,873 (1,235) 427 (626)
Comprehensive loss $ (32,663) $ (18) $ (161,070) $ (150,682)
v3.24.3
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit​
Beginning balance (in shares) at Dec. 31, 2022   177,925,631      
Beginning balance at Dec. 31, 2022 $ 3,043,162 $ 1,780 $ 6,311,644 $ (5,236) $ (3,265,026)
Increase (Decrease) in Stockholders' Equity          
Exercise of common stock options (in shares)   88,228      
Exercise of common stock options, net of shares withheld for taxes 964 $ 1 963    
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures 0 $ 13 (13)    
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures   1,299,071      
Issuance of common stock to fund the Company's 401(k) match (in shares)   517,215      
Issuance of common stock to fund the Company's 401(k) match 35,077 $ 5 35,072    
Stock-based compensation expense 49,139   49,139    
Net income (loss) (74,151)       (74,151)
Other comprehensive income (loss) 3,517     3,517  
Ending balance (in shares) at Mar. 31, 2023   179,830,145      
Ending balance at Mar. 31, 2023 3,057,708 $ 1,799 6,396,805 (1,719) (3,339,177)
Beginning balance (in shares) at Dec. 31, 2022   177,925,631      
Beginning balance at Dec. 31, 2022 3,043,162 $ 1,780 6,311,644 (5,236) (3,265,026)
Increase (Decrease) in Stockholders' Equity          
Stock-based compensation expense 172,700        
Net income (loss) (154,383)        
Ending balance (in shares) at Sep. 30, 2023   180,814,407      
Ending balance at Sep. 30, 2023 3,121,227 $ 1,809 6,540,362 (1,535) (3,419,409)
Beginning balance (in shares) at Mar. 31, 2023   179,830,145      
Beginning balance at Mar. 31, 2023 3,057,708 $ 1,799 6,396,805 (1,719) (3,339,177)
Increase (Decrease) in Stockholders' Equity          
Exercise of common stock options (in shares)   36,728      
Exercise of common stock options, net of shares withheld for taxes 852 $ 1 851    
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures 0 $ 1 (1)    
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures   134,002      
Stock Issued During Period, Value, Employee Stock Purchase Plan 16,344 $ 5 16,339    
Purchase of employee stock purchase plan shares (in shares)   544,453      
Issuance of common stock to fund the Company's 401(k) match (in shares)   335      
Issuance of common stock to fund the Company's 401(k) match 23 $ 0 23    
Stock-based compensation expense 61,725   61,725    
Net income (loss) (81,026)       (81,026)
Other comprehensive income (loss) 996     996  
Ending balance (in shares) at Jun. 30, 2023   180,545,663      
Ending balance at Jun. 30, 2023 3,056,622 $ 1,806 6,475,742 (723) (3,420,203)
Increase (Decrease) in Stockholders' Equity          
Exercise of common stock options (in shares)   51,262      
Exercise of common stock options, net of shares withheld for taxes 1,077 $ 1 1,076    
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures 0 $ 2 (2)    
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures   217,482      
Stock Replaced During Period, Value, Business Combination 1,675   1,675    
Stock-based compensation expense 61,871   61,871    
Net income (loss) 794       794
Other comprehensive income (loss) (812)     (812)  
Ending balance (in shares) at Sep. 30, 2023   180,814,407      
Ending balance at Sep. 30, 2023 $ 3,121,227 $ 1,809 6,540,362 (1,535) (3,419,409)
Beginning balance (in shares) at Dec. 31, 2023 181,364,180 181,364,180      
Beginning balance at Dec. 31, 2023 $ 3,145,305 $ 1,815 6,611,237 1,428 (3,469,175)
Increase (Decrease) in Stockholders' Equity          
Exercise of common stock options (in shares)   71,537      
Exercise of common stock options, net of shares withheld for taxes (1,408) $ 1 (1,409)    
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures (44) $ 17 (61)    
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures   1,792,087      
Issuance of common stock to fund the Company's 401(k) match (in shares)   617,384      
Issuance of common stock to fund the Company's 401(k) match 40,550 $ 6 40,544    
Stock-based compensation expense 60,370   60,370    
Net income (loss) (110,228)       (110,228)
Other comprehensive income (loss) (1,927)     (1,927)  
Ending balance (in shares) at Mar. 31, 2024   183,845,188      
Ending balance at Mar. 31, 2024 $ 3,132,618 $ 1,839 6,710,681 (499) (3,579,403)
Beginning balance (in shares) at Dec. 31, 2023 181,364,180 181,364,180      
Beginning balance at Dec. 31, 2023 $ 3,145,305 $ 1,815 6,611,237 1,428 (3,469,175)
Increase (Decrease) in Stockholders' Equity          
Stock-based compensation expense 165,700        
Net income (loss) $ (164,272)        
Ending balance (in shares) at Sep. 30, 2024 185,054,760 185,054,760      
Ending balance at Sep. 30, 2024 $ 3,210,511 $ 1,852 6,837,476 4,630 (3,633,447)
Beginning balance (in shares) at Mar. 31, 2024   183,845,188      
Beginning balance at Mar. 31, 2024 3,132,618 $ 1,839 6,710,681 (499) (3,579,403)
Increase (Decrease) in Stockholders' Equity          
Exercise of common stock options (in shares)   8,184      
Exercise of common stock options, net of shares withheld for taxes 43 $ 1 42    
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures (4) $ 2 (6)    
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures   210,590      
Stock Issued During Period, Value, Employee Stock Purchase Plan $ 19,402 $ 6 19,396    
Purchase of employee stock purchase plan shares (in shares) 604,226        
Stock-based compensation expense $ 56,555   56,555    
Net income (loss) (15,808)       (15,808)
Other comprehensive income (loss) (444)     (444)  
Ending balance (in shares) at Jun. 30, 2024   184,668,188      
Ending balance at Jun. 30, 2024 3,192,362 $ 1,848 6,786,668 (943) (3,595,211)
Increase (Decrease) in Stockholders' Equity          
Exercise of common stock options (in shares)   79,871      
Exercise of common stock options, net of shares withheld for taxes 2,132 $ 1 2,131    
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures (77) $ 3 (80)    
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures   306,701      
Stock-based compensation expense 48,757   48,757    
Net income (loss) (38,236)       (38,236)
Other comprehensive income (loss) $ 5,573     5,573  
Ending balance (in shares) at Sep. 30, 2024 185,054,760 185,054,760      
Ending balance at Sep. 30, 2024 $ 3,210,511 $ 1,852 $ 6,837,476 $ 4,630 $ (3,633,447)
v3.24.3
Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) - $ / shares
Sep. 30, 2024
Dec. 31, 2023
Sep. 30, 2023
Statement of Financial Position [Abstract]      
Common stock, par value (in dollars per share) $ 0.01 $ 0.01 $ 0.01
v3.24.3
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Cash flows from operating activities:    
Net loss $ (164,272) $ (154,383)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Depreciation 90,655 83,587
Loss on non-marketable and marketable equity securities 1,772 10,264
Deferred tax expense 1,827 (279)
Stock-based compensation 165,682 172,735
Gain on settlements of convertible notes, net (10,254) (10,324)
Amortization of acquired intangible assets 71,057 68,849
Impairment of long-lived assets 31,296 621
Gain (Loss) On Contingent Consideration From Disposition Of Asset (6,632) (68,900)
Remeasurement of contingent consideration liabilities (2,326) (13,051)
Non-cash lease expense 20,645 20,918
Other Noncash Income (Expense) (1,437) 3,530
Changes in assets and liabilities:    
Accounts receivable, net (61,410) (40,306)
Inventory, net (9,516) (13,074)
Operating lease liabilities (19,345) (19,741)
Accounts payable and accrued liabilities 38,258 51,084
Other assets (6,358) 3,686
Other liabilities 11,115 (1,274)
Net cash provided by operating activities 163,473 86,570
Cash flows from investing activities:    
Purchases of marketable securities (405,385) (75,096)
Maturities and sales of marketable securities 150,916 328,054
Purchases of property, plant and equipment (99,673) (89,268)
Payments to Acquire Businesses, Net of Cash Acquired 0 (50,000)
Purchases of intangible assets (45,000) 0
Payments to Acquire Other Investments 916 6,290
Proceeds From Sale Of Investments In Privately-Held Companies 0 9,296
Other investing activities (225) (250)
Net cash provided by (used in) investing activities (400,283) 116,446
Payment, Tax Withholding, Share-Based Payment Arrangement 767 2,893
Proceeds from Stock Plans 19,402 16,344
Cash flows from financing activities:    
Proceeds from issuance of convertible notes 266,750 137,976
Repayments of Accounts Receivable Securitization (50,000) 0
Other financing activities (15,544) (7,484)
Net cash provided by financing activities 221,375 149,729
Effects of exchange rate changes on cash and cash equivalents 427 (626)
Net increase (decrease) in cash, cash equivalents and restricted cash (15,008) 352,119
Cash, cash equivalents and restricted cash, beginning of period 609,675 242,790
Cash, cash equivalents and restricted cash, end of period 594,667 594,909
Supplemental disclosure of non-cash investing and financing activities    
Property, plant and equipment acquired but not paid 11,904 14,422
Supplemental disclosure of cash flow information:    
Interest paid 21,109 18,176
Reconciliation of cash, cash equivalents and restricted cash:    
Cash and cash equivalents 588,830 594,612
Restricted cash — included in other long-term assets, net 5,837 297
Total cash, cash equivalents and restricted cash $ 594,667 $ 594,909
v3.24.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Business
Exact Sciences Corporation (together with its subsidiaries, “Exact,” or the “Company”) was incorporated in February 1995. A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype DX® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis.
Basis of Presentation and Principles of Consolidation
The accompanying condensed consolidated financial statements, which include the accounts of the Company and those of its wholly owned subsidiaries and variable interest entities, are unaudited and have been prepared on a basis substantially consistent with the Company’s audited financial statements and notes as of and for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K (the “2023 Form 10-K”). All intercompany transactions and balances have been eliminated upon consolidation. These condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted (“GAAP”) in the United States of America (“U.S.”) and follow the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting only of adjustments of a normal and recurring nature) considered necessary for a fair statement of its financial position, operating results and cash flows for the periods presented. The condensed consolidated balance sheet at December 31, 2023 has been derived from audited financial statements, but does not contain all of the footnote disclosures from the 2023 Form 10-K. The results of the Company’s operations for any interim period are not necessarily indicative of the results of the Company’s operations for any other interim period or for a full fiscal year. The statements should be read in conjunction with the audited financial statements and related notes included in the 2023 Form 10-K.
Use of Estimates
The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Critical accounting policies are those that affect the Company’s financial statements materially and involve difficult, subjective or complex judgments by management, and actual results could differ from those estimates. These estimates include revenue recognition, valuation of intangible assets and goodwill, contingent consideration, and accounting for income taxes. The Company’s critical accounting policies and estimates are explained further in the notes to the condensed consolidated financial statements in this Quarterly Report on Form 10-Q and the 2023 Form 10-K.
Significant Accounting Policies
During the nine months ended September 30, 2024, there were no changes to the Company’s significant accounting policies as described in the Company’s 2023 Form 10-K, except as described in the Recently Adopted Accounting Pronouncements sections below.
Recent Accounting Pronouncements
Recently Adopted Accounting Pronouncements
In March 2024, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2024-02: Codification Improvement – Amendments to Remove References to the Concepts Statements. This update amends the Accounting Standards Codification (“ASC”) to remove references to various FASB Concepts Statements. The Company early adopted and prospectively applied the amendments in this update during the first quarter of fiscal year 2024. There was no significant impact to the Company’s condensed consolidated financial statements.
Recently Issued Accounting Pronouncements Not Yet Adopted
In October 2023, the FASB issued ASU No. 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative. This update modifies the disclosure or presentation requirements of a variety of topics in the ASC to conform with certain SEC amendments in Release No. 33-10532, Disclosure Update and Simplification. The amendments in this update should be applied prospectively, and the effective date for each amendment will be the date on which the SEC’s removal of that related disclosure from Regulation S-X or S-K becomes effective. However, if the SEC has not removed the related disclosure from its regulations by June 30, 2027, the amendments will be removed from the Codification and not become effective. Early adoption is prohibited. The Company is currently evaluating the potential impact of this guidance on its condensed consolidated financial statements.
In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This update improves reportable segment disclosure requirements, primarily through enhanced disclosures of significant segment expenses. The amendments in this update should be applied retrospectively to all prior periods presented in the consolidated financial statements and are effective for fiscal years beginning after December 31, 2023 and interim periods within fiscal years beginning after December 31, 2024. Early adoption is permitted. The Company is currently evaluating the potential impact of this guidance on its condensed consolidated financial statements.
In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvement to Income Tax Disclosures. This update improves income tax disclosure requirements, primarily through enhanced transparency and decision usefulness of disclosures. The amendments in this update should be applied prospectively with the option to apply retrospectively and are effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the potential impact of this guidance on its condensed consolidated financial statements.
Net Income (Loss) Per Share
Basic net income (loss) per common share (“EPS”) was determined by dividing net income (loss) applicable to common stockholders by the weighted average common shares outstanding during the period. Diluted EPS is based on shares that are outstanding per the calculation of basic EPS and on potentially dilutive shares.
The following is a reconciliation of the numerator and denominator used to calculate basic EPS and diluted EPS for the periods indicated:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2024202320242023
Net income (loss) available to common shareholders
$(38,236)$794 $(164,272)$(154,383)
Weighted average common shares outstanding - basic
184,795 180,649 183,823 179,817 
Effect of dilutive shares:
Restricted stock awards
— 2,153 — — 
Stock options
— 646 — — 
Employee stock purchase plan
— 589 — — 
Performance share units
— 38 — — 
Dilutive potential common shares
— 3,426 — — 
Weighted average common shares outstanding - diluted
184,795 184,075 183,823 179,817 
Earnings per common share from net earnings - basic
$(0.21)$0.00 $(0.89)$(0.86)
Earnings per common share from net earnings - diluted
$(0.21)$0.00 $(0.89)$(0.86)
The following potentially issuable common shares were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect due to net losses for each period:
Three Months Ended September 30,
Nine Months Ended September 30,
(In thousands)2024202320242023
Shares issuable upon conversion of convertible notes26,526 23,231 26,526 23,231 
Shares issuable upon the release of restricted stock awards7,487 — 7,487 6,423 
Shares issuable upon the release of performance share units2,037 — 2,037 1,584 
Shares issuable upon exercise of stock options1,028 — 1,028 1,305 
37,078 23,231 37,078 32,543 
v3.24.3
REVENUE
 9 Months Ended
Sep. 30, 2024
Revenue from Contract with Customer [Abstract]  
REVENUE REVENUE
The Company’s revenue is primarily generated by its laboratory testing services utilizing its Cologuard and Oncotype® tests. The services are considered completed upon release of a patient’s test result to the ordering healthcare provider.
The following table presents the Company’s revenues disaggregated by revenue source:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2024202320242023
Screening
Medicare Parts B & C$201,423 $173,624 $570,550 $521,370 
Commercial289,637 253,401 827,509 732,182 
Other53,841 44,988 153,246 124,443 
Total Screening544,901 472,013 1,551,305 1,377,995 
Precision Oncology
Medicare Parts B & C$47,080 $46,383 $142,597 $141,352 
Commercial47,685 44,430 143,572 135,574 
International49,433 38,599 140,688 111,453 
Other19,556 26,913 67,281 80,552 
Total Precision Oncology163,754 156,325 494,138 468,931 
COVID-19 Testing$— $— $— $5,955 
Total$708,655 $628,338 $2,045,443 $1,852,881 
Screening revenue primarily includes laboratory service revenue from Cologuard and Prevention Genetics, LLC (“PreventionGenetics”) tests while Precision Oncology revenue primarily includes laboratory service revenue from global Oncotype DX and therapy selection tests.
At each reporting period end, the Company conducts an analysis of the estimates used to calculate the transaction price to determine whether any new information available impacts those estimates made in prior reporting periods. Adjustments to revenue recognized during the period relating to prior period estimates were less than 1% of revenue recorded in the Company’s condensed consolidated statement of operations for the three and nine months ended September 30, 2024. Adjustments to revenue recognized during the period relating to prior period estimates were less than 2% of revenue recorded in the Company’s condensed consolidated statement of operations for the three and nine months ended September 30, 2023.
The Company’s deferred revenue, which is reported in other current liabilities in the Company’s condensed consolidated balance sheets, was not significant as of September 30, 2024 and December 31, 2023.
Revenue recognized for the three and nine months ended September 30, 2024 and 2023 that was included in the deferred revenue balance at the beginning of the period was not significant.
v3.24.3
MARKETABLE SECURITIES
 9 Months Ended
Sep. 30, 2024
Cash and Cash Equivalents [Abstract]  
MARKETABLE SECURITIES MARKETABLE SECURITIES
The following table sets forth the Company’s cash, cash equivalents, and marketable securities at September 30, 2024 and December 31, 2023:
(In thousands)September 30, 2024December 31, 2023
Cash and cash equivalents
Cash and money market$582,741 $530,100 
Cash equivalents6,089 75,278 
Total cash and cash equivalents588,830 605,378 
Marketable securities
Available-for-sale debt securities$427,072 $168,425 
Equity securities5,229 3,841 
Total marketable securities432,301 172,266 
Total cash, cash equivalents and marketable securities$1,021,131 $777,644 
Available-for-sale debt securities, including the classification within the condensed consolidated balance sheet at September 30, 2024, consisted of the following:
(In thousands)Amortized Cost
Gains in Accumulated Other Comprehensive Income (1)
Losses in Accumulated Other Comprehensive Income (1)
Estimated Fair Value
Cash equivalents
U.S. government agency securities$6,089 $— $— $6,089 
Total cash equivalents6,089 — — 6,089 
Marketable securities
Corporate bonds$212,590 $2,039 $(14)$214,615 
U.S. government agency securities126,676 436 (19)127,093 
Asset backed securities84,977 441 (54)85,364 
Total marketable securities424,243 2,916 (87)427,072 
Total available-for-sale securities$430,332 $2,916 $(87)$433,161 
______________
(1)There was no tax impact from the gains and losses in accumulated other comprehensive income (“AOCI”).
Available-for-sale debt securities, including the classification within the condensed consolidated balance sheet at December 31, 2023, consisted of the following:
(In thousands)Amortized Cost
Gains in Accumulated Other Comprehensive Income (1)
Losses in Accumulated Other Comprehensive Income (1)
Estimated Fair Value
Cash equivalents
Commercial paper$72,243 $— $— $72,243 
U.S. government agency securities3,035 — — 3,035 
Total cash equivalents75,278 — — 75,278 
Marketable securities
U.S. government agency securities$56,594 $166 $(44)$56,716 
Corporate bonds55,712 175 (59)55,828 
Asset backed securities35,081 65 (249)34,897 
Commercial paper
20,984 — — 20,984 
Total marketable securities168,371 406 (352)168,425 
Total available-for-sale securities$243,649 $406 $(352)$243,703 
______________
(1)There was no tax impact from the gains and losses in AOCI.
The following table summarizes contractual underlying maturities of the Company’s available-for-sale debt securities at September 30, 2024:
Due one year or lessDue after one year through five years
(In thousands)CostFair ValueCostFair Value
Cash equivalents
U.S. government agency securities$6,089 $6,089 $— $— 
Total cash equivalents6,089 6,089 — — 
Marketable securities
U.S. government agency securities$89,800 $90,048 $36,876 $37,045 
Corporate bonds51,706 51,890 160,884 162,725 
Asset backed securities11,388 11,448 73,589 73,916 
Total marketable securities152,894 153,386 271,349 273,686 
Total available-for-sale securities$158,983 $159,475 $271,349 $273,686 
The following table summarizes the gross unrealized losses and fair values of available-for-sale debt securities in an unrealized loss position as of September 30, 2024 aggregated by investment category and length of time those individual securities have been in a continuous unrealized loss position:
Less than one yearOne year or greaterTotal
(In thousands)Fair ValueGross Unrealized LossFair ValueGross Unrealized LossFair ValueGross Unrealized Loss
Marketable securities
Corporate bonds$9,501 $(13)$3,290 $(1)$12,791 $(14)
U.S. government agency securities8,551 (16)3,963 (3)12,514 (19)
Asset backed securities3,399 (3)3,986 (51)7,385 (54)
Total available-for-sale securities$21,451 $(32)$11,239 $(55)$32,690 $(87)
The Company evaluates investments that are in an unrealized loss position for impairment as a result of credit loss. It was determined that no credit losses exist as of September 30, 2024 and December 31, 2023 because the change in market value for those securities in an unrealized loss position resulted from fluctuating interest rates rather than a deterioration of the credit worthiness of the issuers.
The gains and losses recorded on available-for-sale debt securities and equity securities are included in investment income, net in the Company’s condensed consolidated statements of operations. The gains and losses recorded were not material for the three and nine months ended September 30, 2024 and 2023.
v3.24.3
INVENTORY
 9 Months Ended
Sep. 30, 2024
Inventory Disclosure [Abstract]  
INVENTORY INVENTORY
Inventory consisted of the following:
(In thousands)September 30, 2024December 31, 2023
Raw materials$54,714 $58,593 
Semi-finished and finished goods82,273 68,882 
Total inventory$136,987 $127,475 
v3.24.3
PROPERTY, PLANT AND EQUIPMENT
 9 Months Ended
Sep. 30, 2024
Property, Plant and Equipment [Abstract]  
PROPERTY, PLANT AND EQUIPMENT PROPERTY, PLANT AND EQUIPMENT
The carrying value and estimated useful lives of property, plant and equipment are as follows:
(In thousands)Estimated Useful LifeSeptember 30, 2024December 31, 2023
Property, plant and equipment
Landn/a$4,716 $4,716 
Leasehold and building improvements(1)227,600 214,562 
Land improvements15 years6,747 6,729 
Buildings
30 - 40 years
290,777 290,777 
Computer equipment and computer software3 years199,715 168,131 
Machinery and equipment
3 - 10 years
324,129 290,294 
Furniture and fixtures
3 - 10 years
36,976 35,756 
Assets under constructionn/a80,063 104,592 
Property, plant and equipment, at cost1,170,723 1,115,557 
Accumulated depreciation(480,391)(417,203)
Property, plant and equipment, net$690,332 $698,354 
______________
(1)Lesser of remaining lease term, building life, or estimated useful life.
Depreciation expense for the three months ended September 30, 2024 and 2023 was $30.3 million and $29.3 million, respectively. Depreciation expense for the nine months ended September 30, 2024 and 2023 was $90.7 million and $83.6 million, respectively.
At September 30, 2024, the Company had $80.1 million of assets under construction, which consisted of $52.3 million in machinery and equipment, $12.7 million in capitalized costs related to software projects, $10.0 million in leasehold and building improvements, $5.1 million related to buildings, and minimal furniture and fixtures. Depreciation will begin on these assets once they are placed into service upon completion.
v3.24.3
INTANGIBLE ASSETS AND GOODWILL
 9 Months Ended
Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
INTANGIBLE ASSETS AND GOODWILL INTANGIBLE ASSETS AND GOODWILL
Intangible Assets
The following table summarizes the net-book-value and estimated remaining life of the Company’s intangible assets as of September 30, 2024:
(In thousands)Weighted Average Remaining Life (Years)CostAccumulated Amortization
Net Balance at September 30, 2024
Finite-lived intangible assets
Trade name11.0$104,000 $(33,340)$70,660 
Customer relationships6.34,000 (1,222)2,778 
Patents and licenses9.756,542 (11,811)44,731 
Acquired developed technology (1)6.6887,708 (391,478)496,230 
Total finite-lived intangible assets1,052,250 (437,851)614,399 
In-process research and developmentn/a1,250,000 — 1,250,000 
Total intangible assets$2,302,250 $(437,851)$1,864,399 
The following table summarizes the net-book-value and estimated remaining life of the Company’s intangible assets as of December 31, 2023:
(In thousands)Weighted Average Remaining Life (Years)CostAccumulated Amortization
Net Balance at December 31, 2023
Finite-lived intangible assets
Trade name11.6$104,000 $(27,903)$76,097 
Customer relationships7.04,000 (889)3,111 
Patents and licenses4.511,542 (9,600)1,942 
Acquired developed technology (1)7.3887,789 (328,543)559,246 
Total finite-lived intangible assets1,007,331 (366,935)640,396 
In-process research and developmentn/a1,250,000 — 1,250,000 
Total intangible assets$2,257,331 $(366,935)$1,890,396 
______________
(1)The gross carrying amount includes an insignificant foreign currency translation adjustment related to the intangible asset acquired as a result of the acquisition of OmicEra Diagnostics GmbH (“OmicEra”).
As of September 30, 2024, the estimated future amortization expense associated with the Company’s finite-lived intangible assets for each of the five succeeding fiscal years is as follows:
(In thousands)
2024 (remaining three months)$24,100 
202596,361 
202695,300 
202795,300 
202895,300 
Thereafter208,038 
$614,399 
The Company’s acquired intangible assets are being amortized on a straight-line basis over their estimated useful lives.
There were no impairment losses recorded on finite-lived intangible assets during the three and nine months ended September 30, 2024 and 2023. Updates to key assumptions used to calculate the fair value of the Company’s in-process research and development asset (“IPR&D”) could change the Company’s estimate that it will recover the carrying amount of the IPR&D asset in the near term.
Goodwill
The change in the carrying amount of goodwill for the periods ended September 30, 2024 and December 31, 2023 is as follows:
(In thousands)
Balance, January 1, 2023
$2,346,040 
Resolution Bioscience acquisition
20,692 
Effects of changes in foreign currency exchange rates (1)388 
Balance, December 31, 2023
2,367,120 
Resolution Bioscience acquisition adjustments225 
Effects of changes in foreign currency exchange rates (1)105 
Balance September 30, 2024
$2,367,450 
______________
(1)Represents the impact of foreign currency translation related to the goodwill acquired as a result of the acquisition of OmicEra.
There were no impairment losses for the three and nine months ended September 30, 2024 and 2023.
v3.24.3
FAIR VALUE MEASUREMENTS
 9 Months Ended
Sep. 30, 2024
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS
The three levels of the fair value hierarchy established are as follows:
Level 1    Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2    Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
Level 3    Unobservable inputs that reflect the Company’s assumptions about the assumptions that market participants would use in pricing the asset or liability. Unobservable inputs shall be used to measure fair value to the extent that observable inputs are not available.
The following table presents the Company’s fair value measurements as of September 30, 2024 along with the level within the fair value hierarchy in which the fair value measurements, in their entirety, fall.
(In thousands)Fair Value at September 30, 2024Quoted Prices in Active Markets for Identical Assets (Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)
Cash, cash equivalents, and restricted cash
Cash and money market$582,741 $582,741 $— $— 
U.S. government agency securities6,089 — 6,089 — 
Restricted cash (1)
5,837 5,837 — — 
Marketable securities
Corporate bonds$214,615 $— $214,615 $— 
U.S. government agency securities127,093 — 127,093 — 
Asset backed securities85,364 — 85,364 — 
Equity securities5,229 5,229 — — 
Non-marketable securities$686 $— $— $686 
Liabilities
Contingent consideration$(283,231)$— $— $(283,231)
Total$744,423 $593,807 $433,161 $(282,545)
The following table presents the Company’s fair value measurements as of December 31, 2023 along with the level within the fair value hierarchy in which the fair value measurements, in their entirety, fall.
(In thousands)Fair Value at December 31, 2023Quoted Prices in Active Markets for Identical Assets (Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)
Cash, cash equivalents and restricted cash
Cash and money market$530,100 $530,100 $— $— 
Commercial paper72,243 — 72,243 — 
Restricted cash (1)
4,297 4,297 — — 
U.S. government agency securities3,035 — 3,035 — 
Marketable securities
U.S. government agency securities$56,716 $— $56,716 $— 
Corporate bonds55,828 — 55,828 — 
Asset backed securities34,897 — 34,897 — 
Commercial paper20,984 — 20,984 — 
Equity securities3,841 3,841 — — 
Non-marketable securities$7,650 $— $— $7,650 
Liabilities
Contingent consideration$(288,657)$— $— $(288,657)
Total$500,934 $538,238 $243,703 $(281,007)
_________________________________
(1)Restricted cash primarily represents cash held by a third-party financial institution as part of a cash collateral agreement related to the Company’s credit card program. The restrictions will lapse upon the termination of the agreements or the removal of the cash collateral requirement by the third-parties.
There have been no material changes in valuation techniques or transfers between fair value measurement levels during the three and nine months ended September 30, 2024. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities are valued using a third-party pricing agency where the valuation is based on observable inputs including pricing for similar assets and other observable market factors.
The Company has elected the fair value option under the income approach to measure certain Level 3 non-marketable securities. Gains and losses recorded on non-marketable securities are included in investment income, net in the condensed consolidated statement of operations. The following table provides a reconciliation of the beginning and ending balances of non-marketable securities valued using the fair value option:
(In thousands)Non-Marketable Securities
Beginning balance, January 1, 2024
$7,650 
Changes in fair value(714)
Settlement of non-marketable securities(6,250)
Ending balance, September 30, 2024
$686 
Contingent Consideration Liabilities
The fair value of the contingent consideration liabilities was $283.2 million and $288.7 million as of September 30, 2024 and December 31, 2023, respectively, of which $19.4 million was included in other current liabilities and $263.8 million was included in other long-term liabilities in the condensed consolidated balance sheet as of September 30, 2024. The contingent consideration liabilities were included in other long-term liabilities as of December 31, 2023.
The following table provides a reconciliation of the beginning and ending balances of contingent consideration:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2024202320242023
Beginning balance
$277,921 $302,141 $288,657 $306,927 
Changes in fair value (1)5,310 (8,364)(2,326)(13,051)
Payments (2)
— — (3,100)(99)
Ending balance
$283,231 $293,777 $283,231 $293,777 
______________
(1)The change in fair value of the contingent consideration liability is included in general and administrative expenses in the condensed consolidated statement of operations for the three and nine months ended September 30, 2024 and 2023.
(2)Payment was made in the second quarter of 2024 to settle the contingent consideration liability previously recorded related to the Company’s acquisition of OmicEra.
This fair value measurement of contingent consideration is categorized as a Level 3 liability, as the measurement amount is based primarily on significant inputs not observable in the market.
The fair value of the contingent consideration liabilities recorded from the Company’s acquisitions of Thrive Earlier Detection Corporation (“Thrive”), Ashion Analytics, LLC (“Ashion”), and OmicEra related to regulatory and product development milestones was $283.2 million and $288.7 million as of September 30, 2024 and December 31, 2023, respectively. The Company estimates the fair value of the contingent consideration liabilities related to the regulatory and product development milestones using the probability-weighted scenario based discounted cash flow model, which is consistent with the initial measurement of the contingent consideration liabilities. Probabilities of success are applied to each potential scenario and the resulting values are discounted using a present-value factor. The passage of time in addition to changes in projected milestone achievement timing, present-value factor, the degree of achievement, if applicable, and probabilities of success may result in adjustments to the fair value measurement. The fair value of the contingent consideration liability recorded related to regulatory and product development milestones was determined using a weighted average probability of success of 90% and 89% as of September 30, 2024 and December 31, 2023, respectively, and a weighted average present-value factor of 6.0% and 5.8% as of September 30, 2024 and December 31, 2023, respectively. The projected fiscal year of payment range is from 2025 to 2031. Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities.
The revenue milestone associated with the Ashion acquisition is not expected to be achieved and therefore no liability has been recorded for this milestone.
Non-Marketable Equity Securities
Non-marketable equity securities without readily determinable fair values, which are classified as a component of other long-term assets, net, had the following cumulative upward and downward adjustments and aggregate carrying amounts:
(In thousands)
September 30, 2024September 30, 2023
Cumulative upward adjustments (1)
$5,102 $779 
Cumulative downward adjustments and impairments (2)
15,071 15,071 
Aggregate carrying value (3)
52,227 31,654 
_________________________________
(1)    There were no material upward adjustments recorded on non-marketable equity securities held for the three and nine months ended September 30, 2024 and 2023.
(2)    There were no material downward adjustments or impairments recorded on non-marketable equity securities held for the three and nine months ended September 30, 2024 and 2023, respectively.
(3)    The aggregate carrying value of non-marketable equity securities was $46.0 million as of December 31, 2023.
There were no material realized gains or losses recorded during the three and nine months ended September 30, 2024 and 2023.
The Company has committed capital to venture capital investment funds of $18.0 million, of which $11.7 million remains callable through 2033 as of September 30, 2024. The aggregate carrying amount of these funds, which are classified as a component of other long-term assets, net in the Company’s condensed consolidated balance sheets, was $6.7 million and $5.2 million as of September 30, 2024 and December 31, 2023, respectively.
Derivative Financial Instruments
The Company enters into foreign currency forward contracts on the last day of each month to mitigate the impact of adverse movements in foreign exchange rates related to the remeasurement of monetary assets and liabilities and hedge the Company’s foreign currency exchange rate exposure. As of September 30, 2024 and December 31, 2023 the Company had open foreign currency forward contracts with notional amounts of $47.7 million and $39.5 million, respectively. The Company's foreign exchange derivative instruments are classified as Level 2 within the fair value hierarchy as they are valued using inputs that are observable in the market or can be derived principally from or corroborated by observable market data. The fair value of the open foreign currency forward contracts was zero at September 30, 2024 and December 31, 2023 and there were no gains or losses recorded to adjust the fair value of the open foreign currency contract held as of September 30, 2024. The contracts are closed subsequent to each month-end, and the gains and losses recorded from the contracts were not significant for the three and nine months ended September 30, 2024 and 2023.
v3.24.3
LONG-TERM DEBT
 9 Months Ended
Sep. 30, 2024
Debt Disclosure [Abstract]  
LONG-TERM DEBT LONG-TERM DEBT
Accounts Receivable Securitization Facility
On June 29, 2022, the Company, through a wholly-owned special purpose entity, Exact Receivables LLC (“Exact Receivables”) entered into an accounts receivable securitization program (the “Securitization Facility”) with PNC Bank, National Association (“PNC”), with a scheduled maturity date of June 29, 2024. The Securitization Facility required the Company to maintain minimum borrowings under the facility of $50.0 million. Upon the maturity of the Securitization Facility in June 2024, the Company repaid the previously outstanding balance of $50.0 million in full. The Securitization Facility provided Exact Receivables with a revolving line-of-credit of up to $150.0 million of borrowing capacity, subject to certain borrowing base requirements, by collateralizing a security interest in the domestic customer accounts receivable of certain wholly-owned subsidiaries of the Company. The amount available under the Securitization Facility fluctuated over time based on the total amount of eligible customer accounts receivable generated by the Company during the normal course of operations. The debt issuance costs incurred related to the Securitization Facility were not significant and were amortized over the life of the Securitization Facility through interest expense within the condensed consolidated statements of operations.
In connection with the Securitization Facility, the Company also entered into two Receivables Purchase Agreements (“Receivable Purchase Agreements”) on June 29, 2022. The Receivable Purchase Agreements were among the Company and certain wholly-owned subsidiaries of the Company, and between the Company and Exact Receivables. Under the agreements, the wholly-owned subsidiaries sold all of their right, title and interest in their accounts receivables to Exact Receivables. The receivables were used to collateralize borrowings made under the Securitization Facility. The Company retained the responsibility of servicing the accounts receivable balances pledged as collateral under the Securitization Facility and provided a performance guaranty.
As of December 31, 2023, the Company had an outstanding balance of $50.0 million, which was included in debt, current portion on the Company’s condensed consolidated balance sheet. Prior to the repayment, the outstanding balance accrued interest at a rate equal to a daily secured overnight financing rate (“SOFR”) plus a SOFR adjustment and an applicable margin. The interest rate was 6.89% as of the maturity date.
Revolving Loan Agreement
During November 2021, the Company entered into a revolving loan agreement (the “Revolving Loan Agreement”) with PNC. The Revolving Loan Agreement provides the Company with a revolving line of credit of up to $150.0 million (the “Revolver”). The Revolver is collateralized by the Company’s marketable securities held by PNC, which must continue to maintain a minimum market value of $150.0 million. The Revolver is available for general working capital purposes and all other lawful corporate purposes. In addition, the Company may request, in lieu of cash advances, letters of credit with an aggregate stated amount outstanding not to exceed $20.0 million. The availability of advances under the line of credit will be reduced by the stated amount of each letter of credit issued and outstanding.
Borrowings under the Revolving Loan Agreement accrue interest at an annual rate equal to the sum of the daily Bloomberg Short-Term Bank Yield Index Rate plus the applicable margin of 0.60%. Loans under the Revolving Loan Agreement may be prepaid at any time without penalty. In October 2022, the Revolving Loan Agreement was amended to extend the maturity date from November 5, 2023 to November 5, 2025. There were no other amendments to the Revolver.
The Company has agreed to various financial covenants under the Revolving Loan Agreement, and as of September 30, 2024, the Company is in compliance with all covenants.
In December 2021 and January 2023, PNC issued letters of credit of $2.9 million and $1.5 million, respectively, which reduced the amount available for cash advances under the line of credit to $145.6 million as of September 30, 2024 and December 31, 2023. As of September 30, 2024 and December 31, 2023, the Company has not drawn funds from, nor are any amounts outstanding under, the Revolving Loan Agreement.
v3.24.3
CONVERTIBLE NOTES
 9 Months Ended
Sep. 30, 2024
CONVERTIBLE NOTES [Abstract]  
CONVERTIBLE NOTES CONVERTIBLE NOTES
Convertible note obligations included in the condensed consolidated balance sheet consisted of the following as of September 30, 2024:
Fair Value (1)
(In thousands)Principal AmountUnamortized Debt Discount and Issuance CostsNet Carrying AmountAmountLeveling
2031 Convertible Notes - 1.750%
$620,709 $(14,090)$606,619 $623,558 2
2030 Convertible Notes - 2.000%
572,993 (3,820)569,173 652,244 2
2028 Convertible Notes - 0.375%
589,380 (5,346)584,034 546,650 2
2027 Convertible Notes - 0.375%
563,822 (4,158)559,664 547,668 2
2025 Convertible Notes - 1.000% (2)
249,172 (134)249,038 254,155 2
Convertible note obligations included in the condensed consolidated balance sheet consisted of the following as of December 31, 2023:
Fair Value (1)
(In thousands)Principal AmountUnamortized Debt Discount and Issuance CostsNet Carrying AmountAmountLeveling
2030 Convertible Notes - 2.000%
$572,993 $(4,349)$568,644 $684,475 2
2028 Convertible Notes - 0.375%
949,042 (10,499)938,543 887,354 2
2027 Convertible Notes - 0.375%
563,822 (5,429)558,393 549,839 2
2025 Convertible Notes - 1.000%
249,172 (476)248,696 293,300 2
______________
(1)The fair values are based on observable market prices for this debt, which is traded in less active markets and therefore is classified as a Level 2 fair value measurement.
(2)The Company’s convertible notes due in 2025 (the “2025 Notes”) mature on January 15, 2025 and are included in convertible notes, net, current portion on the condensed consolidated balance sheet as of September 30, 2024. The 2025 Notes were included in convertible notes, net, less current portion as of December 31, 2023.
Issuances and Settlements
In February 2023, the Company entered into a privately negotiated exchange and purchase agreement with a single holder of certain of the Company’s convertible notes due in 2027 (the “2027 Notes”) and 2028 (the “2028 Notes”). The Company issued the holder $500.0 million aggregate principal amount of 2.0% Convertible Notes due in 2030 (the “2030 Notes”) in exchange for $183.7 million of aggregate principal of 2027 Notes, $201.0 million of aggregate principal of 2028 Notes, and $138.0 million of cash. The extinguishment resulted in a gain on settlement of convertible notes of $17.7 million, which is included in interest expense in the condensed consolidated statement of operations for the nine months ended September 30, 2023. The gain represents the difference between (i) the fair value of the consideration transferred and (ii) the carrying value of the debt at the time of exchange.
In March 2023, the Company entered into a privately negotiated exchange agreement with two holders of certain of the 2025 Notes. The Company issued the holder $73.0 million aggregate principal amount of 2030 Notes in exchange for $65.8 million of aggregate principal of 2025 Notes. The extinguishment resulted in a loss on settlement of convertible notes of $7.4 million, which is included in interest expense in the condensed consolidated statement of operations for the nine months ended September 30, 2023. The loss represents the difference between (i) the fair value of the consideration transferred and (ii) the carrying value of the debt at the time of exchange.
The net proceeds from the issuance of the 2030 Notes were approximately $133.0 million, after deducting commissions and offering expenses payable by the Company.
The 2030 Notes will mature on March 1, 2030 and bear interest at a rate of 2.0% per year, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2023.
In April 2024, the Company entered into a privately negotiated exchange and purchase agreement with certain holders of the Company’s 2028 Notes. The Company issued $620.7 million aggregate principal amount of 1.75% Convertible Notes due in 2031 (the “2031 Notes” and, collectively with the 2025 Notes, 2027 Notes, 2028 Notes, and 2030 Notes, the “Notes”) in exchange for $359.7 million of aggregate principal of 2028 Notes, and $266.8 million of cash after deducting underwriting discounts. The extinguishment resulted in a gain on settlement of convertible notes of $10.3 million, which is included in interest expense in the condensed consolidated statement of operations for the nine months ended September 30, 2024. The gain represents the difference between (i) the fair value of the consideration transferred and (ii) the carrying value of the debt at the time of exchange.
The net proceeds from the issuance of the 2031 Notes were approximately $259.8 million, after deducting commissions and offering expenses payable by the Company.
The 2031 Notes will mature on April 15, 2031 and bear interest at a rate of 1.75% per year, payable semi-annually in arrears on October 15 and April 15 of each year, beginning on October 15, 2024. The Company has the ability to repurchase the 2031 Notes after April 17, 2029 upon the occurrence of certain events and during certain periods, as set forth in the Indenture filed at the time of the offering.
Summary of Conversion Features
Until the six-months immediately preceding the maturity date of the applicable series of the Company’s convertible notes, each series of Notes is convertible only upon the occurrence of certain events and during certain periods, as set forth in the Indentures filed at the time of the original offerings. On or after the date that is six-months immediately preceding the maturity date of the applicable series of Notes until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may elect to convert such Notes at any time, and if elected, the conversion would occur on the maturity date. The Notes will be convertible into cash, shares of the Company’s common stock (plus, if applicable, cash in lieu of any fractional share), or a combination of cash and shares of the Company’s common stock, at the Company’s election. If the Notes are not converted prior to the maturity date, the principal amount will be settled in cash upon maturity.
It is the Company’s intent to settle all conversions through combination settlement. The initial conversion rate is 13.26, 8.96, 8.21, 12.37, and 10.06 shares of common stock per $1,000 principal amount for the 2025 Notes, 2027 Notes, 2028 Notes, 2030 Notes, and 2031 Notes, respectively, which is equivalent to an initial conversion price of approximately $75.43, $111.66, $121.84, $80.83, and $99.36 per share of the Company’s common stock for the 2025 Notes, 2027 Notes, 2028 Notes, 2030 Notes, and 2031 Notes, respectively. The 2025 Notes, 2027 Notes, 2028 Notes, 2030 Notes, and 2031 Notes are potentially convertible into up to 3.3 million, 5.0 million, 4.8 million, 7.1 million, and 6.2 million shares, respectively. The conversion rate is subject to adjustment upon the occurrence of certain specified events as set forth in the Indentures filed at the time of the original offerings but will not be adjusted for accrued and unpaid interest. In addition, holders of the Notes who convert their Notes in connection with a “make-whole fundamental change” (as defined in the Indentures), will, under certain circumstances, be entitled to an increase in the conversion rate.
If the Company undergoes a “fundamental change” (as defined in the Indentures), holders of the Notes may require the Company to repurchase for cash all or part of their Notes at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest.
Based on the closing price of the Company’s common stock of $68.12 on September 30, 2024, the if-converted values on the Notes do not exceed the principal amount.
The Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness, or the issuance or repurchase of securities by the Company.
Ranking of Convertible Notes
The Notes are the Company’s senior unsecured obligations and (i) rank senior in right of payment to all of its future indebtedness that is expressly subordinated in right of payment to the Notes; (ii) rank equal in right of payment to each outstanding series thereof and to all of the Company’s future liabilities that are not so subordinated, unsecured indebtedness; (iii) are effectively junior to all of the Company’s existing and future secured indebtedness and other secured obligations, to the extent of the value of the assets securing that indebtedness and other secured obligations; and (iv) are structurally subordinated to all indebtedness and other liabilities of the Company’s subsidiaries.
Issuance Costs
Issuance costs are amortized to interest expense over the term of the Notes. The following table summarizes the original issuance costs at the time of issuance for each set of Notes:
(In thousands)
2031 Convertible Notes
$6,820 
2030 Convertible Notes4,938 
2028 Convertible Notes24,453 
2027 Convertible Notes14,285 
2025 Convertible Notes17,646 
Interest Expense
Interest expense on the Notes includes the following:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2024202320242023
Debt issuance costs amortization$1,334 $1,329 $3,965 $4,021 
Debt discount amortization322 25 611 81 
Gain on settlements of convertible notes— — (10,254)(10,324)
Coupon interest expense7,285 4,906 19,054 13,166 
Total interest expense (income) on convertible notes$8,941 $6,260 $13,376 $6,944 
The following table summarizes the effective interest rates of the Notes:
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
2031 Convertible Notes
2.10 %— %2.06 %— %
2030 Convertible Notes2.12 %2.12 %2.09 %2.09 %
2028 Convertible Notes0.64 %0.64 %0.63 %0.63 %
2027 Convertible Notes0.68 %0.68 %0.67 %0.67 %
2025 Convertible Notes1.18 %1.18 %1.17 %1.17 %
The remaining period over which the unamortized debt discount will be recognized as non-cash interest expense is 0.29, 2.45, 3.42, 5.42, and 6.54 years for the 2025 Notes, 2027 Notes, 2028 Notes, 2030 Notes, and 2031 Notes, respectively.
v3.24.3
LICENSE AND COLLABORATION AGREEMENTS
 9 Months Ended
Sep. 30, 2024
LICENSE AGREEMENTS [Abstract]  
LICENSE AND COLLABORATION AGREEMENTS LICENSE AND COLLABORATION AGREEMENTS
The Company licenses certain technologies that are, or may be, incorporated into its technology under several license agreements, as well as the rights to commercialize certain diagnostic tests through collaboration agreements. Generally, the license agreements require the Company to pay single-digit royalties based on net revenues received using the technologies and may require minimum royalty amounts, milestone payments, or maintenance fees.
Mayo Foundation for Medical Education and Research
In June 2009, the Company entered into an exclusive, worldwide license agreement with the Mayo Foundation for Medical Education and Research (“Mayo”), under which Mayo granted the Company an exclusive, worldwide license to certain Mayo patents and patent applications, as well as a non-exclusive, worldwide license with regard to certain Mayo know-how. The scope of the license covers any screening, surveillance or diagnostic test or tool for use in connection with any type of cancer, pre-cancer, disease or condition. The Company’s license agreement with Mayo was most recently amended and restated in September 2020.
The licensed Mayo patents and patent applications contain both method and composition claims that relate to sample processing, analytical testing and data analysis associated with nucleic acid screening for cancers and other diseases. The jurisdictions covered by these patents and patent applications include the U.S., Australia, Canada, the European Union, China, Japan and Korea. Under the license agreement, the Company assumed the obligation and expense of prosecuting and maintaining the licensed Mayo patents and is obligated to make commercially reasonable efforts to bring to market products using the licensed Mayo intellectual property.
Pursuant to the Company’s agreement with Mayo, the Company is required to pay Mayo a low-single-digit royalty on the Company’s net sales of current and future products using the licensed Mayo intellectual property each year during the term of the Mayo agreement.
The Company is also required to pay Mayo up to $3.0 million in sales-based milestone payments upon cumulative net sales of each product using the licensed Mayo intellectual property reaching specified levels.
The license agreement will remain in effect, unless earlier terminated by the parties in accordance with the agreement, until the last of the licensed patents expires in 2039 (or later, if certain licensed patent applications are issued). However, if the Company is still using the licensed Mayo know-how or certain Mayo-provided biological specimens or their derivatives on such expiration date, the term shall continue until the earlier of the date the Company stops using such know-how and materials and the date that is five years after the last licensed patent expires. The license agreement contains customary termination provisions and permits Mayo to terminate the license agreement if the Company sues Mayo or its affiliates, other than any such suit claiming an uncured material breach by Mayo of the license agreement.
In addition to granting the Company a license to the covered Mayo intellectual property, Mayo provides the Company with product development and research and development assistance pursuant to the license agreement and other collaborative arrangements. In September 2020, Mayo also agreed to make available certain personnel to provide such assistance through January 2025. In connection with this collaboration, the Company has incurred insignificant charges for the three months ended September 30, 2024 and 2023, respectively. The charges incurred in connection with this collaboration are recorded in research and development expenses in the Company’s condensed consolidated statements of operations.
Johns Hopkins University
Through the acquisition of Thrive, the Company acquired a worldwide exclusive license agreement with Johns Hopkins University (“JHU”) for use of several JHU patents and licensed know-how. The license is designed to enable the Company to leverage JHU intellectual property in the development and commercialization of a blood-based, multi-cancer screening test. The agreement terms would require the Company to pay single-digit sales-based royalties and up to $45.0 million in sales-based milestone payments for each JHU licensed product that reaches specified net sales levels. The Company will record the sales-based royalties once sales of licensed products have occurred and sales-based milestones once achievement is deemed probable. The Company has not incurred charges related to the achievement of any sales-based royalties or sales-based milestones as of September 30, 2024.
Targeted Digital Sequencing (“TARDIS”) License Agreement
In January 2021, the Company entered into an exclusive, worldwide license to the proprietary TARDIS technology from The Translational Genomics Research Institute (“TGen”). Under the agreement, the Company acquired a royalty-free, worldwide exclusive license to proprietary TARDIS patents and know-how. Under the agreement, the Company was obligated to make milestone payments to TGen of up to $45.0 million in sales-based milestone payments upon cumulative net sales related to molecular residual disease (“MRD”) detection and/or treatment reaching specified levels. These payments were contingent upon achievement of these cumulative revenues on or before December 31, 2030, which was not achieved prior to the termination.
Effective May 1, 2024, the Company entered into termination agreements (the “Termination Agreements”) with TGen for the purpose of terminating the license and sponsored research agreement relating to the TARDIS technology and an additional sponsored research agreement with a broader scope (collectively, the “Original Agreements”). As part of the Termination Agreements, the Company will pay TGen $27.6 million in compensation for the termination of the Original Agreements, which will be allocated into three annual installments of $9.2 million per year beginning in the second quarter of 2024. The fair value of the termination payments as of the date of the Termination Agreements was $25.8 million, which was recorded as research and development expense in the condensed consolidated statement of operations in the second quarter of 2024. The remaining $1.8 million in expense is being recognized ratably through the date of the final payment in the second quarter of 2026. The Company has recorded a liability of $17.1 million representing the fair value of the remaining payments, of which $8.8 million is included in accrued liabilities and $8.3 million is included in other long-term liabilities on the condensed consolidated balance sheet as of September 30, 2024. The termination payments eliminate the Company’s obligation to pay TGen any further payments, equities, fees, costs, or other amounts that would have been due under the Original Agreements, including the milestone payments. The Company’s ongoing development efforts for its pipeline tests are not impacted by the Termination Agreements.
Broad Institute, Inc.
In June 2023, the Company entered into an exclusive license agreement with Broad Institute, Inc. (“Broad Institute”) to utilize the Minor Allele Enriched Sequencing Through Recognition Oligonucleotides (“MAESTRO”) technology in the Company’s MRD testing. Under the license agreement, the Company is obligated to make development milestone payments to Broad Institute of up to $6.5 million upon achievement of certain development milestones related to prospective MRD tests that use the MAESTRO technology. In addition, the Company is obligated to make sales-based milestone payments to Broad Institute that equate up to a mid-single-digit royalty upon the achievement of certain cumulative net sales targets of licensed products using the MAESTRO technology beginning at $500.0 million. The Company will record the development milestones once achieved and the sales milestones once achievement is deemed probable. The Company has not incurred charges related to the achievement of development milestones or sales milestones as of September 30, 2024.
Watchmaker Genomics, Inc.
In July 2023, the Company entered into a co-exclusive development and license agreement with Watchmaker Genomics, Inc. (“Watchmaker”) under which the Company granted Watchmaker a co-exclusive license to the non-bisulfite technology for the detection of methylated DNA and other epigenetic modifications (“TAPS”). TAPS is based on patents obtained by the Company through an exclusive license agreement with the Ludwig Institute for Cancer Research. Under the agreement, both parties have the right to use and develop TAPS for commercial purposes. The Company has the potential to receive up to $82.0 million in sales-based milestone payments and mid-single-digit royalties based on future Watchmaker net sales of licensed products including TAPS. Additionally, Watchmaker has the right to sublicense TAPS, and the Company has the potential to receive royalties based on future Watchmaker sublicense receipts.
TwinStrand Biosciences, Inc.
On July 1, 2024, the Company entered into an agreement with TwinStrand Biosciences, Inc. (“TwinStrand”), under which TwinStrand licensed to the Company intellectual property related to the error correction technology in next-generation sequencing. The Company’s rights are broadly exclusive with respect to cell-free nucleic acid sequencing, subject to certain non-exclusive relationships in the field. Under the license agreement, the Company made upfront payments to TwinStrand totaling $45.0 million in July 2024. The upfront payments were capitalized as a patent and license intangible asset in the condensed consolidated balance sheet, which is amortized through amortization of acquired intangible assets in the condensed consolidated statement of operations over its estimated useful life of 10 years. In addition, the Company agreed to pay TwinStrand a low-single-digit royalty on the Company’s net sales of certain licensed products and services. The Company will record the sales-based royalties once sales using relevant licensed products and services have occurred. The Company has not incurred charges related to the sales-based royalties as of September 30, 2024.
v3.24.3
STOCKHOLDERS' EQUITY
 9 Months Ended
Sep. 30, 2024
Equity [Abstract]  
STOCKHOLDERS' EQUITY STOCKHOLDERS’ EQUITY
Changes in Accumulated Other Comprehensive Income
The amounts recognized in AOCI for the nine months ended September 30, 2024 were as follows:
(In thousands)Cumulative Translation Adjustment
Unrealized Gain on Securities (1)
AOCI
Balance at December 31, 2023$1,374 $54 $1,428 
Other comprehensive loss before reclassifications
427 2,723 3,150 
Amounts reclassified from accumulated other comprehensive income
— 52 52 
Net current period change in accumulated other comprehensive income
427 2,775 3,202 
Balance at September 30, 2024$1,801 $2,829 $4,630 
______________
(1)There was no tax impact from the amounts recognized in AOCI for the three and nine months ended September 30, 2024.
The amounts recognized in AOCI for the nine months ended September 30, 2023 were as follows:
(In thousands)Cumulative Translation AdjustmentUnrealized Gain (Loss) on Securities (1)
AOCI
Balance at December 31, 2022$53 $(5,289)$(5,236)
Other comprehensive income before reclassifications
(626)748 122 
Amounts reclassified from accumulated other comprehensive income
— 3,579 3,579 
Net current period change in accumulated other comprehensive income
(626)4,327 3,701 
Balance at September 30, 2023$(573)$(962)$(1,535)
______________
(1)There was no tax impact from the amounts recognized in AOCI for the nine months ended September 30, 2023.
Amounts reclassified from AOCI for the nine months ended September 30, 2024 and 2023 were as follows:
Affected Line Item in the
Statements of Operations		Nine Months Ended September 30,
Details about AOCI Components (In thousands)20242023
Change in value of available-for-sale investments
Sales and maturities of available-for-sale investments
Investment income, net
$52 $3,579 
Total reclassifications$52 $3,579 
v3.24.3
STOCK-BASED COMPENSATION
 9 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION STOCK-BASED COMPENSATION
Stock-Based Compensation Plans
The Company maintains the following plans for which awards were granted from or had awards outstanding in 2023: the 2010 Omnibus Long-Term Incentive Plan (as Amended and Restated effective July 27, 2017), the 2019 Omnibus Long-Term Incentive Plan, and the 2010 Employee Stock Purchase Plan. These plans are collectively referred to as the “Stock Plans” and are administered in conjunction with the Company’s Equity Award Death, Disability and Retirement Policy, which was adopted in February 2023. Refer to the Company’s 2023 Form 10-K for further information regarding this policy.
Stock-Based Compensation Expense
The Company records stock-based compensation expense in connection with the amortization of restricted stock and restricted stock unit awards (“RSUs”), performance share units (“PSUs”), stock purchase rights granted under the Company’s employee stock purchase plan (“ESPP”) and stock options granted to employees, non-employee consultants and non-employee directors. The Company recorded $48.8 million and $61.9 million in stock-based compensation expense during the three months ended September 30, 2024 and 2023, respectively. The Company recorded $165.7 million and $172.7 million in stock-based compensation expense during the nine months ended September 30, 2024 and 2023, respectively.
As of September 30, 2024, there was approximately $383.8 million of expected total unrecognized compensation cost related to non-vested stock-based compensation arrangements granted under all equity compensation plans. The Company expects to recognize that cost over a weighted average period of 2.6 years.
Stock Options
A summary of stock option activity under the Stock Plans is as follows:
Option SharesWeighted Average Exercise PriceWeighted Average Remaining Contractual Term (Years)Aggregate Intrinsic Value (1)
(Aggregate intrinsic value in thousands)
Outstanding, January 1, 20241,286,173 $47.67 3.8
Exercised(221,374)19.50 
Forfeited(36,575)91.37 
Outstanding, September 30, 20241,028,224 $52.18 3.3$26,970 
Vested and expected to vest, September 30, 2024
1,028,224 $52.18 3.3$26,970 
Exercisable, September 30, 20241,028,224 $52.18 3.3$26,970 
______________
(1)The total intrinsic value of options exercised, net of shares withheld for taxes, during the nine months ended September 30, 2024 and 2023 was $6.2 million and $10.6 million, respectively, determined as of the date of exercise.
Restricted Stock and Restricted Stock Units
The fair value of restricted stock and RSUs is determined on the date of grant using the closing stock price on that day.
A summary of restricted stock and RSU activity during the nine months ended September 30, 2024 is as follows:
Restricted SharesWeighted Average Grant Date Fair Value (1)
Outstanding, January 1, 20246,272,763 $73.39 
Granted4,227,223 56.67 
Released (2)(2,232,590)77.62 
Forfeited(780,430)61.93 
Outstanding, September 30, 20247,486,966 $63.07 
______________
(1)The weighted average grant date fair value of the RSUs granted during the nine months ended September 30, 2023 was $62.28.
(2)The fair value of RSUs vested and converted to shares of the Company’s common stock was $173.3 million and $146.7 million during the nine months ended September 30, 2024 and 2023, respectively.
Performance Share Units
The Company has issued performance-based equity awards to certain employees which vest upon the achievement of certain performance goals, including financial performance targets and operational milestones.
A summary of PSU activity during the nine months ended September 30, 2024 is as follows:
Performance Share Units (1)Weighted Average Grant Date Fair Value (2)
Outstanding, January 1, 20241,597,801 $92.73 
Granted913,533 63.68 
Released (3)(70,662)140.20 
Forfeited(403,454)92.47 
Outstanding, September 30, 20242,037,218 $75.47 
______________
(1)The PSUs listed above assumes attainment of maximum payout rates as set forth in the performance criteria. Applying actual or expected payout rates, the number of outstanding PSUs as of September 30, 2024 was 820,015.
(2)The weighted average grant date fair value of the PSUs granted during the nine months ended September 30, 2023 was $79.11.
(3)The fair value of PSUs vested and converted to shares of the Company’s common stock was $9.9 million and $1.0 million for the nine months ended September 30, 2024 and 2023, respectively.
Employee Stock Purchase Plan
The fair value of shares purchased during the three and nine months ended September 30, 2024 and 2023 under the ESPP is based on the assumptions in the following table:
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
ESPP Shares
Risk-free interest rates
(1)
(1)
4.71% - 5.30%
4.68%
Expected term (in years)
(1)
(1)
1.171.25
Expected volatility
(1)
(1)
55.67% - 63.13%
67.30%
Dividend yield
(1)
(1)
—%—%
______________
(1)The Company did not issue stock purchase rights under its 2010 Employee Stock Purchase Plan during the period indicated.
v3.24.3
COMMITMENTS AND CONTINGENCIES
 9 Months Ended
Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
Leases
Supplemental disclosure of cash flow information related to the Company’s cash and non-cash activities with its leases are as follows:
Nine Months Ended September 30,
(In thousands)20242023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$28,658$29,212
Operating cash flows from finance leases991559
Finance cash flows from finance leases4,8902,545
Non-cash investing and financing activities:
Right-of-use assets obtained in exchange for new operating lease liabilities
$17,860$2,097
Right-of-use assets obtained in exchange for new finance lease liabilities15,9954,940
Weighted-average remaining lease term - operating leases (in years)7.587.00
Weighted-average remaining lease term - finance leases (in years)3.082.99
Weighted-average discount rate - operating leases6.55 %6.50 %
Weighted-average discount rate - finance leases6.71 %7.32 %
As of September 30, 2024 and December 31, 2023, the Company’s right-of-use assets from operating leases are $122.5 million and $143.7 million, respectively, which are reported in operating lease right-of-use assets in the Company’s condensed consolidated balance sheets. As of September 30, 2024, the Company has outstanding operating lease obligations of $189.9 million, of which $27.2 million is reported in operating lease liabilities, current portion and $162.7 million is reported in operating lease liabilities, less current portion in the Company’s condensed consolidated balance sheets. As of December 31, 2023, the Company had outstanding operating lease obligations of $190.4 million, of which $29.4 million is reported in operating lease liabilities, current portion and $161.1 million is reported in operating lease liabilities, less current portion in the Company’s condensed consolidated balance sheets.
In the third quarter of 2024, the Company recorded an impairment charge of $18.7 million, which consisted of a right-of-use asset of $11.8 million and associated leasehold improvements of $6.9 million relating to one of its domestic facilities that will be vacated in the fourth quarter of 2024 as a result of a change in strategic priorities. The Company used the income approach, under which the recoverability of the assets was measured by comparing the carrying amount of the asset to future undiscounted, pre-tax cash flows generated by the assets held. The fair value of the assets was determined using discounted cash flows, and the impairment charge recorded represents the difference between the carrying value and fair value of the impaired assets. The impairment charge recorded is included in impairment of long-lived assets in the Company’s condensed consolidated statement of operations for the three and nine months ended September 30, 2024.
As of September 30, 2024 and December 31, 2023, the Company’s right-of-use assets from finance leases are $21.6 million and $11.3 million, respectively, which are reported in other long-term assets, net in the Company’s condensed consolidated balance sheets. As of September 30, 2024, the Company has outstanding finance lease obligations of $22.7 million, of which $7.9 million is reported in other current liabilities and $14.8 million is reported in other long-term liabilities in the Company’s condensed consolidated balance sheets. As of December 31, 2023, the Company had outstanding finance lease obligations of $11.9 million, of which $4.4 million is reported in other current liabilities and $7.5 million is reported in other long-term liabilities in the Company’s condensed consolidated balance sheets.
Legal Matters
In addition to commitments and obligations incurred in the ordinary course of business, from time to time the Company may be subject to a variety of claims and legal proceedings, including legal actions for damages, governmental investigations and other matters. The Company has also instituted, and may in the future institute, additional legal proceedings to enforce its rights and seek remedies, such as monetary damages, injunctive relief and declaratory relief.
The Company accrues costs for certain legal proceedings and regulatory matters to the extent that it determines an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. While such accrued costs reflect the Company’s best estimate of the probable loss for such matters, the recorded amounts may differ materially from the actual amount of any such losses. In some cases, no estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made because of the inherently unpredictable nature of legal and regulatory proceedings, which may be exacerbated by various factors, including but not limited to, that they may involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or legal uncertainties; involve disputed facts; represent a shift in regulatory policy; involve a large number of parties, claimants or regulatory bodies; are in the early stages of the proceedings; involve a number of separate proceedings and/or a wide range of potential outcomes; or result in a change of business practices.
As of the date of this Quarterly Report on Form 10-Q, amounts accrued for legal proceedings and regulatory matters were not material. The Company believes that the ultimate outcome of any of the regulatory and legal proceedings that are currently pending against it should not have a material adverse effect on financial condition, results of operations, cash flow or liquidity. However, it is possible that in a particular quarter or annual period the Company’s financial condition, results of operations, cash flow and/or liquidity could be materially adversely affected by an ultimate unfavorable resolution of, or development in, legal and/or regulatory proceedings.
Refer to the Company’s 2023 Form 10-K for detailed disclosures on legal matters that were settled in 2023.
Intellectual Property Litigation Matters
In May 2023, after receiving a cease-and-desist letter from the Company regarding its patent infringement, Geneoscopy Inc. (“Geneoscopy”) requested a reexamination of the Company’s U.S. Patent No. 11,634,781 (the “’781 Patent”) by the United States Patent and Trademark Office (the “USPTO”). Upon completion of the reexamination in October 2023, the USPTO rejected Geneoscopy’s challenge. In November 2023, the Company filed suit against Geneoscopy in the United States District Court for the District of Delaware, alleging that certain of Geneoscopy’s products infringe the ‘781 Patent and seeking unspecified monetary damages and injunctive relief (the “’781 Action”) and in May 2024, the Company filed a second complaint against Geneoscopy alleging infringement of the Company’s U.S. Patent No. 11,970,746 (the “’746 Patent”), which has been consolidated with the ’781 Action. On June 28, 2024, Geneoscopy filed counterclaims against the Company challenging the validity of the patents at issue and alleging breach of contract, misappropriation of trade secrets, unfair competition, and other violations of state and federal law seeking unspecified monetary damages and injunctive relief, which were amended on August 16, 2024. On July 16, 2024, the Company filed a motion for preliminary injunction seeking an order prohibiting Geneoscopy from selling its infringing Colosense test in the United States. On August 8, 2024, Geneoscopy filed a motion to stay pending inter partes review of the ‘781 Patent, which is fully briefed. On August 30, 2024, the Company filed a motion to dismiss the amended counterclaim, which is fully briefed. On September 3, 2024, the Court entered a stipulated order for briefing and expedited discovery for the Company’s preliminary injunction motion. On September 27, 2024, Geneoscopy filed its opposition to the Company’s motion for preliminary injunction, and the parties are currently engaged in expedited discovery. Briefing for the Company’s motion for preliminary injunction will be complete by the end of November 2024.
In January 2024, Geneoscopy petitioned the USPTO to institute an inter partes review (“IPR”) challenging the validity of the ‘781 Patent before the Patent Trial and Appeals Board (“PTAB”). On July 26, 2024, the PTAB notified the Company that it decided to institute review. The Company filed its Patent Owner Response on October 25, 2024, and the parties are currently engaged in discovery. The Company intends to defend the validity of the ‘781 Patent, and a final decision of that review will be made on or before July 30, 2025.
On August 20, 2024, Geneoscopy filed a petition for inter partes review of the ‘746 Patent before the PTAB. The Company’s Patent Owner Preliminary Response is due November 27, 2024. The PTAB is expected to decide on or before February 27, 2025, whether it will institute the IPR. If the IPR is instituted, the Company intends to defend the validity of the ‘746 Patent, and a final decision of that review will be made on or before February 27, 2026.
v3.24.3
WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS
 9 Months Ended
Sep. 30, 2024
WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS [Abstract]  
WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS
During December 2021, the Company entered into an amended agreement (“Amended WEDC Agreement”) with the Wisconsin Economic Development Corporation (“WEDC”) to earn an additional $18.5 million in refundable tax credits on the condition that the Company expends $350.0 million in capital investments and establishes and maintains 1,300 additional full-time positions over a five-year period. The capital investment credits are earned at a rate of 10% of eligible capital investments up to a maximum of $7.0 million, while the jobs creation credits are earned annually pursuant to the Amended WEDC Agreement.
The tax credits earned are first applied against the tax liability otherwise due, and if there is no such liability present, the claim for tax credits will be reimbursed in cash to the Company. The maximum amount of the refundable tax credit to be earned for each year is fixed, and the Company earns the credits by meeting certain capital investment and job creation thresholds over the term of the Amended WEDC Agreement. Should the Company earn and receive the job creation tax credits but not maintain those full-time positions through the end of the agreement, the Company may be required to pay those credits back to the WEDC.
The Company records the earned tax credits as job creation and capital investments occurs. The tax credits earned from capital investment are recognized as a reduction to capital expenditures at the time the costs are incurred, and then as an offset to depreciation expense over the expected life of the acquired capital assets. The tax credits earned related to job creation are recognized as an offset to operational expenses in the period in which the credits are earned.
As of September 30, 2024, the Company has earned $14.3 million of the refundable tax credits under the Amended WEDC Agreement. The unpaid portion is $8.8 million, of which $4.2 million is reported in prepaid expenses and other current assets and $4.6 million is reported in other long-term assets, net in the Company’s condensed consolidated balance sheets reflecting when collection of the refundable tax credits is expected to occur. During the three and nine months ended September 30, 2024 and 2023, the amounts recorded as an offset to capital expenditures and operating expenses for the tax credits earned were not significant.
v3.24.3
ACQUISITIONS AND DIVESTITURES
 9 Months Ended
Sep. 30, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]  
ACQUISITIONS AND DIVESTITURES ACQUISITIONS AND DIVESTITURES
Business Combinations
Resolution Bioscience, Inc.
On September 12, 2023, the Company completed the acquisition of all of the outstanding capital stock of Resolution Bioscience, Inc. (“Resolution Bioscience”) from Agilent Technologies, Inc. The acquisition provides the Company with a high-quality blood-based therapy selection platform, complementing its comprehensive, tissue-based OncoExTra® test.
Refer to the Company’s 2023 Form 10-K for detailed disclosures on the combination, including the fair value of the consideration transferred, purchase price allocation, and goodwill and intangible assets identified in the transaction. During the three and nine months ended September 30, 2024, there were no significant changes to the purchase price and purchase price allocation, and the measurement period has closed.
Divestitures
Oncotype DX Genomic Prostate Score Test
On August 2, 2022, pursuant to an asset purchase agreement (the “Asset Purchase Agreement”) with MDxHealth SA (“MDxHealth”), the Company completed the sale of the intellectual property and know-how related to the Company’s Oncotype DX Genomic Prostate Score test (“GPS test”). On August 23, 2023, the Company and MDxHealth executed the Second Amendment to the Asset Purchase Agreement (the “Second Amendment”). Under the Second Amendment, the Company agreed to allow MDxHealth to defer the 2023 contingent consideration payment by three years in exchange for additional consideration and more favorable contingent consideration terms, including elimination of the minimum revenue thresholds previously required to be met under the Asset Purchase Agreement. Refer to the Company’s 2023 Form 10-K for additional details on the agreements.
As of September 30, 2024 and December 31, 2023, a portion of the contingent consideration is classified as a contract asset. As of September 30, 2024, the contract asset was $48.3 million, of which $25.8 million is included in prepaid expenses and other current assets and $22.5 million is included in other long-term assets, net on the condensed consolidated balance sheet. As of December 31, 2023, the contract asset was $41.7 million, which is included in other long-term assets on the condensed consolidated balance sheet. The contract asset was estimated using historical GPS test revenues by MDxHealth under the most likely amount method. The remaining consideration balance as of September 30, 2024 and December 31, 2023 was $31.6 million, which includes the amount earned during the 2023 earnout year and is classified as a receivable within other long-term assets, net on the condensed consolidated balance sheet. The Company recorded an insignificant contingent consideration gain for the three and nine months ended September 30, 2024, which is included in other operating income in the condensed consolidated statement of operations.
v3.24.3
SEGMENT INFORMATION
 9 Months Ended
Sep. 30, 2024
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
Management determined that the Company functions as a single operating segment, and thus reports as a single reportable segment. This operating segment is focused on the development and global commercialization of clinical laboratory services allowing healthcare providers and patients to make individualized treatment decisions. Management assessed the financial information routinely reviewed by the Company's Chief Operating Decision Maker, its President and Chief Executive Officer, to monitor the Company's operating performance and support decisions regarding allocation of resources to its operations. Performance is continuously monitored at the consolidated level to timely identify deviations from expected results.
The following table summarizes total revenue from customers by geographic region. Product revenues are attributed to countries based on ship-to location.
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2024202320242023
United States$659,222 $589,739 $1,904,755 $1,741,428 
Outside of United States49,433 38,599 140,688 111,453 
Total revenues$708,655 $628,338 $2,045,443 $1,852,881 
Long-lived assets located in countries outside of the U.S. are not significant.
v3.24.3
INCOME TAXES
 9 Months Ended
Sep. 30, 2024
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
The Company recorded income tax expense of $0.8 million and $0.2 million for the three months ended September 30, 2024 and 2023, respectively. The Company recorded income tax expense of $4.1 million and $3.0 million for the nine months ended September 30, 2024 and 2023, respectively. The Company’s income tax expense recorded during the three and nine months ended September 30, 2024 is primarily related to current foreign and state tax expense. A deferred tax liability of $19.3 million and $17.3 million was recorded as of September 30, 2024 and December 31, 2023, respectively, which is included in other long-term liabilities on the Company’s condensed consolidated balance sheet. The Company continues to maintain a full valuation allowance against its deferred tax assets based on management’s determination that it is more likely than not the benefit will not be realized.
The Company had $42.0 million and $36.4 million of unrecognized tax benefits at September 30, 2024 and December 31, 2023, respectively. These amounts have been recorded as a reduction to the Company’s deferred tax asset, if recognized they would not have an impact on the effective tax rate due to the existing valuation allowance. Certain of the Company's unrecognized tax benefits could change due to activities of various tax authorities, including possible settlement of audits, or through normal expiration of various statutes of limitations. The Company does not expect a material change in unrecognized tax benefits in the next twelve months.
As of September 30, 2024, due to the carryforward of unutilized net operating losses and research and development credits, the Company is subject to U.S. federal income tax examinations for the tax years 2000 through 2024, and to state income tax examinations for the tax years 2000 through 2024. No interest or penalties related to income taxes have been accrued or recognized as of September 30, 2024.
The Organization for Economic Co-operation and Development has endorsed a framework (“Pillar Two”) with model rules introducing a global minimum corporate tax rate via a system where multinational groups with consolidated revenue over €750.0 million are subject to a minimum effective tax rate of 15% on income arising in low-tax jurisdictions on a country-by-country basis. Many countries have implemented laws based on these model rules, with effective dates beginning January 1, 2024. These rules do not have a material impact on the Company for the current period and, as currently designed, are not expected to materially increase the Company’s global tax costs. The Company will continue to monitor U.S. and global legislative action related to Pillar Two for potential impacts.
v3.24.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
Basis of Presentation and Principles of Consolidation
Basis of Presentation and Principles of Consolidation
The accompanying condensed consolidated financial statements, which include the accounts of the Company and those of its wholly owned subsidiaries and variable interest entities, are unaudited and have been prepared on a basis substantially consistent with the Company’s audited financial statements and notes as of and for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K (the “2023 Form 10-K”). All intercompany transactions and balances have been eliminated upon consolidation. These condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted (“GAAP”) in the United States of America (“U.S.”) and follow the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting only of adjustments of a normal and recurring nature) considered necessary for a fair statement of its financial position, operating results and cash flows for the periods presented. The condensed consolidated balance sheet at December 31, 2023 has been derived from audited financial statements, but does not contain all of the footnote disclosures from the 2023 Form 10-K. The results of the Company’s operations for any interim period are not necessarily indicative of the results of the Company’s operations for any other interim period or for a full fiscal year. The statements should be read in conjunction with the audited financial statements and related notes included in the 2023 Form 10-K.
Use of Estimates
Use of Estimates
The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Critical accounting policies are those that affect the Company’s financial statements materially and involve difficult, subjective or complex judgments by management, and actual results could differ from those estimates. These estimates include revenue recognition, valuation of intangible assets and goodwill, contingent consideration, and accounting for income taxes. The Company’s critical accounting policies and estimates are explained further in the notes to the condensed consolidated financial statements in this Quarterly Report on Form 10-Q and the 2023 Form 10-K.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
Recently Adopted Accounting Pronouncements
In March 2024, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2024-02: Codification Improvement – Amendments to Remove References to the Concepts Statements. This update amends the Accounting Standards Codification (“ASC”) to remove references to various FASB Concepts Statements. The Company early adopted and prospectively applied the amendments in this update during the first quarter of fiscal year 2024. There was no significant impact to the Company’s condensed consolidated financial statements.
Recently Issued Accounting Pronouncements Not Yet Adopted
In October 2023, the FASB issued ASU No. 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative. This update modifies the disclosure or presentation requirements of a variety of topics in the ASC to conform with certain SEC amendments in Release No. 33-10532, Disclosure Update and Simplification. The amendments in this update should be applied prospectively, and the effective date for each amendment will be the date on which the SEC’s removal of that related disclosure from Regulation S-X or S-K becomes effective. However, if the SEC has not removed the related disclosure from its regulations by June 30, 2027, the amendments will be removed from the Codification and not become effective. Early adoption is prohibited. The Company is currently evaluating the potential impact of this guidance on its condensed consolidated financial statements.
In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This update improves reportable segment disclosure requirements, primarily through enhanced disclosures of significant segment expenses. The amendments in this update should be applied retrospectively to all prior periods presented in the consolidated financial statements and are effective for fiscal years beginning after December 31, 2023 and interim periods within fiscal years beginning after December 31, 2024. Early adoption is permitted. The Company is currently evaluating the potential impact of this guidance on its condensed consolidated financial statements.
In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvement to Income Tax Disclosures. This update improves income tax disclosure requirements, primarily through enhanced transparency and decision usefulness of disclosures. The amendments in this update should be applied prospectively with the option to apply retrospectively and are effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the potential impact of this guidance on its condensed consolidated financial statements.
Net Loss Per Share
Net Income (Loss) Per Share
Basic net income (loss) per common share (“EPS”) was determined by dividing net income (loss) applicable to common stockholders by the weighted average common shares outstanding during the period. Diluted EPS is based on shares that are outstanding per the calculation of basic EPS and on potentially dilutive shares.
v3.24.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
The following potentially issuable common shares were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect due to net losses for each period:
Three Months Ended September 30,
Nine Months Ended September 30,
(In thousands)2024202320242023
Shares issuable upon conversion of convertible notes26,526 23,231 26,526 23,231 
Shares issuable upon the release of restricted stock awards7,487 — 7,487 6,423 
Shares issuable upon the release of performance share units2,037 — 2,037 1,584 
Shares issuable upon exercise of stock options1,028 — 1,028 1,305 
37,078 23,231 37,078 32,543 
Schedule of Weighted Average Number of Shares
The following is a reconciliation of the numerator and denominator used to calculate basic EPS and diluted EPS for the periods indicated:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2024202320242023
Net income (loss) available to common shareholders
$(38,236)$794 $(164,272)$(154,383)
Weighted average common shares outstanding - basic
184,795 180,649 183,823 179,817 
Effect of dilutive shares:
Restricted stock awards
— 2,153 — — 
Stock options
— 646 — — 
Employee stock purchase plan
— 589 — — 
Performance share units
— 38 — — 
Dilutive potential common shares
— 3,426 — — 
Weighted average common shares outstanding - diluted
184,795 184,075 183,823 179,817 
Earnings per common share from net earnings - basic
$(0.21)$0.00 $(0.89)$(0.86)
Earnings per common share from net earnings - diluted
$(0.21)$0.00 $(0.89)$(0.86)
v3.24.3
REVENUE (Tables)
 9 Months Ended
Sep. 30, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of disaggregation of revenue
The following table presents the Company’s revenues disaggregated by revenue source:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2024202320242023
Screening
Medicare Parts B & C$201,423 $173,624 $570,550 $521,370 
Commercial289,637 253,401 827,509 732,182 
Other53,841 44,988 153,246 124,443 
Total Screening544,901 472,013 1,551,305 1,377,995 
Precision Oncology
Medicare Parts B & C$47,080 $46,383 $142,597 $141,352 
Commercial47,685 44,430 143,572 135,574 
International49,433 38,599 140,688 111,453 
Other19,556 26,913 67,281 80,552 
Total Precision Oncology163,754 156,325 494,138 468,931 
COVID-19 Testing$— $— $— $5,955 
Total$708,655 $628,338 $2,045,443 $1,852,881 
v3.24.3
MARKETABLE SECURITIES (Tables)
 9 Months Ended
Sep. 30, 2024
Cash and Cash Equivalents [Abstract]  
Cash, Cash Equivalents and Investments
The following table sets forth the Company’s cash, cash equivalents, and marketable securities at September 30, 2024 and December 31, 2023:
(In thousands)September 30, 2024December 31, 2023
Cash and cash equivalents
Cash and money market$582,741 $530,100 
Cash equivalents6,089 75,278 
Total cash and cash equivalents588,830 605,378 
Marketable securities
Available-for-sale debt securities$427,072 $168,425 
Equity securities5,229 3,841 
Total marketable securities432,301 172,266 
Total cash, cash equivalents and marketable securities$1,021,131 $777,644 
Schedule of available-for-sale securities
Available-for-sale debt securities, including the classification within the condensed consolidated balance sheet at September 30, 2024, consisted of the following:
(In thousands)Amortized Cost
Gains in Accumulated Other Comprehensive Income (1)
Losses in Accumulated Other Comprehensive Income (1)
Estimated Fair Value
Cash equivalents
U.S. government agency securities$6,089 $— $— $6,089 
Total cash equivalents6,089 — — 6,089 
Marketable securities
Corporate bonds$212,590 $2,039 $(14)$214,615 
U.S. government agency securities126,676 436 (19)127,093 
Asset backed securities84,977 441 (54)85,364 
Total marketable securities424,243 2,916 (87)427,072 
Total available-for-sale securities$430,332 $2,916 $(87)$433,161 
______________
(1)There was no tax impact from the gains and losses in accumulated other comprehensive income (“AOCI”).
Available-for-sale debt securities, including the classification within the condensed consolidated balance sheet at December 31, 2023, consisted of the following:
(In thousands)Amortized Cost
Gains in Accumulated Other Comprehensive Income (1)
Losses in Accumulated Other Comprehensive Income (1)
Estimated Fair Value
Cash equivalents
Commercial paper$72,243 $— $— $72,243 
U.S. government agency securities3,035 — — 3,035 
Total cash equivalents75,278 — — 75,278 
Marketable securities
U.S. government agency securities$56,594 $166 $(44)$56,716 
Corporate bonds55,712 175 (59)55,828 
Asset backed securities35,081 65 (249)34,897 
Commercial paper
20,984 — — 20,984 
Total marketable securities168,371 406 (352)168,425 
Total available-for-sale securities$243,649 $406 $(352)$243,703 
______________
(1)There was no tax impact from the gains and losses in AOCI.
Schedule of contractual maturities of available-for-sale investments
The following table summarizes contractual underlying maturities of the Company’s available-for-sale debt securities at September 30, 2024:
Due one year or lessDue after one year through five years
(In thousands)CostFair ValueCostFair Value
Cash equivalents
U.S. government agency securities$6,089 $6,089 $— $— 
Total cash equivalents6,089 6,089 — — 
Marketable securities
U.S. government agency securities$89,800 $90,048 $36,876 $37,045 
Corporate bonds51,706 51,890 160,884 162,725 
Asset backed securities11,388 11,448 73,589 73,916 
Total marketable securities152,894 153,386 271,349 273,686 
Total available-for-sale securities$158,983 $159,475 $271,349 $273,686 
Schedule of gross unrealized losses and fair values of investments in an unrealized loss position
The following table summarizes the gross unrealized losses and fair values of available-for-sale debt securities in an unrealized loss position as of September 30, 2024 aggregated by investment category and length of time those individual securities have been in a continuous unrealized loss position:
Less than one yearOne year or greaterTotal
(In thousands)Fair ValueGross Unrealized LossFair ValueGross Unrealized LossFair ValueGross Unrealized Loss
Marketable securities
Corporate bonds$9,501 $(13)$3,290 $(1)$12,791 $(14)
U.S. government agency securities8,551 (16)3,963 (3)12,514 (19)
Asset backed securities3,399 (3)3,986 (51)7,385 (54)
Total available-for-sale securities$21,451 $(32)$11,239 $(55)$32,690 $(87)
v3.24.3
INVENTORY (Tables)
 9 Months Ended
Sep. 30, 2024
Inventory Disclosure [Abstract]  
Schedule of inventory
Inventory consisted of the following:
(In thousands)September 30, 2024December 31, 2023
Raw materials$54,714 $58,593 
Semi-finished and finished goods82,273 68,882 
Total inventory$136,987 $127,475 
v3.24.3
PROPERTY, PLANT AND EQUIPMENT (Tables)
 9 Months Ended
Sep. 30, 2024
Property, Plant and Equipment [Abstract]  
Schedule of property, plant and equipment, net
The carrying value and estimated useful lives of property, plant and equipment are as follows:
(In thousands)Estimated Useful LifeSeptember 30, 2024December 31, 2023
Property, plant and equipment
Landn/a$4,716 $4,716 
Leasehold and building improvements(1)227,600 214,562 
Land improvements15 years6,747 6,729 
Buildings
30 - 40 years
290,777 290,777 
Computer equipment and computer software3 years199,715 168,131 
Machinery and equipment
3 - 10 years
324,129 290,294 
Furniture and fixtures
3 - 10 years
36,976 35,756 
Assets under constructionn/a80,063 104,592 
Property, plant and equipment, at cost1,170,723 1,115,557 
Accumulated depreciation(480,391)(417,203)
Property, plant and equipment, net$690,332 $698,354 
______________
(1)Lesser of remaining lease term, building life, or estimated useful life.
v3.24.3
INTANGIBLE ASSETS AND GOODWILL (Tables)
 9 Months Ended
Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of net-book value and estimated remaining life and finite lived intangible assets
The following table summarizes the net-book-value and estimated remaining life of the Company’s intangible assets as of September 30, 2024:
(In thousands)Weighted Average Remaining Life (Years)CostAccumulated Amortization
Net Balance at September 30, 2024
Finite-lived intangible assets
Trade name11.0$104,000 $(33,340)$70,660 
Customer relationships6.34,000 (1,222)2,778 
Patents and licenses9.756,542 (11,811)44,731 
Acquired developed technology (1)6.6887,708 (391,478)496,230 
Total finite-lived intangible assets1,052,250 (437,851)614,399 
In-process research and developmentn/a1,250,000 — 1,250,000 
Total intangible assets$2,302,250 $(437,851)$1,864,399 
The following table summarizes the net-book-value and estimated remaining life of the Company’s intangible assets as of December 31, 2023:
(In thousands)Weighted Average Remaining Life (Years)CostAccumulated Amortization
Net Balance at December 31, 2023
Finite-lived intangible assets
Trade name11.6$104,000 $(27,903)$76,097 
Customer relationships7.04,000 (889)3,111 
Patents and licenses4.511,542 (9,600)1,942 
Acquired developed technology (1)7.3887,789 (328,543)559,246 
Total finite-lived intangible assets1,007,331 (366,935)640,396 
In-process research and developmentn/a1,250,000 — 1,250,000 
Total intangible assets$2,257,331 $(366,935)$1,890,396 
______________
(1)The gross carrying amount includes an insignificant foreign currency translation adjustment related to the intangible asset acquired as a result of the acquisition of OmicEra Diagnostics GmbH (“OmicEra”).
Schedule of estimated future amortization expense, intangible assets
As of September 30, 2024, the estimated future amortization expense associated with the Company’s finite-lived intangible assets for each of the five succeeding fiscal years is as follows:
(In thousands)
2024 (remaining three months)$24,100 
202596,361 
202695,300 
202795,300 
202895,300 
Thereafter208,038 
$614,399 
Schedule of carrying amount of goodwill
The change in the carrying amount of goodwill for the periods ended September 30, 2024 and December 31, 2023 is as follows:
(In thousands)
Balance, January 1, 2023
$2,346,040 
Resolution Bioscience acquisition
20,692 
Effects of changes in foreign currency exchange rates (1)388 
Balance, December 31, 2023
2,367,120 
Resolution Bioscience acquisition adjustments225 
Effects of changes in foreign currency exchange rates (1)105 
Balance September 30, 2024
$2,367,450 
______________
(1)Represents the impact of foreign currency translation related to the goodwill acquired as a result of the acquisition of OmicEra.
v3.24.3
FAIR VALUE MEASUREMENTS (Tables)
 9 Months Ended
Sep. 30, 2024
Fair Value Disclosures [Abstract]  
Schedule of fair value measurements along with the level within the fair value hierarchy in which the fair value measurements fall
The following table presents the Company’s fair value measurements as of September 30, 2024 along with the level within the fair value hierarchy in which the fair value measurements, in their entirety, fall.
(In thousands)Fair Value at September 30, 2024Quoted Prices in Active Markets for Identical Assets (Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)
Cash, cash equivalents, and restricted cash
Cash and money market$582,741 $582,741 $— $— 
U.S. government agency securities6,089 — 6,089 — 
Restricted cash (1)
5,837 5,837 — — 
Marketable securities
Corporate bonds$214,615 $— $214,615 $— 
U.S. government agency securities127,093 — 127,093 — 
Asset backed securities85,364 — 85,364 — 
Equity securities5,229 5,229 — — 
Non-marketable securities$686 $— $— $686 
Liabilities
Contingent consideration$(283,231)$— $— $(283,231)
Total$744,423 $593,807 $433,161 $(282,545)
The following table presents the Company’s fair value measurements as of December 31, 2023 along with the level within the fair value hierarchy in which the fair value measurements, in their entirety, fall.
(In thousands)Fair Value at December 31, 2023Quoted Prices in Active Markets for Identical Assets (Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)
Cash, cash equivalents and restricted cash
Cash and money market$530,100 $530,100 $— $— 
Commercial paper72,243 — 72,243 — 
Restricted cash (1)
4,297 4,297 — — 
U.S. government agency securities3,035 — 3,035 — 
Marketable securities
U.S. government agency securities$56,716 $— $56,716 $— 
Corporate bonds55,828 — 55,828 — 
Asset backed securities34,897 — 34,897 — 
Commercial paper20,984 — 20,984 — 
Equity securities3,841 3,841 — — 
Non-marketable securities$7,650 $— $— $7,650 
Liabilities
Contingent consideration$(288,657)$— $— $(288,657)
Total$500,934 $538,238 $243,703 $(281,007)
_________________________________
(1)Restricted cash primarily represents cash held by a third-party financial institution as part of a cash collateral agreement related to the Company’s credit card program. The restrictions will lapse upon the termination of the agreements or the removal of the cash collateral requirement by the third-parties.
Schedule of fair value of contingent consideration
The following table provides a reconciliation of the beginning and ending balances of contingent consideration:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2024202320242023
Beginning balance
$277,921 $302,141 $288,657 $306,927 
Changes in fair value (1)5,310 (8,364)(2,326)(13,051)
Payments (2)
— — (3,100)(99)
Ending balance
$283,231 $293,777 $283,231 $293,777 
______________
(1)The change in fair value of the contingent consideration liability is included in general and administrative expenses in the condensed consolidated statement of operations for the three and nine months ended September 30, 2024 and 2023.
(2)Payment was made in the second quarter of 2024 to settle the contingent consideration liability previously recorded related to the Company’s acquisition of OmicEra.
Securities Owned Not Readily Marketable
The Company has elected the fair value option under the income approach to measure certain Level 3 non-marketable securities. Gains and losses recorded on non-marketable securities are included in investment income, net in the condensed consolidated statement of operations. The following table provides a reconciliation of the beginning and ending balances of non-marketable securities valued using the fair value option:
(In thousands)Non-Marketable Securities
Beginning balance, January 1, 2024
$7,650 
Changes in fair value(714)
Settlement of non-marketable securities(6,250)
Ending balance, September 30, 2024
$686 
Other Investments Not Readily Marketable
Non-Marketable Equity Securities
Non-marketable equity securities without readily determinable fair values, which are classified as a component of other long-term assets, net, had the following cumulative upward and downward adjustments and aggregate carrying amounts:
(In thousands)
September 30, 2024September 30, 2023
Cumulative upward adjustments (1)
$5,102 $779 
Cumulative downward adjustments and impairments (2)
15,071 15,071 
Aggregate carrying value (3)
52,227 31,654 
_________________________________
(1)    There were no material upward adjustments recorded on non-marketable equity securities held for the three and nine months ended September 30, 2024 and 2023.
(2)    There were no material downward adjustments or impairments recorded on non-marketable equity securities held for the three and nine months ended September 30, 2024 and 2023, respectively.
(3)    The aggregate carrying value of non-marketable equity securities was $46.0 million as of December 31, 2023.
v3.24.3
CONVERTIBLE NOTES (Tables)
 9 Months Ended
Sep. 30, 2024
CONVERTIBLE NOTES [Abstract]  
Schedule of convertible note obligations included in the condensed consolidated balance sheets
Convertible note obligations included in the condensed consolidated balance sheet consisted of the following as of September 30, 2024:
Fair Value (1)
(In thousands)Principal AmountUnamortized Debt Discount and Issuance CostsNet Carrying AmountAmountLeveling
2031 Convertible Notes - 1.750%
$620,709 $(14,090)$606,619 $623,558 2
2030 Convertible Notes - 2.000%
572,993 (3,820)569,173 652,244 2
2028 Convertible Notes - 0.375%
589,380 (5,346)584,034 546,650 2
2027 Convertible Notes - 0.375%
563,822 (4,158)559,664 547,668 2
2025 Convertible Notes - 1.000% (2)
249,172 (134)249,038 254,155 2
Convertible note obligations included in the condensed consolidated balance sheet consisted of the following as of December 31, 2023:
Fair Value (1)
(In thousands)Principal AmountUnamortized Debt Discount and Issuance CostsNet Carrying AmountAmountLeveling
2030 Convertible Notes - 2.000%
$572,993 $(4,349)$568,644 $684,475 2
2028 Convertible Notes - 0.375%
949,042 (10,499)938,543 887,354 2
2027 Convertible Notes - 0.375%
563,822 (5,429)558,393 549,839 2
2025 Convertible Notes - 1.000%
249,172 (476)248,696 293,300 2
______________
(1)The fair values are based on observable market prices for this debt, which is traded in less active markets and therefore is classified as a Level 2 fair value measurement.
(2)The Company’s convertible notes due in 2025 (the “2025 Notes”) mature on January 15, 2025 and are included in convertible notes, net, current portion on the condensed consolidated balance sheet as of September 30, 2024. The 2025 Notes were included in convertible notes, net, less current portion as of December 31, 2023.
Schedule of allocation of transaction costs related to convertible debt
Issuance costs are amortized to interest expense over the term of the Notes. The following table summarizes the original issuance costs at the time of issuance for each set of Notes:
(In thousands)
2031 Convertible Notes
$6,820 
2030 Convertible Notes4,938 
2028 Convertible Notes24,453 
2027 Convertible Notes14,285 
2025 Convertible Notes17,646 
Schedule of interest expense
Interest expense on the Notes includes the following:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2024202320242023
Debt issuance costs amortization$1,334 $1,329 $3,965 $4,021 
Debt discount amortization322 25 611 81 
Gain on settlements of convertible notes— — (10,254)(10,324)
Coupon interest expense7,285 4,906 19,054 13,166 
Total interest expense (income) on convertible notes$8,941 $6,260 $13,376 $6,944 
Schedule of effective interest rates related to convertible debt
The following table summarizes the effective interest rates of the Notes:
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
2031 Convertible Notes
2.10 %— %2.06 %— %
2030 Convertible Notes2.12 %2.12 %2.09 %2.09 %
2028 Convertible Notes0.64 %0.64 %0.63 %0.63 %
2027 Convertible Notes0.68 %0.68 %0.67 %0.67 %
2025 Convertible Notes1.18 %1.18 %1.17 %1.17 %
v3.24.3
STOCKHOLDERS' EQUITY (Tables)
 9 Months Ended
Sep. 30, 2024
Equity [Abstract]  
Schedule of amounts recognized in accumulated other comprehensive income (loss) (AOCI)
The amounts recognized in AOCI for the nine months ended September 30, 2024 were as follows:
(In thousands)Cumulative Translation Adjustment
Unrealized Gain on Securities (1)
AOCI
Balance at December 31, 2023$1,374 $54 $1,428 
Other comprehensive loss before reclassifications
427 2,723 3,150 
Amounts reclassified from accumulated other comprehensive income
— 52 52 
Net current period change in accumulated other comprehensive income
427 2,775 3,202 
Balance at September 30, 2024$1,801 $2,829 $4,630 
______________
(1)There was no tax impact from the amounts recognized in AOCI for the three and nine months ended September 30, 2024.
The amounts recognized in AOCI for the nine months ended September 30, 2023 were as follows:
(In thousands)Cumulative Translation AdjustmentUnrealized Gain (Loss) on Securities (1)
AOCI
Balance at December 31, 2022$53 $(5,289)$(5,236)
Other comprehensive income before reclassifications
(626)748 122 
Amounts reclassified from accumulated other comprehensive income
— 3,579 3,579 
Net current period change in accumulated other comprehensive income
(626)4,327 3,701 
Balance at September 30, 2023$(573)$(962)$(1,535)
______________
(1)There was no tax impact from the amounts recognized in AOCI for the nine months ended September 30, 2023.
Schedule of amounts reclassified from accumulated other comprehensive income (loss)
Amounts reclassified from AOCI for the nine months ended September 30, 2024 and 2023 were as follows:
Affected Line Item in the
Statements of Operations		Nine Months Ended September 30,
Details about AOCI Components (In thousands)20242023
Change in value of available-for-sale investments
Sales and maturities of available-for-sale investments
Investment income, net
$52 $3,579 
Total reclassifications$52 $3,579 
v3.24.3
STOCK-BASED COMPENSATION (Tables)
 9 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Summary of Stock Option Activity Under the Stock Plans
A summary of stock option activity under the Stock Plans is as follows:
Option SharesWeighted Average Exercise PriceWeighted Average Remaining Contractual Term (Years)Aggregate Intrinsic Value (1)
(Aggregate intrinsic value in thousands)
Outstanding, January 1, 20241,286,173 $47.67 3.8
Exercised(221,374)19.50 
Forfeited(36,575)91.37 
Outstanding, September 30, 20241,028,224 $52.18 3.3$26,970 
Vested and expected to vest, September 30, 2024
1,028,224 $52.18 3.3$26,970 
Exercisable, September 30, 20241,028,224 $52.18 3.3$26,970 
______________
(1)The total intrinsic value of options exercised, net of shares withheld for taxes, during the nine months ended September 30, 2024 and 2023 was $6.2 million and $10.6 million, respectively, determined as of the date of exercise.
Summary of Restricted Stock and Restricted Stock Unit Activity Under the Stock Plans
A summary of restricted stock and RSU activity during the nine months ended September 30, 2024 is as follows:
Restricted SharesWeighted Average Grant Date Fair Value (1)
Outstanding, January 1, 20246,272,763 $73.39 
Granted4,227,223 56.67 
Released (2)(2,232,590)77.62 
Forfeited(780,430)61.93 
Outstanding, September 30, 20247,486,966 $63.07 
______________
(1)The weighted average grant date fair value of the RSUs granted during the nine months ended September 30, 2023 was $62.28.
(2)The fair value of RSUs vested and converted to shares of the Company’s common stock was $173.3 million and $146.7 million during the nine months ended September 30, 2024 and 2023, respectively.
Share-based Payment Arrangement, Performance Shares, Activity
A summary of PSU activity during the nine months ended September 30, 2024 is as follows:
Performance Share Units (1)Weighted Average Grant Date Fair Value (2)
Outstanding, January 1, 20241,597,801 $92.73 
Granted913,533 63.68 
Released (3)(70,662)140.20 
Forfeited(403,454)92.47 
Outstanding, September 30, 20242,037,218 $75.47 
______________
(1)The PSUs listed above assumes attainment of maximum payout rates as set forth in the performance criteria. Applying actual or expected payout rates, the number of outstanding PSUs as of September 30, 2024 was 820,015.
(2)The weighted average grant date fair value of the PSUs granted during the nine months ended September 30, 2023 was $79.11.
(3)The fair value of PSUs vested and converted to shares of the Company’s common stock was $9.9 million and $1.0 million for the nine months ended September 30, 2024 and 2023, respectively.
Schedule of Share-Based Compensation, Employee Stock Purchase Plan, Activity
The fair value of shares purchased during the three and nine months ended September 30, 2024 and 2023 under the ESPP is based on the assumptions in the following table:
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
ESPP Shares
Risk-free interest rates
(1)
(1)
4.71% - 5.30%
4.68%
Expected term (in years)
(1)
(1)
1.171.25
Expected volatility
(1)
(1)
55.67% - 63.13%
67.30%
Dividend yield
(1)
(1)
—%—%
______________
(1)The Company did not issue stock purchase rights under its 2010 Employee Stock Purchase Plan during the period indicated.
v3.24.3
COMMITMENTS AND CONTINGENCIES (Tables)
 9 Months Ended
Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
Supplemental disclosure of cash flow information related to our operating leases
Supplemental disclosure of cash flow information related to the Company’s cash and non-cash activities with its leases are as follows:
Nine Months Ended September 30,
(In thousands)20242023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$28,658$29,212
Operating cash flows from finance leases991559
Finance cash flows from finance leases4,8902,545
Non-cash investing and financing activities:
Right-of-use assets obtained in exchange for new operating lease liabilities
$17,860$2,097
Right-of-use assets obtained in exchange for new finance lease liabilities15,9954,940
Weighted-average remaining lease term - operating leases (in years)7.587.00
Weighted-average remaining lease term - finance leases (in years)3.082.99
Weighted-average discount rate - operating leases6.55 %6.50 %
Weighted-average discount rate - finance leases6.71 %7.32 %
v3.24.3
SEGMENT INFORMATION (Tables)
 9 Months Ended
Sep. 30, 2024
Segment Reporting [Abstract]  
Revenue from external customers by geographic areas
The following table summarizes total revenue from customers by geographic region. Product revenues are attributed to countries based on ship-to location.
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2024202320242023
United States$659,222 $589,739 $1,904,755 $1,741,428 
Outside of United States49,433 38,599 140,688 111,453 
Total revenues$708,655 $628,338 $2,045,443 $1,852,881 
v3.24.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of the Numerator and Denominator Used to Calculate Basic EPS and Diluted EPS (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]        
Weighted average common shares outstanding—basic (in shares) 184,795 180,649 183,823 179,817
Effect of dilutive shares (in shares) 0 3,426 0 0
Weighted average common shares outstanding—diluted (in shares) 184,795 184,075 183,823 179,817
Increase (decrease) in net loss per share (in usd per share) $ (0.21) $ 0.00 $ (0.89) $ (0.86)
Increase (decrease) in net loss per share (in usd per share) $ (0.21) $ 0.00 $ (0.89) $ (0.86)
Net earnings available to common shareholders - basic $ (38,236) $ 794 $ (164,272) $ (154,383)
Undistributed Earnings (Loss) Available to Common Shareholders, Diluted $ (38,236) $ 794 $ (164,272) $ (154,383)
Stock option        
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]        
Effect of dilutive shares (in shares) 0 646 0 0
Shares issuable upon the release of restricted stock awards        
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]        
Effect of dilutive shares (in shares) 0 2,153 0 0
Shares issuable upon the release of performance share units        
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]        
Effect of dilutive shares (in shares) 0 38 0 0
Employee stock        
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]        
Effect of dilutive shares (in shares) 0 589 0 0
v3.24.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Loss Per Share (Details) - shares
shares in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Common shares not included in the computation of diluted net loss per share        
Potentially issuable common shares not included in the computation of diluted net loss per share because they would have an anti-dilutive effect 37,078 23,231 37,078 32,543
Shares issuable upon exercise of stock options        
Common shares not included in the computation of diluted net loss per share        
Potentially issuable common shares not included in the computation of diluted net loss per share because they would have an anti-dilutive effect 1,028 0 1,028 1,305
Shares issuable upon the release of restricted stock awards        
Common shares not included in the computation of diluted net loss per share        
Potentially issuable common shares not included in the computation of diluted net loss per share because they would have an anti-dilutive effect 7,487 0 7,487 6,423
Shares issuable upon the release of performance share units        
Common shares not included in the computation of diluted net loss per share        
Potentially issuable common shares not included in the computation of diluted net loss per share because they would have an anti-dilutive effect 2,037 0 2,037 1,584
Shares issuable upon conversion of convertible notes        
Common shares not included in the computation of diluted net loss per share        
Potentially issuable common shares not included in the computation of diluted net loss per share because they would have an anti-dilutive effect 26,526 23,231 26,526 23,231
v3.24.3
REVENUE - Schedule of Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Disaggregation of Revenue [Line Items]        
Revenue recognized $ 708,655 $ 628,338 $ 2,045,443 $ 1,852,881
Screening        
Disaggregation of Revenue [Line Items]        
Revenue recognized 544,901 472,013 1,551,305 1,377,995
Screening | Medicare Parts B & C        
Disaggregation of Revenue [Line Items]        
Revenue recognized 201,423 173,624 570,550 521,370
Screening | Commercial        
Disaggregation of Revenue [Line Items]        
Revenue recognized 289,637 253,401 827,509 732,182
Screening | Other        
Disaggregation of Revenue [Line Items]        
Revenue recognized 53,841 44,988 153,246 124,443
Precision Oncology        
Disaggregation of Revenue [Line Items]        
Revenue recognized 163,754 156,325 494,138 468,931
Precision Oncology | Medicare Parts B & C        
Disaggregation of Revenue [Line Items]        
Revenue recognized 47,080 46,383 142,597 141,352
Precision Oncology | Commercial        
Disaggregation of Revenue [Line Items]        
Revenue recognized 47,685 44,430 143,572 135,574
Precision Oncology | International        
Disaggregation of Revenue [Line Items]        
Revenue recognized 49,433 38,599 140,688 111,453
Precision Oncology | Other        
Disaggregation of Revenue [Line Items]        
Revenue recognized 19,556 26,913 67,281 80,552
COVID-19 Testing        
Disaggregation of Revenue [Line Items]        
Revenue recognized $ 0 $ 0 $ 0 $ 5,955
v3.24.3
REVENUE - Narrative (Details)
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Disaggregation of Revenue [Line Items]        
Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price as a Percentage of Revenue   2.00% 1.00%  
Variable consideration        
Disaggregation of Revenue [Line Items]        
Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price as a Percentage of Revenue 1.00%     2.00%
v3.24.3
MARKETABLE SECURITIES - Schedule of Cash and Cash Equivalents (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Sep. 30, 2023
Marketable securities      
Cash and money market $ 582,741 $ 530,100  
Cash equivalents 6,089 75,278  
Total cash, cash equivalents and restricted cash 588,830 605,378 $ 594,612
Estimated Fair Value 433,161 243,703  
Equity securities 5,229 3,841  
Marketable securities 432,301 172,266  
Total cash, cash equivalents and marketable securities 1,021,131 777,644  
Marketable securities      
Marketable securities      
Estimated Fair Value 427,072 168,425  
Available-for-sale debt securities $ 427,072 $ 168,425  
v3.24.3
MARKETABLE SECURITIES - Schedule of Available For Sale Securities (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Available-for-sale securities    
Amortized Cost $ 430,332 $ 243,649
Gains in Accumulated Other Comprehensive Income (Loss) 2,916 406
Losses in Accumulated Other Comprehensive Income (Loss) (87) (352)
Estimated Fair Value 433,161 243,703
Cash equivalents    
Available-for-sale securities    
Amortized Cost 6,089  
Gains in Accumulated Other Comprehensive Income (Loss) 0 0
Losses in Accumulated Other Comprehensive Income (Loss) 0 0
Estimated Fair Value 6,089 75,278
Marketable securities    
Available-for-sale securities    
Amortized Cost 424,243 168,371
Gains in Accumulated Other Comprehensive Income (Loss) 2,916 406
Losses in Accumulated Other Comprehensive Income (Loss) (87) (352)
Estimated Fair Value 427,072 168,425
Commercial paper | Cash equivalents    
Available-for-sale securities    
Gains in Accumulated Other Comprehensive Income (Loss)   0
Losses in Accumulated Other Comprehensive Income (Loss)   0
Estimated Fair Value   72,243
Commercial paper | Marketable securities    
Available-for-sale securities    
Amortized Cost   20,984
Gains in Accumulated Other Comprehensive Income (Loss)   0
Estimated Fair Value   20,984
U.S. government agency securities | Cash equivalents    
Available-for-sale securities    
Amortized Cost 6,089 3,035
Gains in Accumulated Other Comprehensive Income (Loss) 0 0
Losses in Accumulated Other Comprehensive Income (Loss) 0 0
Estimated Fair Value 6,089 3,035
U.S. government agency securities | Marketable securities    
Available-for-sale securities    
Amortized Cost 126,676 56,594
Gains in Accumulated Other Comprehensive Income (Loss) 436 166
Losses in Accumulated Other Comprehensive Income (Loss) (19) (44)
Estimated Fair Value 127,093 56,716
Corporate bonds | Marketable securities    
Available-for-sale securities    
Amortized Cost 212,590 55,712
Gains in Accumulated Other Comprehensive Income (Loss) 2,039 175
Losses in Accumulated Other Comprehensive Income (Loss) (14) (59)
Estimated Fair Value 214,615 55,828
Asset backed securities | Marketable securities    
Available-for-sale securities    
Amortized Cost 84,977 35,081
Gains in Accumulated Other Comprehensive Income (Loss) 441 65
Losses in Accumulated Other Comprehensive Income (Loss) (54) (249)
Estimated Fair Value $ 85,364 $ 34,897
v3.24.3
MARKETABLE SECURITIES - Schedule of Underlying Maturities of AFS Securities (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Available-for-sale securities    
Due in one year or less, Cost $ 158,983  
Due in one year or less, Fair Value 159,475  
Due after one year through five years, Cost 271,349  
Due after one year through five years, Fair Value 273,686  
Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss 430,332 $ 243,649
Gains in Accumulated Other Comprehensive Income (Loss) 2,916 406
Losses in Accumulated Other Comprehensive Income (Loss) (87) (352)
Estimated Fair Value 433,161 243,703
Cash equivalents    
Available-for-sale securities    
Due in one year or less, Cost 6,089  
Due in one year or less, Fair Value 6,089  
Due after one year through five years, Cost 0  
Due after one year through five years, Fair Value 0  
Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss 6,089  
Gains in Accumulated Other Comprehensive Income (Loss) 0 0
Losses in Accumulated Other Comprehensive Income (Loss) 0 0
Estimated Fair Value 6,089 75,278
Debt Securities, Held-to-Maturity, Excluding Accrued Interest, before Allowance for Credit Loss   75,278
Cash equivalents | Commercial paper    
Available-for-sale securities    
Gains in Accumulated Other Comprehensive Income (Loss)   0
Losses in Accumulated Other Comprehensive Income (Loss)   0
Estimated Fair Value   72,243
Debt Securities, Held-to-Maturity, Excluding Accrued Interest, before Allowance for Credit Loss   72,243
Cash equivalents | U.S. government agency securities    
Available-for-sale securities    
Due in one year or less, Cost 6,089  
Due in one year or less, Fair Value 6,089  
Due after one year through five years, Cost 0  
Due after one year through five years, Fair Value 0  
Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss 6,089 3,035
Gains in Accumulated Other Comprehensive Income (Loss) 0 0
Losses in Accumulated Other Comprehensive Income (Loss) 0 0
Estimated Fair Value 6,089 3,035
Marketable securities    
Available-for-sale securities    
Due in one year or less, Cost 152,894  
Due in one year or less, Fair Value 153,386  
Due after one year through five years, Cost 271,349  
Due after one year through five years, Fair Value 273,686  
Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss 424,243 168,371
Gains in Accumulated Other Comprehensive Income (Loss) 2,916 406
Losses in Accumulated Other Comprehensive Income (Loss) (87) (352)
Estimated Fair Value 427,072 168,425
Marketable securities | Commercial paper    
Available-for-sale securities    
Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss   20,984
Gains in Accumulated Other Comprehensive Income (Loss)   0
Estimated Fair Value   20,984
Marketable securities | U.S. government agency securities    
Available-for-sale securities    
Due in one year or less, Cost 89,800  
Due in one year or less, Fair Value 90,048  
Due after one year through five years, Cost 36,876  
Due after one year through five years, Fair Value 37,045  
Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss 126,676 56,594
Gains in Accumulated Other Comprehensive Income (Loss) 436 166
Losses in Accumulated Other Comprehensive Income (Loss) (19) (44)
Estimated Fair Value 127,093 56,716
Marketable securities | Corporate bonds    
Available-for-sale securities    
Due in one year or less, Cost 51,706  
Due in one year or less, Fair Value 51,890  
Due after one year through five years, Cost 160,884  
Due after one year through five years, Fair Value 162,725  
Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss 212,590 55,712
Gains in Accumulated Other Comprehensive Income (Loss) 2,039 175
Losses in Accumulated Other Comprehensive Income (Loss) (14) (59)
Estimated Fair Value 214,615 55,828
Marketable securities | Asset backed securities    
Available-for-sale securities    
Due in one year or less, Cost 11,388  
Due in one year or less, Fair Value 11,448  
Due after one year through five years, Cost 73,589  
Due after one year through five years, Fair Value 73,916  
Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss 84,977 35,081
Gains in Accumulated Other Comprehensive Income (Loss) 441 65
Losses in Accumulated Other Comprehensive Income (Loss) (54) (249)
Estimated Fair Value $ 85,364 $ 34,897
v3.24.3
MARKETABLE SECURITIES - Schedule of Gross Unrealized Losses and Fair Values of Investments in an Unrealized Loss Position (Details)
$ in Thousands
Sep. 30, 2024
USD ($)
Marketable securities  
Total fair value of available-for-sale securities in a continuous unrealized loss position for less than twelve months $ 21,451
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position for less than twelve months (32)
Debt securities, available-for-sale, continuous unrealized loss position, 12 months of longer 11,239
Debt securities, available-for-sale, continuous unrealized loss position, 12 months of longer, accumulated loss (55)
Total fair value of available-for-sale securities in a continuous unrealized loss position 32,690
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position (87)
Corporate bonds | Marketable securities  
Marketable securities  
Total fair value of available-for-sale securities in a continuous unrealized loss position for less than twelve months 9,501
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position for less than twelve months (13)
Debt securities, available-for-sale, continuous unrealized loss position, 12 months of longer 3,290
Debt securities, available-for-sale, continuous unrealized loss position, 12 months of longer, accumulated loss (1)
Total fair value of available-for-sale securities in a continuous unrealized loss position 12,791
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position (14)
Asset backed securities | Marketable securities  
Marketable securities  
Total fair value of available-for-sale securities in a continuous unrealized loss position for less than twelve months 3,399
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position for less than twelve months (3)
Debt securities, available-for-sale, continuous unrealized loss position, 12 months of longer 3,986
Debt securities, available-for-sale, continuous unrealized loss position, 12 months of longer, accumulated loss (51)
Total fair value of available-for-sale securities in a continuous unrealized loss position 7,385
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position (54)
U.S. government agency securities | Marketable securities  
Marketable securities  
Total fair value of available-for-sale securities in a continuous unrealized loss position for less than twelve months 8,551
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position for less than twelve months (16)
Debt securities, available-for-sale, continuous unrealized loss position, 12 months of longer 3,963
Debt securities, available-for-sale, continuous unrealized loss position, 12 months of longer, accumulated loss (3)
Total fair value of available-for-sale securities in a continuous unrealized loss position 12,514
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position $ (19)
v3.24.3
INVENTORY (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Inventory Disclosure [Abstract]    
Raw materials $ 54,714 $ 58,593
Semi-finished and finished goods 82,273 68,882
Total inventory $ 136,987 $ 127,475
v3.24.3
PROPERTY, PLANT AND EQUIPMENT - Schedule of Estimated Useful Lives (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Property, plant and equipment    
Property, plant and equipment, at cost $ 1,170,723 $ 1,115,557
Accumulated depreciation (480,391) (417,203)
Property, plant and equipment, net 690,332 698,354
Land    
Property, plant and equipment    
Property, plant and equipment, at cost 4,716 4,716
Leasehold and building improvements    
Property, plant and equipment    
Property, plant and equipment, at cost $ 227,600 214,562
Land improvements    
Property, plant and equipment    
Estimated Useful Life 15 years  
Property, plant and equipment, at cost $ 6,747 6,729
Buildings    
Property, plant and equipment    
Property, plant and equipment, at cost $ 290,777 290,777
Computer equipment and computer software    
Property, plant and equipment    
Estimated Useful Life 3 years  
Property, plant and equipment, at cost $ 199,715 168,131
Machinery and equipment    
Property, plant and equipment    
Property, plant and equipment, at cost 324,129 290,294
Furniture and fixtures    
Property, plant and equipment    
Property, plant and equipment, at cost 36,976 35,756
Assets under construction    
Property, plant and equipment    
Property, plant and equipment, at cost $ 80,063 $ 104,592
Minimum | Buildings    
Property, plant and equipment    
Estimated Useful Life 30 years  
Minimum | Machinery and equipment    
Property, plant and equipment    
Estimated Useful Life 3 years  
Minimum | Furniture and fixtures    
Property, plant and equipment    
Estimated Useful Life 3 years  
Maximum | Buildings    
Property, plant and equipment    
Estimated Useful Life 40 years  
Maximum | Machinery and equipment    
Property, plant and equipment    
Estimated Useful Life 10 years  
Maximum | Furniture and fixtures    
Property, plant and equipment    
Estimated Useful Life 10 years  
v3.24.3
PROPERTY, PLANT AND EQUIPMENT - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Property, plant and equipment        
Depreciation $ 30,300 $ 29,300 $ 90,655 $ 83,587
Assets under construction 80,100   80,100  
Buildings        
Property, plant and equipment        
Assets under construction 5,100   5,100  
Machinery and equipment        
Property, plant and equipment        
Assets under construction 52,300   52,300  
Leasehold and building improvements        
Property, plant and equipment        
Assets under construction 10,000   10,000  
Computer software        
Property, plant and equipment        
Assets under construction $ 12,700   $ 12,700  
v3.24.3
INTANGIBLE ASSETS AND GOODWILL - Schedule of Finite Lived Intangible Assets Net Balances and Weighted Average Useful Lives (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]          
Cost $ 1,052,250   $ 1,052,250   $ 1,007,331
Accumulated Amortization (437,851)   (437,851)   (366,935)
Intangibles, net 614,399   614,399   640,396
In-process research and development 1,250,000   1,250,000   1,250,000
Finite-lived and indefinite-lived intangible assets, gross 2,302,250   2,302,250   2,257,331
Finite-lived and indefinite-lived intangible assets, net 1,864,399   1,864,399   $ 1,890,396
Impairment of intangible assets, finite-lived $ 0 $ 0 $ 0 $ 0  
Trade name          
Finite-Lived Intangible Assets [Line Items]          
Weighted-average remaining useful life of finite-lived intangible asset (in years) 11 years   11 years   11 years 7 months 6 days
Cost $ 104,000   $ 104,000   $ 104,000
Accumulated Amortization (33,340)   (33,340)   (27,903)
Intangibles, net $ 70,660   $ 70,660   $ 76,097
Customer relationships          
Finite-Lived Intangible Assets [Line Items]          
Weighted-average remaining useful life of finite-lived intangible asset (in years) 6 years 3 months 18 days   6 years 3 months 18 days   7 years
Cost $ 4,000   $ 4,000   $ 4,000
Accumulated Amortization (1,222)   (1,222)   (889)
Intangibles, net $ 2,778   $ 2,778   $ 3,111
Patents and licenses          
Finite-Lived Intangible Assets [Line Items]          
Weighted-average remaining useful life of finite-lived intangible asset (in years) 9 years 8 months 12 days   9 years 8 months 12 days   4 years 6 months
Cost $ 56,542   $ 56,542   $ 11,542
Accumulated Amortization (11,811)   (11,811)   (9,600)
Intangibles, net $ 44,731   $ 44,731   $ 1,942
Developed Technology Rights          
Finite-Lived Intangible Assets [Line Items]          
Weighted-average remaining useful life of finite-lived intangible asset (in years) 6 years 7 months 6 days   6 years 7 months 6 days   7 years 3 months 18 days
Cost $ 887,708   $ 887,708   $ 887,789
Accumulated Amortization (391,478)   (391,478)   (328,543)
Intangibles, net $ 496,230   $ 496,230   $ 559,246
v3.24.3
INTANGIBLE ASSETS AND GOODWILL - Schedule of Future Amortization Expense (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]    
2024 $ 24,100  
2025 96,361  
2026 95,300  
2027 95,300  
2028 95,300  
Thereafter 208,038  
Intangibles, net $ 614,399 $ 640,396
v3.24.3
INTANGIBLE ASSETS AND GOODWILL - Schedule of Changes in Goodwill (Details) - USD ($)
$ in Thousands
 9 Months Ended 12 Months Ended
Sep. 30, 2024
Dec. 31, 2023
Recognized Goodwill    
Beginning balance $ 2,367,120 $ 2,346,040
Goodwill, foreign currency translation gain (loss) 105 388
Ending balance 2,367,450 2,367,120
Resolution Bioscience    
Recognized Goodwill    
Resolution Bioscience acquisition   $ 20,692
Goodwill, Purchase Accounting Adjustments $ 225  
v3.24.3
INTANGIBLE ASSETS AND GOODWILL - Narrative (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]          
Gross value of intangible asset $ 1,052,250,000   $ 1,052,250,000   $ 1,007,331,000
Finite-lived intangible assets, accumulated amortization 437,851,000   437,851,000   366,935,000
Intangibles, net 614,399,000   614,399,000   640,396,000
Impairment losses 0 $ 0 0 $ 0  
Developed Technology Rights          
Finite-Lived Intangible Assets [Line Items]          
Gross value of intangible asset 887,708,000   887,708,000   887,789,000
Finite-lived intangible assets, accumulated amortization 391,478,000   391,478,000   328,543,000
Intangibles, net $ 496,230,000   $ 496,230,000   $ 559,246,000
v3.24.3
FAIR VALUE MEASUREMENTS - Schedule of Fair Value (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Jun. 30, 2024
Dec. 31, 2023
Sep. 30, 2023
Jun. 30, 2023
Dec. 31, 2022
Fair value measurements            
Equity securities $ 5,229   $ 3,841      
Non-marketable securities 686   7,650      
Contingent consideration 283,231 $ 277,921 288,657 $ 293,777 $ 302,141 $ 306,927
Contingent consideration (19,400)          
Fair Value, Recurring            
Fair value measurements            
Restricted cash (1) 5,837   4,297      
Equity securities 5,229   3,841      
Non-marketable securities 686   7,650      
Contingent consideration     288,657      
Contingent consideration (283,231)          
Total 744,423   500,934      
Fair Value, Recurring | Corporate bonds            
Fair value measurements            
Estimated Fair Value 214,615   55,828      
Fair Value, Recurring | Commercial paper            
Fair value measurements            
Estimated Fair Value     20,984      
Fair Value, Recurring | U.S. government agency securities            
Fair value measurements            
Estimated Fair Value 127,093   56,716      
Fair Value, Recurring | Asset backed securities            
Fair value measurements            
Estimated Fair Value 85,364   34,897      
Fair Value, Recurring | Cash and money market            
Fair value measurements            
Cash and cash equivalents, fair value 582,741   530,100      
Fair Value, Recurring | U.S. government agency securities            
Fair value measurements            
Cash and cash equivalents, fair value 6,089   3,035      
Fair Value, Recurring | Commercial paper            
Fair value measurements            
Cash and cash equivalents, fair value     72,243      
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Recurring            
Fair value measurements            
Restricted cash (1) 5,837   4,297      
Equity securities 5,229   3,841      
Non-marketable securities 0   0      
Contingent consideration     0      
Contingent consideration 0          
Total 593,807   538,238      
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Recurring | Corporate bonds            
Fair value measurements            
Estimated Fair Value 0   0      
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Recurring | Commercial paper            
Fair value measurements            
Estimated Fair Value     0      
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Recurring | U.S. government agency securities            
Fair value measurements            
Estimated Fair Value 0   0      
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Recurring | Asset backed securities            
Fair value measurements            
Estimated Fair Value 0   0      
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Recurring | Cash and money market            
Fair value measurements            
Cash and cash equivalents, fair value 582,741   530,100      
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Recurring | U.S. government agency securities            
Fair value measurements            
Cash and cash equivalents, fair value 0   0      
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Recurring | Commercial paper            
Fair value measurements            
Cash and cash equivalents, fair value     0      
Significant Other Observable Inputs (Level 2) | Fair Value, Recurring            
Fair value measurements            
Restricted cash (1) 0   0      
Equity securities 0   0      
Non-marketable securities 0   0      
Contingent consideration     0      
Contingent consideration 0          
Total 433,161   243,703      
Significant Other Observable Inputs (Level 2) | Fair Value, Recurring | Corporate bonds            
Fair value measurements            
Estimated Fair Value 214,615   55,828      
Significant Other Observable Inputs (Level 2) | Fair Value, Recurring | Commercial paper            
Fair value measurements            
Estimated Fair Value     20,984      
Significant Other Observable Inputs (Level 2) | Fair Value, Recurring | U.S. government agency securities            
Fair value measurements            
Estimated Fair Value 127,093   56,716      
Significant Other Observable Inputs (Level 2) | Fair Value, Recurring | Asset backed securities            
Fair value measurements            
Estimated Fair Value 85,364   34,897      
Significant Other Observable Inputs (Level 2) | Fair Value, Recurring | Cash and money market            
Fair value measurements            
Cash and cash equivalents, fair value 0   0      
Significant Other Observable Inputs (Level 2) | Fair Value, Recurring | U.S. government agency securities            
Fair value measurements            
Cash and cash equivalents, fair value 6,089   3,035      
Significant Other Observable Inputs (Level 2) | Fair Value, Recurring | Commercial paper            
Fair value measurements            
Cash and cash equivalents, fair value     72,243      
Significant Unobservable Inputs (Level 3) | Fair Value, Recurring            
Fair value measurements            
Restricted cash (1) 0   0      
Equity securities 0   0      
Non-marketable securities 686   7,650      
Contingent consideration     288,657      
Contingent consideration (283,231)          
Total (282,545)   (281,007)      
Significant Unobservable Inputs (Level 3) | Fair Value, Recurring | Corporate bonds            
Fair value measurements            
Estimated Fair Value 0   0      
Significant Unobservable Inputs (Level 3) | Fair Value, Recurring | Commercial paper            
Fair value measurements            
Estimated Fair Value     0      
Significant Unobservable Inputs (Level 3) | Fair Value, Recurring | U.S. government agency securities            
Fair value measurements            
Estimated Fair Value 0   0      
Significant Unobservable Inputs (Level 3) | Fair Value, Recurring | Asset backed securities            
Fair value measurements            
Estimated Fair Value 0   0      
Significant Unobservable Inputs (Level 3) | Fair Value, Recurring | Cash and money market            
Fair value measurements            
Cash and cash equivalents, fair value 0   0      
Significant Unobservable Inputs (Level 3) | Fair Value, Recurring | U.S. government agency securities            
Fair value measurements            
Cash and cash equivalents, fair value $ 0   0      
Significant Unobservable Inputs (Level 3) | Fair Value, Recurring | Commercial paper            
Fair value measurements            
Cash and cash equivalents, fair value     $ 0      
v3.24.3
FAIR VALUE MEASUREMENTS - Fair Value of Contingent Consideration (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Fair Value Disclosures [Abstract]        
Beginning balance $ 277,921 $ 302,141 $ 288,657 $ 306,927
Ending balance 283,231 293,777 283,231 293,777
Change in amount of contingent consideration liability 5,310 (8,364) (2,326) (13,051)
Payment for Contingent Consideration Liability, Investing Activities $ 0 $ 0 $ 3,100 $ 99
v3.24.3
FAIR VALUE MEASUREMENTS - Schedule of Non-marketable Equity Investments (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Fair Value Disclosures [Abstract]          
Non-marketable securities $ 686,000   $ 686,000   $ 7,650,000
Changes in fair value     (714,000)    
Settlement of non-marketable securities     (6,250,000)    
Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount 5,102,000 $ 779,000 5,102,000 $ 779,000  
Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount 15,071,000 15,071,000 15,071,000 15,071,000  
Other Investment Not Readily Marketable, Fair Value 52,227,000 31,654,000 52,227,000 31,654,000  
Debt and Equity Securities, Realized Gain (Loss) $ 0 $ 0 $ 0 $ 0  
v3.24.3
FAIR VALUE MEASUREMENTS - Narrative (Details)
 3 Months Ended 9 Months Ended
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Jun. 30, 2024
USD ($)
Dec. 31, 2023
USD ($)
Jun. 30, 2023
USD ($)
Dec. 31, 2022
USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                
Contingent consideration $ 283,231,000 $ 293,777,000 $ 283,231,000 $ 293,777,000 $ 277,921,000 $ 288,657,000 $ 302,141,000 $ 306,927,000
Business Combination, Contingent Consideration, Liability, Current 19,400,000   19,400,000          
Business Combination, Contingent Consideration, Liability, Noncurrent 263,800,000   263,800,000          
Venture capital investment fund                
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                
Investment owned, at fair value 6,700,000   6,700,000     $ 5,200,000    
Committed capital     18,000,000          
Committed capital callable $ 11,700,000   $ 11,700,000          
Product development and other milestone-based payments | Weighted average | Measurement Input, Probability of Success                
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                
Contingent consideration liability, measurement input 0.90   0.90     0.89    
Product development and other milestone-based payments | Weighted average | Measurement Input, Present-value Factor                
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                
Contingent consideration liability, measurement input 0.060   0.060     0.058    
Foreign exchange forward                
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                
Derivative, notional amount $ 47,700,000   $ 47,700,000     $ 39,500,000    
Derivative, fair value 0   0     0    
Gain (Loss) on derivative instruments, net, pretax 0 $ 0 0 $ 0        
Thrive, Ashion and OmicEra | Fair value                
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                
Contingent consideration $ 283,200,000   $ 283,200,000     $ 288,700,000    
v3.24.3
LONG-TERM DEBT - Narrative (Details) - USD ($)
 1 Months Ended 6 Months Ended 9 Months Ended
Jan. 31, 2023
Dec. 31, 2021
Nov. 30, 2021
Jun. 30, 2024
Sep. 30, 2024
Sep. 30, 2023
Jun. 29, 2024
Dec. 31, 2023
Jun. 29, 2022
Long-term debt                  
Repayments of Accounts Receivable Securitization         $ 50,000,000 $ 0      
Securitized receivables                  
Long-term debt                  
Maximum borrowing capacity                 $ 150,000,000
Line of credit facility, interest rate at period end             6.89%    
Long-Term Debt, Excluding Current Maturities               $ 50,000,000  
Repayments of Accounts Receivable Securitization       $ 50,000,000          
Securitized receivables | Minimum                  
Long-term debt                  
Long-Term Debt, Excluding Current Maturities                 $ 50,000,000
Revolving loan agreement | Revolving loan agreement | Line of credit                  
Long-term debt                  
Maximum borrowing capacity     $ 150,000,000            
Minimum market value covenant     150,000,000            
Maximum outstanding cash advances threshold     $ 20,000,000.0            
Variable rate     0.60%            
Remaining borrowing capacity         $ 145,600,000     $ 145,600,000  
City letter of credit | Revolving loan agreement | Line of credit                  
Long-term debt                  
Proceeds from lines of credit $ 1,500,000 $ 2,900,000              
v3.24.3
CONVERTIBLE NOTES - Schedule of Convertible Notes (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
2027 Convertible Notes    
Long-term debt    
Coupon interest rate 0.375% 0.375%
Principal Amount $ 589,380 $ 949,042
Unamortized Debt Discount and Issuance Costs (5,346) (10,499)
Net Carrying Amount 584,034 938,543
2027 Convertible Notes | Significant Other Observable Inputs (Level 2) | Fair value    
Long-term debt    
Amount $ 546,650 $ 887,354
2028 Convertible Notes    
Long-term debt    
Coupon interest rate 0.375% 0.375%
Principal Amount $ 563,822 $ 563,822
Unamortized Debt Discount and Issuance Costs (4,158) (5,429)
Net Carrying Amount 559,664 558,393
2028 Convertible Notes | Significant Other Observable Inputs (Level 2) | Fair value    
Long-term debt    
Amount $ 547,668 $ 549,839
2030 Convertible Notes    
Long-term debt    
Coupon interest rate 1.00% 1.00%
Principal Amount $ 249,172 $ 249,172
Unamortized Debt Discount and Issuance Costs (134) (476)
Net Carrying Amount 249,038 248,696
2030 Convertible Notes | Significant Other Observable Inputs (Level 2) | Fair value    
Long-term debt    
Amount $ 254,155 $ 293,300
Convertible Notes Payable2030    
Long-term debt    
Coupon interest rate 2.00% 2.00%
Principal Amount $ 572,993 $ 572,993
Unamortized Debt Discount and Issuance Costs (3,820) (4,349)
Net Carrying Amount 569,173 568,644
Convertible Notes Payable2030 | Significant Other Observable Inputs (Level 2) | Fair value    
Long-term debt    
Amount $ 652,244 $ 684,475
Convertible Notes Payable2031    
Long-term debt    
Coupon interest rate 1.75%  
Principal Amount $ 620,709  
Unamortized Debt Discount and Issuance Costs (14,090)  
Net Carrying Amount 606,619  
Convertible Notes Payable2031 | Significant Other Observable Inputs (Level 2) | Fair value    
Long-term debt    
Amount $ 623,558  
v3.24.3
CONVERTIBLE NOTES - Narrative (Details)
$ / shares in Units, $ in Thousands, shares in Millions
 1 Months Ended 3 Months Ended 9 Months Ended
Apr. 30, 2024
USD ($)
Mar. 31, 2023
USD ($)
Sep. 30, 2024
USD ($)
$ / shares
Sep. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
$ / shares
shares
Sep. 30, 2023
USD ($)
Apr. 17, 2024
USD ($)
Dec. 31, 2023
USD ($)
Mar. 06, 2023
USD ($)
Mar. 01, 2023
USD ($)
Long-term debt                    
Principal amount, convertible note         $ 1          
Repurchase price, as percentage of principal amount, if company undergoes change of control         100          
Market price (in dollars per share) | $ / shares     $ 68.12   $ 68.12          
Proceeds from issuance of convertible notes         $ 266,750 $ 137,976        
Gain (Loss) on Extinguishment of Debt $ 10,300 $ 17,700                
Other Investment Not Readily Marketable, Fair Value     $ 52,227 $ 31,654 $ 52,227 $ 31,654        
Significant Unobservable Inputs (Level 3) | Fair value, nonrecurring                    
Long-term debt                    
Other Investment Not Readily Marketable, Fair Value               $ 46,000    
2030 Convertible Notes                    
Long-term debt                    
Gain (Loss) on Extinguishment of Debt   7,400                
2030 Convertible Notes                    
Long-term debt                    
Conversion rate, number of shares to be issued per $1,000 of principal amount (in shares)         13.26          
Conversion price (in dollars per share) | $ / shares     $ 75.43   $ 75.43          
Potential shares issued from convertible instrument (in shares) | shares         3.3          
Effective interest rate (as a percent)     1.18% 1.18% 1.17% 1.17%        
Amount of debt extinguished   65,800                
Interest expense amortization term     3 months 14 days   3 months 14 days          
Convertible Notes Payable2027                    
Long-term debt                    
Conversion rate, number of shares to be issued per $1,000 of principal amount (in shares)         8.96          
Conversion price (in dollars per share) | $ / shares     $ 111.66   $ 111.66          
Potential shares issued from convertible instrument (in shares) | shares         5.0          
Effective interest rate (as a percent)     0.68% 0.68% 0.67% 0.67%        
Amount of debt extinguished   183,700                
Interest expense amortization term     2 years 5 months 12 days   2 years 5 months 12 days          
2027 Convertible Notes                    
Long-term debt                    
Conversion rate, number of shares to be issued per $1,000 of principal amount (in shares)         8.21          
Conversion price (in dollars per share) | $ / shares     $ 121.84   $ 121.84          
Potential shares issued from convertible instrument (in shares) | shares         4.8          
Effective interest rate (as a percent)     0.64% 0.64% 0.63% 0.63%        
Amount of debt extinguished 359,700 201,000                
Interest expense amortization term     3 years 5 months 1 day   3 years 5 months 1 day          
Convertible Notes Payable2030                    
Long-term debt                    
Conversion rate, number of shares to be issued per $1,000 of principal amount (in shares)         12.37          
Conversion price (in dollars per share) | $ / shares     $ 80.83   $ 80.83          
Potential shares issued from convertible instrument (in shares) | shares         7.1          
Effective interest rate (as a percent)     2.12% 2.12% 2.09% 2.09%        
Face amount                   $ 500,000
Proceeds from issuance of convertible notes   138,000                
Proceeds from Debt, Net of Issuance Costs   $ 133,000                
Interest expense amortization term     5 years 5 months 1 day   5 years 5 months 1 day          
Convertible Notes Payable2030 | 2030 Convertible Notes                    
Long-term debt                    
Face amount                 $ 73,000  
Convertible Notes Payable2031                    
Long-term debt                    
Conversion rate, number of shares to be issued per $1,000 of principal amount (in shares)         10.06          
Conversion price (in dollars per share) | $ / shares     $ 99.36   $ 99.36          
Potential shares issued from convertible instrument (in shares) | shares         6.2          
Effective interest rate (as a percent)     2.10% 0.00% 2.06% 0.00%        
Face amount             $ 620,700      
Proceeds from issuance of convertible notes 266,800                  
Proceeds from Debt, Net of Issuance Costs $ 259,800                  
Interest expense amortization term     6 years 6 months 14 days   6 years 6 months 14 days          
v3.24.3
CONVERTIBLE NOTES - Schedule of Transaction Costs (Details)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
USD ($)
Convertible Notes Payable2027  
Long-term debt  
Total transaction costs $ 14,285
Convertible Notes Payable2028  
Long-term debt  
Total transaction costs 24,453
Convertible Notes Payable2030  
Long-term debt  
Total transaction costs 4,938
2030 Convertible Notes  
Long-term debt  
Total transaction costs 17,646
Convertible Notes Payable2031  
Long-term debt  
Total transaction costs $ 6,820
v3.24.3
CONVERTIBLE NOTES - Summary of Interest Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Debt Disclosure [Abstract]        
Debt issuance costs amortization $ 1,334 $ 1,329 $ 3,965 $ 4,021
Debt discount amortization 322 25 611 81
Gain on settlements of convertible notes, net 0 0 (10,254) (10,324)
Coupon interest expense 7,285 4,906 19,054 13,166
Total interest expense (income) on convertible notes $ 8,941 $ 6,260 $ 13,376 $ 6,944
v3.24.3
CONVERTIBLE NOTES - Schedule of Effective Interest Rates Related to Convertible Debt (Details)
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
2030 Convertible Notes        
Schedule of Convertible notes [Line Items]        
Effective interest rate (as a percent) 1.18% 1.18% 1.17% 1.17%
2028 Convertible Notes        
Schedule of Convertible notes [Line Items]        
Effective interest rate (as a percent) 0.68% 0.68% 0.67% 0.67%
2027 Convertible Notes        
Schedule of Convertible notes [Line Items]        
Effective interest rate (as a percent) 0.64% 0.64% 0.63% 0.63%
Convertible Notes Payable2030        
Schedule of Convertible notes [Line Items]        
Effective interest rate (as a percent) 2.12% 2.12% 2.09% 2.09%
Convertible Notes Payable2031        
Schedule of Convertible notes [Line Items]        
Effective interest rate (as a percent) 2.10% 0.00% 2.06% 0.00%
v3.24.3
LICENSE AND COLLABORATION AGREEMENTS - Mayo (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Oct. 31, 2017
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Research and development expense $ 100,101 $ 111,446 $ 331,593 $ 310,960  
Licensing agreements | Mayo          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Period patent remains in effect     5 years    
Collaborative Arrangements Amount Agreed to Pay upon Achievement of Sale Milestones         $ 3,000
v3.24.3
LICENSE AND COLLABORATION AGREEMENTS - John Hopkins University (Details) - Licensing agreements - USD ($)
$ in Millions
Jun. 30, 2023
Jan. 05, 2021
Resolution Bioscience acquisition    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Sales-based Milestone Payments   $ 45.0
Sales milestone range one | The Broad Institute, LLC    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Collaborative arrangement sales milestone amount $ 500.0  
v3.24.3
LICENSE AND COLLABORATION AGREEMENTS - The Broad Institute (Details)
$ in Thousands
Jun. 30, 2023
USD ($)
Product development and other milestone-based payments | The Broad Institute, LLC | Licensing agreements  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Collaborative Arrangements Development Milestone Amount $ 6,500
v3.24.3
LICENSE AND COLLABORATION AGREEMENTS - Translational Genomics Research Institute (Details) - TARDIS Technology - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
May 01, 2024
Jan. 11, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales-based Milestone Payments     $ 45,000
Contract Termination Fee, Unamortized Liability $ 1,800    
Contract Termination, Current Liability 8,800    
Contract Termination, Long Term Liability 8,300    
Contract Termination Fee, Fair-Value   $ 25,800  
Contract Termination Fee, Liability $ 17,100    
Contract termination fee   27,600  
Contract Termination Fee Annual Installments   $ 9,200  
v3.24.3
LICENSE AND COLLABORATION AGREEMENTS - Watchmaker Genomics (Details)
$ in Millions
Jul. 31, 2023
USD ($)
Watchmaker Genomics, Inc | Licensing agreements  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Collaboration arrangement, milestones to be paid $ 82.0
v3.24.3
LICENSE AND COLLABORATION AGREEMENTS - TwinStrand Biosciences (Details) - TwinStrand Biosciences, Inc - USD ($)
$ in Millions
Jul. 01, 2024
Sep. 30, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Intangible asset acquired $ 45  
Weighted-average remaining useful life of finite-lived intangible asset (in years)   10 years
v3.24.3
STOCKHOLDERS' EQUITY - Schedule of OCI (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance $ 3,145,305 $ 3,043,162
Other comprehensive income before reclassifications 3,150 122
Amounts reclassified from accumulated other comprehensive income 52 3,579
Net current period change in accumulated other comprehensive income 3,202 3,701
Ending balance 3,210,511 3,121,227
Cumulative Translation Adjustment    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance 1,374 53
Other comprehensive income before reclassifications 427 (626)
Amounts reclassified from accumulated other comprehensive income 0 0
Net current period change in accumulated other comprehensive income 427 (626)
Ending balance 1,801 (573)
Unrealized Gain (Loss) on Marketable Securities    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance 54 (5,289)
Other comprehensive income before reclassifications 2,723 748
Amounts reclassified from accumulated other comprehensive income 52 3,579
Net current period change in accumulated other comprehensive income 2,775 4,327
Ending balance 2,829 (962)
AOCI    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance 1,428 (5,236)
Ending balance $ 4,630 $ (1,535)
v3.24.3
STOCKHOLDERS' EQUITY - Schedule of Amounts Reclassified from AOCI (Details) - Reclassification out of accumulated other comprehensive income - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Changes in Accumulated Other Comprehensive Income (Loss)    
Total reclassifications $ 52 $ 3,579
Unrealized Gain (Loss) on Marketable Securities    
Changes in Accumulated Other Comprehensive Income (Loss)    
Investment income, net $ 52 $ 3,579
v3.24.3
STOCK-BASED COMPENSATION - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2024
Sep. 30, 2023
Stock-based compensation                
Stock-based compensation expense $ 48,757 $ 56,555 $ 60,370 $ 61,871 $ 61,725 $ 49,139 $ 165,700 $ 172,700
Stock plans                
Stock-based compensation                
Unrecognized compensation cost $ 383,800           $ 383,800  
Weighted average period for recognition of cost             2 years 7 months 6 days  
v3.24.3
STOCK-BASED COMPENSATION - Fair Value and Activity (Details) - Stock plans - USD ($)
$ / shares in Units, $ in Thousands
 9 Months Ended
Dec. 31, 2023
Sep. 30, 2024
Sep. 30, 2023
Shares      
Outstanding at the beginning of the period (in shares)   1,286,173  
Exercised (in shares)   (221,374)  
Forfeited (in shares)   (36,575)  
Outstanding at the end of the period (in shares) 1,286,173 1,028,224  
Vested and expected to vest at end of period (in shares)   1,028,224  
Exercisable at the end of the period (in shares)   1,028,224  
Weighted Average Exercise Price      
Outstanding at the beginning of the period (in dollars per share)   $ 47.67  
Exercised (in dollars per share)   19.50  
Forfeited (in dollars per share)   91.37  
Outstanding at the end of the period (in dollars per share) $ 47.67 52.18  
Vested and expected to vest at end of period (in dollars per share)   52.18  
Exercisable at the end of the period (in dollars per share)   $ 52.18  
Weighted Average Remaining Contractual Term      
Outstanding 3 years 9 months 18 days 3 years 3 months 18 days  
Vested and expected to vest at end of period   3 years 3 months 18 days  
Exercisable at the end of the period   3 years 3 months 18 days  
Aggregate Intrinsic Value      
Outstanding at the end of the period   $ 26,970  
Vested and expected to vest at end of period   26,970  
Exercisable at the end of the period   26,970  
Total intrinsic value of options exercised   $ 6,200 $ 10,600
v3.24.3
STOCK-BASED COMPENSATION - Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity (Details) - USD ($)
$ / shares in Units, $ in Millions
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Restricted Shares and RSUs    
Restricted Shares    
Outstanding at the beginning of the period (in shares) 6,272,763  
Granted (in shares) 4,227,223  
Released (in shares) (2,232,590)  
Forfeited (in shares) (780,430)  
Outstanding at the end of the period (in shares) 7,486,966  
Weighted Average Exercise Price    
Outstanding at the beginning of the period (in dollars per share) $ 73.39  
Granted (in dollars per share) 56.67  
Released (in dollars per share) 77.62  
Forfeited (in dollars per share) 61.93  
Outstanding at the end of the period (in dollars per share) $ 63.07  
Fair value of equity instruments other than options vested in period $ 173.3 $ 146.7
Restricted stock units    
Weighted Average Exercise Price    
Granted (in dollars per share)   $ 62.28
v3.24.3
STOCK-BASED COMPENSATION - Share-based Payment Arrangement, Performance Shares, Activity (Details) - Shares issuable upon the release of performance share units - USD ($)
$ / shares in Units, $ in Millions
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Stock-based compensation      
Outstanding (in shares) 2,037,218   1,597,801
Outstanding (in dollars per share) $ 75.47   $ 92.73
Granted (in shares) 913,533    
Granted (in dollars per share) $ 63.68 $ 79.11  
Released (in shares) (70,662)    
Released (in dollars per share) $ 140.20    
Forfeited (in shares) (403,454)    
Forfeited (in dollars per share) $ 92.47    
Number of outstanding performance share units (in shares) 820,015    
Fair value of equity instruments other than options vested in period $ 9.9 $ 1.0  
v3.24.3
STOCK-BASED COMPENSATION - Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions (Details)
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Stock-based compensation    
Risk-free interest rates, maximum (as a percent) 5.30%  
Expected volatility, maximum (as a percent) 63.13%  
Employee stock    
Stock-based compensation    
Risk-free interest rates, minimum (as a percent) 4.71% 4.68%
Expected Volatility Rate, Minimum (as a percent) 55.67% 67.30%
Dividend yield (as a percent) 0.00% 0.00%
Employee stock | Minimum    
Stock-based compensation    
Expected term (in years) 1 year 2 months 1 day 1 year 3 months
v3.24.3
COMMITMENTS AND CONTINGENCIES - Supplemental Disclosure of Cash Flow Information (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Cash paid for amounts included in the measurement of lease liabilities:    
Operating cash flows from operating leases $ 28,658 $ 29,212
Operating cash flows from finance leases 991 559
Finance cash flows from finance leases 4,890 2,545
Non-cash investing and financing activities:    
Right-of-use assets obtained in exchange for new operating lease liabilities 17,860 2,097
Right-of-use assets obtained in exchange for new finance lease liabilities $ 15,995 $ 4,940
Weighted-average remaining lease term - operating leases (in years) 7 years 6 months 29 days 7 years
Weighted-average remaining lease term - finance leases (in years) 3 years 29 days 2 years 11 months 26 days
Weighted-average discount rate - operating leases 6.55% 6.50%
Weighted-average discount rate - finance leases 6.71% 7.32%
v3.24.3
COMMITMENTS AND CONTINGENCIES - Additional Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2024
Dec. 31, 2023
Lessee, Lease, Description [Line Items]      
Operating lease right-of-use assets $ 122,452 $ 122,452 $ 143,708
Additional amount to be recognized at lease commencement for the lease liability 189,900 189,900 190,400
Operating lease liability, current 27,170 27,170 29,379
Operating lease liability, noncurrent 162,695 162,695 161,070
Finance lease, right-of-use asset $ 21,600 $ 21,600 11,300
Finance lease, right-of-use asset, statement of financial position, extensible list Other long-term assets, net Other long-term assets, net  
Finance lease liability $ 22,700 $ 22,700 11,900
Finance lease liability, current $ 7,900 $ 7,900 $ 4,400
Finance lease, liability, current, statement of financial position, extensible list Other current liabilities Other current liabilities Other current liabilities
Finance lease liability, noncurrent $ 14,800 $ 14,800 $ 7,500
Finance lease, liability, noncurrent, statement of financial position, extensible list Other long-term liabilities Other long-term liabilities Other long-term liabilities
Impairment of long-lived assets $ 18,700    
Leasehold Improvements      
Lessee, Lease, Description [Line Items]      
Impairment of Leasehold   $ 6,900  
Assets      
Lessee, Lease, Description [Line Items]      
Operating Lease, Impairment Loss   $ 11,800  
v3.24.3
WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS (Details) - Amended wisconsin economic development tax credit agreement
$ in Millions
 1 Months Ended
Dec. 31, 2021
USD ($)
position
Sep. 30, 2024
USD ($)
Agreements    
Capital investment expenditures over specified period, requirement to earn the refundable tax credits $ 350.0  
Full-time positions that must be created over a specified time period to earn the refundable tax credits | position 1,300  
Period over which the capital investment expenditures must be incurred and the creation of full-time positions must be completed 5 years  
Refundable tax credits earned $ 18.5 $ 14.3
Credit earning rate 10.00%  
Maximum credits available to earn $ 7.0  
Refundable tax credit receivable   8.8
Prepaid expenses and other current assets    
Agreements    
Refundable tax credit receivable   4.2
Other long-term assets    
Agreements    
Refundable tax credit receivable   $ 4.6
v3.24.3
ACQUISITIONS AND DIVESTITURES - Narrative (Details) - USD ($)
$ in Millions
Sep. 30, 2024
Dec. 31, 2023
Business Acquisition [Line Items]    
Contract asset $ 48.3 $ 41.7
Contract with Customer, Receivable, after Allowance for Credit Loss 31.6 $ 31.6
Contract with Customer, Asset, after Allowance for Credit Loss, Current 25.8  
Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent $ 22.5  
Developed Technology Rights    
Business Acquisition [Line Items]    
Weighted-average remaining useful life of finite-lived intangible asset (in years) 6 years 7 months 6 days 7 years 3 months 18 days
v3.24.3
ACQUISITIONS AND DIVESTITURES - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Dec. 31, 2022
Business Acquisition [Line Items]      
Goodwill $ 2,367,450 $ 2,367,120 $ 2,346,040
v3.24.3
SEGMENT INFORMATION (Details)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
segment
Sep. 30, 2023
USD ($)
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue $ 708,655 $ 628,338 $ 2,045,443 $ 1,852,881
Number of Operating Segments | segment     1  
United States        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue 659,222 589,739 $ 1,904,755 1,741,428
Outside of United States        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue $ 49,433 $ 38,599 $ 140,688 $ 111,453
v3.24.3
INCOME TAXES (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Income Tax Disclosure [Abstract]          
Tax expense (benefit) $ 808 $ 249 $ 4,077 $ 3,013  
Deferred tax liabilities, net 19,300   19,300   $ 17,300
Unrecognized tax benefits $ 42,000   $ 42,000   $ 36,400
EXACT Sciences (NASDAQ:EXAS)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024 Haga Click aquí para más Gráficas EXACT Sciences.
EXACT Sciences (NASDAQ:EXAS)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024 Haga Click aquí para más Gráficas EXACT Sciences.